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SUMMARY	
Helicobacter pylori is a highly successful bacterial pathogen uniquely adapted to 
colonize the human stomach. It is an infectious agent responsible for causing type B 
gastritis, peptic ulcers, gastric adenocarcinoma and MALT lymphoma. Upon contact 
with the host cell, H. pylori forms a transmembrane multi-protein complex and a 
needle-like structure, termed the Cag Type IV Secretion System (Cag-T4SS), to mediate 
the injection of its effector protein CagA into gastric epithelial cells. The translocated 
CagA influences several host cell signaling pathways and results in reorgnization of the 
cytoskeleton and in inflammation.  
The cag pathogenicity island (cag-PAI) harbors 27-30 genes coding for components of 
the Cag type IV secretion apparatus. CagH, CagI and CagL, which are encoded by 
contiguous genes on the cag-PAI, are known to play roles as essential components of 
the Cag-T4SS. It has been shown that several Cag proteins, including CagI and CagL, 
contribute to the interaction between the secretion apparatus and the integrin β1 
receptor, which might facilitate the translocation of CagA across the host cell 
membrane. However, the functional roles and the interactions between these three 
proteins and other Cag proteins, which lead to Cag-T4SS assembly, are not well 
defined.  
In this thesis, we show that CagH, CagI and CagL are independently required for both 
CagA translocation and IL-8 induction, the hallmark of proinflammatory activity 
induced by the Cag-T4SS. Although the genes coding for these three proteins are 
located in the same operon and have overlapping open reading frames, there was no 
transcriptional effect of cagI deletion on cagL, but we found stabilizing effects at the 
protein level. Secondly, we show by immunoprecipitation and pull-down assays that 
CagH, CagI and CagL interact with each other to form a complex in H. pylori, which 
might play an important role in Cag-T4SS functionality. Additionally, using different 
biochemical methods, we provide evidence for different/distinct subcellular pools, as 
well as bacterial surface localization, of CagI and CagL. Importantly, we were able to 
identify functional domains of CagH, CagI and CagL. We found that the CagH, CagI 
and CagL proteins contain a conserved C-terminal motif, and that this motif is important 
Summary 
xii 
 
for the function of at least CagH and CagL, as well as for the interaction of CagH, CagI 
and CagL. Finally, we provide evidence for an influence of another cag gene, cagP, on 
production of CagI and CagL proteins. We show that there is no transcriptional effect 
exerted by deletion of cagP, or of the associated small non-coding RNA HPnc2630, on 
transcription of the cagI gene, but that the CagP protein is required for the full function 
of the Cag-T4SS. In conclusion, these findings reveal for the first time an important role 
of these proteins and their interaction for the activity of the Cag-T4SS and give novel 
insights for understanding the way how pili are assembled. 
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ZUSAMMENFASSUNG	
Helicobacter pylori ist ein sehr erfolgreicher Krankheitserreger, der auf einzigartige 
Weise an die Kolonisierung des menschlichen Magens angepasst ist. Infektionen mit 
diesem Bakterium verursachen die Typ B-Gastritis, Magen- und Duodenalulzera sowie 
Magenkarzinome und MALT-Lymphome. Nach Kontakt mit Wirtszellen bildet H. 
pylori einen membranständigen Multiproteinkomplex sowie nadelartige Fortsätze oder 
Pili aus, das sogenannte Cag-Typ IV-Sekretionssystem (Cag-T4SS), und injiziert damit 
sein Effektorprotein CagA in Magenepithelzellen. Transloziertes CagA beeinflusst 
verschiedene Signaltransduktionswege der Wirtszelle und bewirkt eine Reorganisation 
des Zytoskeletts sowie eine Entzündungsreaktion. 
Die cag-Pathogenitätsinsel (cag-PAI) enthält 27-30 Gene, die für Komponenten des 
Typ IV-Sekretionsapparats kodieren. CagH, CagI und CagL, die von benachbarten 
Genen der cag-PAI kodiert werden, sind als essenzielle Komponenten des Cag-T4SS 
beschrieben. Es wurde gezeigt, dass mehrere Cag-Proteine, darunter CagI und CagL, zu 
einer Wechselwirkung des Sekretionsapparats mit β1-Integrin-Rezeptoren beitragen, die 
die Translokation von CagA über die Wirtszellmembran ermöglicht. Die Funktionen 
dieser drei Proteine und ihre Wechselwirkungen untereinander bzw. mit anderen 
Proteinen des Sekretionsapparats sind hingegen bislang nicht untersucht. 
In dieser Arbeit wurde eine umfassende funktionelle Analyse der Proteine CagH, CagI 
und CagL mittels verschiedener genetischer Deletions- und 
Komplementationsstrategien durchgeführt, um ihre Rolle für das Cag-T4SS zu 
bestimmen. Es konnte gezeigt werden, dass CagH, CagI und CagL unabhängig 
voneinander für die Translokation des CagA-Proteins und für die Induktion von 
Interleukin-8 (IL-8) als Marker für die proinflammatorische Aktivität des T4SS benötigt 
werden. Obwohl die Gene für diese drei Proteine im gleichen Operon lokalisiert sind 
und teilweise überlappende Leserahmen aufweisen, konnte kein transkriptioneller 
Effekt von Gendeletionen auf stromabwärts liegende Gene nachgewiesen werden, es 
wurden jedoch stabilisierende Effekte auf Proteinebene gefunden. Weiterhin konnte 
durch Immunpräzipitation und Pulldown-Experimente gezeigt werden, dass CagH, CagI 
und CagL miteinander interagieren und in H. pylori einen Komplex bilden, dem 
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vermutlich eine wichtige Rolle bei der Funktionalität des T4SS zukommt. Mit 
verschiedenen biochemischen Methoden konnten wir zeigen, dass CagI und CagL in 
verschiedenen Kompartimenten in der Bakterienzelle vorliegen, unter anderem auf der 
Bakterienoberfläche. Ein wichtiger Schritt war der Nachweis funktioneller Domänen 
von CagH, CagI und CagL. Alle drei Proteine enthalten unter anderem ein konserviertes 
C-terminales Motiv, das zumindest für die Funktion von CagH und CagL, sowie für die 
Wechselwirkung zwischen allen drei Proteinen von Bedeutung ist. Schließlich konnten 
Hinweise auf den Einfluss eines weiteren cag-Gens, cagP, auf die Menge an CagL und 
vor allem CagI in der Bakterienzelle erbracht werden. Wir zeigen, dass eine Deletion 
des cagP-Gens oder der assoziierten nichtkodierenden RNA HPnc2630 keinen 
transkriptionellen Effekt auf die Expression von cagI hat, dass die Anwesenheit des 
CagP-Proteins jedoch für die volle Funktion des Cag-T4SS notwendig ist.  
Zusammengefasst belegen die Ergebnisse dieser Arbeit die bedeutende Rolle dieser 
Proteine und ihrer Wechselwirkung für die Aktivität des Cag-T4SS, und sie könnten ein 
wichtiger Schritt zum Verständnis der Assemblierung der Typ-IV-Sekretions-Pili sein. 
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1 INTRODUCTION	
1.1 Helicobacter	pylori		
1.1.1 Bacteriology	
Helicobacter pylori (H. pylori) was first discovered in the stomachs of patients with 
gastritis and stomach ulcers in 1982 [Marshall and Warren, 1984]. It was originally 
named Campylobacter pyloridis and later was renamed as the first species of a new 
genus as H. pylori. It is a microaerophilic, Gram-negative bacterium with a curved rod 
shape (3.5 µm in length and 0.5 µm in width) [Goodwin and Worsley, 1993]. H. pylori 
is a highly motile bacterium and carries multiple unipolar flagella, usually 2-6 per 
bacterium. Each flagellum is approximately 3 µm in length. The motility facilitates 
rapid migration of H. pylori through the gastric mucus environment [O'Toole et al., 
2000]. The bacteria are able to transform their normal morphology to a coccoid 
morphology with a diversity in viability and ultrastructure in response to different stress 
conditions. These coccoid forms were observed to have metabolic activities, but are  
non-culturable in vitro [Bode et al., 1993; Mizoguchi et al., 1998]. The precoccoid 
forms were observed by negative staining to carry flagella filaments on a single pole 
and coccoid forms are usually devoid of flagella [Worku et al., 1999]. In contrast, some 
coccoid forms are eletron-dense with intact membrane and flagella [Zheng et al., 1999].  
H. pylori requires a nutrient-rich medium containing serum or cholesterol, and a 
microaerobic environment for growth. Generally, under optimal conditions and on a 
nonselective solid medium, small colonies are formed after 2 to 3 days [Morgan et al., 
1987]. The optimal growth conditions comprise O2 levels of 2 to 5% and additionally 
CO2 levels of 5 to 10%, as well as a high humidity. A standard microaerobic condition 
of 85% N2, 10% CO2, and 5% O2 is commonly used for H. pylori culture. Growth 
occurs at 34 to 40°C, with an optimum of 37°C and at pH values ranging from 5.5 to 8.0 
(reviewed in [Kusters et al., 2006]). 
1.1.2 Epidemiology	
Infection with H. pylori is one of the most common chronic bacterial infection of 
humans. The prevalence of H. pylori shows large geographical variations. H. pylori 
infection is more frequent in developing countries than in developed countries 
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(reviewed in [Pounder and Ng, 1995]). A recent review revealed a widely varying 
prevalence of H. pylori infection within populations of all ages, ranging from 31.7 to 
93.6% in adults, and from 11 to 66.2% in children [Eusebi et al., 2014]. Typically, 
acquisition of the bacteria happens early during childhood (reviewed in [Yucel, 2014]) 
and infection persists through life and leads to chronic gastric infection [Portal-Celhay 
and Perez-Perez, 2006]. Although more than 50% of the world population harbor H. 
pylori in their stomachs, most cases remain asymptomatic throughout life, with no 
specific clinical signs. The risk of being infected with H. pylori is associated with 
different factors such as socioeconomic status and living conditions. Persons of higher 
socioeconomic status, higher family income, and higher educational levels seem to have 
a lower risk of acquiring H. pylori infection (reviewed in [Eusebi et al., 2014]). The 
exact route of H. pylori transmission remains unclear. The most likely mode of 
transmission is from person to person via fecal/oral or oral/oral contacts (reviewed in 
[Yucel, 2014]). H. pylori infection can be effectively cured by a proton pump inhibitor 
(PPI)-based triple therapy, including antibiotics such as clarithromycin, amoxicillin or 
metronidazole, and proton pump inhibitors such as pantoprazole. However, the 
increasing prevalence of regional antimicrobial resistance raised a challenge in H. pylori 
eradication treatment [Egan et al., 2007; Egan and O'Morain, 2007]. 
1.1.3 Infection	process	
Originally, H. pylori was observed in the stomach of patients with gastritis and peptic 
ulcers [Marshall and Warren, 1984]. Additionally, it was later found to be involved in 
the development of gastric adenocarcinoma and MALT lymphoma (mucosa-associated 
lymphoid tissue) [Blaser et al., 1995; Parsonnet et al., 1991; Parsonnet et al., 1994]. In 
1994, H. pylori was classified as a type 1 carcinogen for gastric cancer by the 
International Agency for Research on Cancer (WHO) [Parkin et al., 2005]. 
H. pylori is able to colonize the host stomach with the contribution of colonization 
factors and virulence factors (reviewed in [Dunn et al., 1997]). Motility using the 
flagella and urease activity, which is required for neutralizing the microenvironment 
within the gastric lumen with pH values of 2 are important factors for a successful 
adaptation and colonization of the human gastric mucosa [Eaton et al., 1991; Eaton et 
al., 1992]. Once it reaches the mucus layer which is overlying the epithelial cells, H. 
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pylori induces gastric inflammatory responses and increases the secretion of interleukin 
(IL)-8 and other chemokines in gastric epithelial cells, which play a critical role for the 
survival of H. pylori [Censini et al., 1996; Crabtree and Farmery, 1995; Huang et al., 
1995; Sharma et al., 1995]. The ability of producing urease, catalase, phospholipases 
and further virulence factors (section 1.2) causes disruption of the gastric mucosal layer 
and damage of epithelial cells [Dunn et al., 1997; Mauch et al., 1993; Ottlecz et al., 
1993; Penta et al., 2005]. For a long-term persistence of infection in the stomach, the 
tight adherence of H. pylori to gastric epithelial cells plays an important role, which is 
maintained by interaction between adhesins embedded in the bacterial outer membrane, 
such as BabA, SabA, AlpA, AlpB, OipA, HopZ and HomB, and gastric epithelium 
receptors (reviewed in [Oleastro and Menard, 2013]). In addition, H. pylori is able to 
produce and efficiently deliver virulence factors, such as the vacuolating cytotoxin 
VacA and the cytotoxin-associated antigen CagA, which exert multiple effects on host 
cells [Salama et al., 2013].  
1.2 Virulence	factors	of	H.	pylori	and	interaction	with	host	cells		
1.2.1 Outer	membrane	proteins	(OMPs)	
To maintain a persistent colonization through lifetime, H. pylori uses its ability to 
adhere to mucosal structures, like many other pathogens do. H. pylori is not only 
localized at the apical surface of gastric epithelial cells, but also within the surface 
mucous gel layer [Shimizu et al., 1996]. Once inside the mucus, H. pylori penetrates the 
mucus layer using its spiral shape and flagellar motility, to reach the surface of 
epithelial cells and to adhere through interactions between outer membrane protein 
adhesins and different host receptors (reviewed in [Evans and Evans, 2000]). H. pylori 
adhesion to gastric epithelial cells is a crucial step in establishment of a long-term 
infection of the gastric mucosa. A variety of outer membrane proteins that serve as 
bacterial adhesins have been characterized (reviewed in [Oleastro and Menard, 2013]).  
The blood group antigen-binding adhesin BabA (HopS or OMP28) is a major H. pylori 
adhesin of about 80 kDa. BabA recognizes Lewis b blood-group antigen and other 
fucosylated blood-group antigens such as the H-type 1 and the A and B blood group 
antigens, which are found on mucin proteins and on the surface of the gastric epithelium 
[Aspholm-Hurtig et al., 2004; Boren et al., 1993; Ilver et al., 1998]. The BabA adhesin 
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also mediates binding of H. pylori to salivary mucin glycoprotein found in saliva and 
the non-mucin glycoprotein gp340 [Walz et al., 2005; Walz et al., 2009]. The presence 
of babA is typically associated with cagA and vacA toxigenic s1 strains [Fujimoto et al., 
2007], suggesting a crucial role of BabA in H. pylori pathogenesis. 
SabA (SabA or HopP or OMP17) is a sialic acid-binding adhesin with a size of 70 kDa. 
It is known to adhere to sialyl-Lewis a and sialyl-Lewis x glycoprotein serving as 
additional functional receptors to promote binding of H. pylori to inflamed gastric 
mucosa [Mahdavi et al., 2002]. Although there was no correlation between the sabA 
status and the severity of disease, a widely divergent prevalence of SabA in clinical 
isolates suggests differences between SabA and clinical outcome [Yamaoka, 2010].  
The adherence-associated lipoproteins AlpA (HopC or OMP20) and AlpB (HopB or 
OMP21) are 56 kDa and 57 kDa proteins, respectively. AlpA and AlpB proteins seem to 
be produced by all clinical isolates, suggesting their important role for H. pylori 
[Odenbreit et al., 2009]. Both lipoproteins were found to contribute to gastric 
colonization (reviewed in [Oleastro and Menard, 2013]). However, host receptors for 
both adhesins have not been identified. Recently, laminin, an extracellular matrix 
protein which is found in nearly every tissue, was demonstrated as a target for these two 
adhesins [Senkovich et al., 2011].  
The outer inflammatory protein A (OipA, HopH or OMP13) with a size of 34 kDa was 
initially reported as a surface protein capable of inducing IL-8 expression in a T4SS-
independent manner [Yamaoka et al., 2000]. Expression analysis of the oipA gene 
showed a significant correlation of OipA with high H pylori density, with severe 
neutrophil infiltration, and with development of duodenal ulcers and gastric cancer, 
[Yamaoka, 2010]. In addition, OipA influences the adherence capacity of H. pylori to 
the gastric cancer cell lines AGS and Kato-III [Dossumbekova et al., 2006]. 
Further putative adhesins, HopZ [Peck et al., 1999] and HomB [Oleastro et al., 2008] 
have been identified. 
1.2.2 Vacuolating	cytotoxin	A	
The vacuolating cytotxin A (VacA), an immunogenic 95-kDa protein, is the most 
intensely investigated toxin secreted by H. pylori. The vacA gene is present in all strains 
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of H. pylori but about 50% of clinical isolates produce inactive or less active VacA 
toxins due to the different genotypes of the vacA gene. Based on diversity near the 5' 
end of the vacA gene (s-region) and in the mid-region of the gene (m-region). Different 
genotypes of vacA, generated from combination of different alleles (s1m1, s1m2 and 
s2m2), have been observed and correlated with different H. pylori-associated diseases. 
Strains containing vacA s1m1 have higher levels of cytotoxic activities in a wider range 
of cell types than strains vacA s1/m2, whereas strains harboring vacA s2 have cytotoxic 
activities for some cells only (reviewed in [Cover and Blanke, 2005]). The VacA 
protein encoded by the s1/m1 genotype is known to be correlated with the development 
of peptic ulcer disease and gastric cancer (reviewed in [Kusters et al., 2006]). The vacA 
gene encodes for a 140 kDa precursor toxin, which contains an N-terminal signal 
sequence, a passenger domain and a C-terminal auto-transporter domain. This pretoxin 
undergoes proteolytic cleavage to release the mature 88 kDa toxin during transport to 
the extracellular space via an autotransporter (Type Va) pathway [Cover and Blanke, 
2005; Fischer et al., 2001a; Schmitt and Haas, 1994; Telford et al., 1994]. The secreted 
88 kDa monomers assemble into large water-soluble polymeric complexes with a 
molecular mass of about 900 kDa that insert into the host cell membrane to form anion-
selective channels which are important for VacA cytotoxicity [Cover and Blanke, 2005; 
McClain et al., 2013; Papini et al., 2001]. VacA induces vacuole formation in the 
cytoplasm of gastric cells [de Bernard et al., 1997]. In addition, VacA exerts a wide 
range of activities on host cells such as disruption of endosomal and lysosomal 
trafficking, triggering of apoptosis, and modulation of inflammatory responses 
(reviewed in [Cover and Blanke, 2005]). For these activities, VacA is able to intoxicate 
multiple types of human cells including gastric epithelial cells, and VacA alters the 
function of T lymphocytes, B cells, macrophages, and mast cells as well [Algood and 
Cover, 2006]. With respect to lymphocytes, VacA might contribute to pathogenesis by 
suppressing T-cell proliferation [Boncristiano et al., 2003; Gebert et al., 2003; Sundrud 
et al., 2004] at the level of the Ca2+-calmodulin-dependent phosphatase calcineurin 
[Gebert et al., 2003]. In vivo, VacA was found to be associated in initial host 
colonization of H. pylori [Salama et al., 2001]. 
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1.2.3 The	Cytotoxin-associated	antigen	and	the	cag pathogenicity	island	
The gene product of the Cytotoxin-Associated Gene (cagA) (120 to 145 kDa) is one of 
the most well-studied H. pylori virulence proteins. The CagA protein was demonstrated 
as a cancer-associated factor, since the gene is frequently found in H. pylori strains 
isolated from cancer patients, but less frequent from asymptomatic cases or patients 
with mild gastritis [Cover et al., 1995]. In other studies, CagA production was 
associated with the development of atrophic gastritis, peptic ulcer disease and gastric 
carcinoma [Blaser et al., 1995; Parsonnet et al., 1997]. H. pylori producing active VacA 
(s1/i1/m1) and CagA proteins are classified as Type I strains, while Type II strains lack 
expression of these 2 proteins [Xiang et al., 1995]. The CagA effector protein is 
delivered directly into host cells underneath the attachment site via the Cag-T4SS 
[Odenbreit et al., 2000]. The Cag-T4SS is responsible for transporting the CagA 
virulence protein into gastric epithelial cells [Hatakeyama and Higashi, 2005]. CagA is 
the only known effector protein, which is transported by the Cag system to date. 
Immunogold-staining revealed that CagA is located at the tip of T4SS pili [Jimenez-
Soto et al., 2009; Kwok et al., 2007] or on the bacterial surface [Murata-Kamiya et al., 
2010]. Following the translocation event, the CagA molecules localize to the inner 
surface of the plasma membrane [Higashi et al., 2005]. 
Recently, structural studies showed that CagA consists of a structured N-terminal region 
and an intrinsically disordered C-terminal region. The N-terminal region contains three 
distinct domains: an alpha-helical N-terminal domain (Domain I), a more complex 
phosphatidylserine binding domain (Domain II), and Domain III interacting 
intramolecularly with the disordered C-terminal region [Hayashi et al., 2012]. The core 
domain (Domain II) is formed by an extended single-layer β-sheet which is stabilized 
by two independent helical subdomains. The specific single-layer β-sheet region (SLB) 
was determined as a binding domain of CagA to β1 integrin. This interaction is 
critically involved in the delivery of CagA into host cells [Kaplan-Turkoz et al., 2012]. 
The cag pathogenicity island (cag-PAI) found in H. pylori Type 1 strains is a 37 kbp 
genome island. This DNA region was acquired during the evolution of H. pylori 
[Akopyants et al., 1998; Censini et al., 1996]. The cag-PAI is well-characterized and is 
harbored by approximately 60-70% of Western H. pylori strains, while nearly 100% of 
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the East Asian H. pylori strains are cag-PAI-positive (reviewed in [Noto and Peek, 
2012]). The H. pylori cag-PAI-bearing strains (cag+) are found to be adjacent and 
frequently adherent to epithelial cells while H. pylori cag-PAI-negative (cag-) 
predominate in the mucus gel, suggesting that the topology of colonization is influenced 
by the cag genotype [Camorlinga-Ponce et al., 2004]. The cag-PAI contains ~30 
putative open reading frames encoding multiple structural components of the type IV 
secretion apparatus, as well as the immunodominant antigen CagA. The cagA gene is 
localized to the end of the island (reviewed in [Hatakeyama and Higashi, 2005]). 
1.2.4 Integrins	as	host	cell	receptors	
Integrins belong to a large family of a αβ heterodimeric cell surface receptors found in 
multiple cellular organisms, from sponges to mammals [Humphries, 2000; Kim et al., 
2011]. These receptors are known to mediate cell-cell, cell-extracellular matrix and cell-
pathogen interactions. 
Integrins consist of two distinct subunits (α and β) forming heterodimers. These α and β 
subunits assemble into a head segment built on top of two V-shaped legs [Campbell and 
Humphries, 2011]. In mammals, integrins form 24 different receptors assembled from 
18 α subunits and 8 β subunits [Barczyk et al., 2010; Hynes, 2002]. 
Each subunit of the integrin αβ heterodimers consists of a large extracellular domain, a 
single-spanning transmembrane domain, and a short cytoplasmic tail. The extracellular 
part of the α and β subunits contains several subdomains organized into a globular 
ligand-binding-terminal head domain standing on two C-terminal legs, that connect to 
the transmembrane and cytoplasmic domain of each subunit. The transmembrane 
domains are single spanning structures (25-29 amino acid residues) forming α-helical 
coiled-coils that either homo- or heterodimerize. The cytoplasmic domains (10-70 
amino acids) are generally short and unstructured (reviewed in [Takada et al., 2007]). 
Structural and functional studies revealed that integrins can exist in different affinity 
states: low, intermediate and high [Luo et al., 2007]. Additionally, analysis of crystal 
structures showed that integrin heterodimers occur in the low affinity state (inactive 
form) as a bent V-shape with the head close to the membrane-proximal regions of the 
legs [Xiong et al., 2001; Xiong et al., 2002], maintained by the α/β salt bridges at the 
inner membrane region and the helix packing of the transmembrane regions [Partridge 
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et al., 2005]. This low affinity structure undergoes rapid, reversible conformational 
changes to increase ligand affinity, termed "activation", to release an active form. 
(reviewed in [Banno and Ginsberg, 2008; Calderwood, 2004; Shimaoka et al., 2002]).  
It has been shown that the translocation of CagA requires a cellular host cell receptor, 
the β1 integrin [Jimenez-Soto et al., 2009; Kwok et al., 2007]. Several Cag components 
have been demonstrated to bind to integrin, including CagA, CagI, CagY [Jimenez-Soto 
et al., 2009] and CagL [Kwok et al., 2007]. The binding of these proteins to β1 integrin 
(extended, open conformation) was assumed to induce conformational changes of 
integrin heterodimers, which may allow translocation of CagA into host cells. Apart 
from α5β1, the αvβ5 and αvβ3 integrins were shown to be putative interacting partners 
of CagL in an RGD motif-dependent manner [Conradi et al., 2012; Wiedemann et al., 
2012]. The interaction with αvβ5 activates gastrin expression via an integrin linked 
kinase (ILK) signaling complex [Wiedemann et al., 2012] 
1.2.5 Effects	of	CagA	and	the	Cag-T4SS	on	host	cells	
Upon injection, CagA undergoes phosphorylation on tyrosine residues found in a five 
amino acid repeat, Glu-Pro-Ile-Tyr-Ala (EPIYA) motif by multiple members of either 
Abl or Src family kinases. The repeats were subclassified into EPIYA-A, -B, -C and -D 
motfis, based on the surrounding amino acids. H. pylori isolates from Western countries 
carry the ‘A-B-C’-type CagA, whereas H. pylori strains from East-Asia CagA contain 
an ‘A-B-D’-type CagA (reviewed in [Hatakeyama and Higashi, 2005]). The most 
outstanding event in H. pylori infection of some epithelial cell lines such as AGS cells is 
the induction of a morphological change termed the humming-bird phenotype, a form of 
cell scattering [Backert et al., 2001], which is caused by interaction of phosphorylated 
CagA with the SHP2 (a cytoplasmic SRC homology domain-containing protein tyrosine 
phosphatase) [Jones et al., 2010]. SHP2 links growth factor signaling with the activation 
of ERK1/2, which are members of the mitogen-activated protein kinase family 
(MAPK). The activation of the ERK-MAPK pathway may lead to enhanced cell-cycle 
progression and increased cell proliferation [Hatakeyama, 2004; Higashi et al., 2002].  
CagA exerts several effects on host cells in a phosphorylation independent manner, such 
as changes in cellular tight junction integrity, cellular polarity, cell proliferation and 
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differentiation, cell scattering, or induction of a pro-inflammatory response (reviewed in 
[Jones et al., 2010]).  
The resulting chronic inflammation caused by infection with H. pylori is a major step in 
the initiation and development of gastric cancer. H. pylori utilizes a variety of pathways 
to promote inflammation in the stomach (reviewed in [Lamb and Chen, 2013]). 
Inflammatory molecules found to be upregulated in the stomachs of H. pylori-infected 
patients include IL-1, IL-6, IL-8, TNF-α, and RANTES [McGee and Mobley, 2000]. 
Considerable induction of IL-8 during gastric infection has a key role in the 
pathogenesis of H. pylori [Crabtree, 1996; Naumann and Crabtree, 2004]. IL-8, a 
leukocyte chemotactic cytokine (chemokine), is produced by different cell types upon 
stimulation by various inflammatory stimuli and exerts a variety of functions on 
leukocytes as well as on neutrophils in vitro (reviewed in [Lamb and Chen, 2013]). 
Several studies showed that the expression of IL-8 upon H. pylori infection is triggered 
by various signaling pathways in a CagA-dependent or -independent manner [Fischer et 
al., 2001b; Gorrell et al., 2012; Kim et al., 2006; Naito et al., 2006; Nozawa et al., 
2004; Selbach et al., 2002; Sharma et al., 1998; Zhang et al., 2006].  
The CagA-dependent pathway of IL-8 induction involves in activation of NF-κB 
(nuclear factor kappa B), AP-1 (essential transcriptional factors for IL-8 gene 
transcription), and NFAT (nuclear factor of activated T cells) [Backert and Naumann, 
2010]. Infection of Mongolian gerbils with the cagA deletion mutant led to a 
considerable reduction of NF-κB activation and  the level of inflammation compared to 
infection with wild-type strain [Shibata et al., 2006]. However, the ability of CagA to 
activate NF-κB and IL-8 production seems to be H. pylori strain-specific [Brandt et al., 
2005].  
In a CagA-independent manner, binding of the type IV secretion apparatus to host cells 
has been proposed to induce IL-8 production [Fischer et al., 2001b]. The Cag-T4SS 
triggers IL-8 secretion via interaction of the CagL protein which is surface exposed with 
the host receptor β1 integrin, and subsequent activation of MAPKs and NF- κB [Gorrell 
et al., 2012]. Several adhesion proteins such as OipA and BabA were also found to be 
important for IL-8 production [Sugimoto et al., 2011; Yamaoka et al., 2000]. In 
addition, peptidoglycan is another virulence factor, which might be delivered into host 
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cells via the Cag apparatus or outer membrane vesicles [Kaparakis et al., 2010]. 
Peptidoglycan is specifically recognized by a host intracellular sensor NOD1 (nuleotide 
oligomerization domain) [Boughan et al., 2006; Viala et al., 2004]. The activation of 
NOD1 triggers the proinflammatory cytokines MIP-2 (human IL-8 homolog), β-
defensin, and IL-8 production through induction of signaling molecules in host cells 
such as NF-κB, p38, and ERK [Allison et al., 2009; Viala et al., 2004]. Furthermore, the 
activated NOD1 regulates the production of type I interferon (IFN), which likely affects 
Th1 cell differentiation [Watanabe et al., 2010]. 
1.3 The	Cag	type	IV	secretion	system		
1.3.1 Functions	of	the	T4SSs	
The Type IV Secretion Systems (T4SSs) are multi-subunit cell-envelope-spanning 
structures of Gram-negative and Gram-positive bacteria. They are widely used for 
transport of a broad range of macromolecules, from single proteins to DNA-protein 
complexes across the cell [Alvarez-Martinez and Christie, 2009; Fronzes et al., 2009; 
Juhas et al., 2008]. These translocation systems usually consist of a secretion channel 
and often a pilus or other surface filament that might be used as a conduit for substrate 
transport or to establish contacts with target cells [Juhas et al., 2008]. There are 3 
subfamilies of the T4SSs that have been classified according to their functions: 
Conjugation systems: 
Conjugation systems are the most widely distributed of the T4SSs and found in a wide 
range of bacterial species [Alvarez-Martinez and Christie, 2009]. They are used to 
transfer DNA from one bacterial cell to another in a cell contact-dependent manner. 
These systems play major roles in the conjugative transfer of autonomously replicating 
plasmids and Integrative and conjugative elements (ICEs) in Gram (+) and Gram (-) 
bacteria [Smillie et al., 2010; Wozniak and Waldor, 2010]. These ICEs can be found to 
be integrated into the chromosome, often as parts of transposons. The conjugation event 
contributes to bacterial genome plasticity and facilitates adaptation of bacteria to 
changes in the environment. Conjugation is also involved in the spread of antibiotic 
resistance genes among pathogenic bacteria [Fronzes et al., 2009; Wallden et al., 2010].  
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DNA transport is generally initiated by a multiprotein complex called relaxosome. The 
enzyme relaxase, which acts as a site-specific endonuclease, nicks double-stranded 
DNA and covalently binds to the 5’ end of the resulting single-stranded DNA at the 
origin of transfer. This DNA-protein complex is subsequently specifically recognized 
by a type IV coupling protein (T4CP) for subsequent transfer via the T4SS (reviewed in 
[Zechner et al., 2012]).  
Agrobacterium tumefaciens (A. tumefaciens) VirB/D4 is a well-charaterized DNA 
transfer system which is similar to conjugation systems. A. tumefaciens uses this system 
for delivering transfer-DNA (T-DNA), a part of the tumor-inducing (Ti) plasmid as well 
as several virulence proteins to plant cells to cause formation of tumors [Christie, 2004].  
DNA release or uptake systems 
The second subfamily of the T4SSs consists of 2 transport systems involved in DNA 
uptake or release from/to the extracellular space: The ComB transformation competence 
system in H. pylori which is responsible for DNA uptake from the extracellular milieu 
and the DNA release system encoded on the Neisseria gonorrhoeae gonococcal genetic 
island (GGI) [Hamilton and Dillard, 2006; Hofreuter et al., 2001; Smeets and Kusters, 
2002]. 
Effector translocation systems 
Many Gram-negative bacteria, such as the phytopathogen A.tumefaciens and some 
human pathogens, including H. pylori, Legionella pneumophila, and Brucella and 
Bartonella species use T4SSs for delivery of effector protein molecules across the cell 
envelope and directly into the cytosol of plant or mammalian host cells [Cascales and 
Christie, 2003; Zechner et al., 2012]. These systems play important roles in bacterial 
colonization and survival within host cells or during infection [Alvarez-Martinez and 
Christie, 2009].  
1.3.2 Agrobacterium tumefaciens	 VirB/D4	 Type	 IV	 secretion	 system	 as	 a	
prototypical	T4SS	
A. tumefaciens is a phytopathogen, which causes crown gall disease in infected plant 
tissues. The VirB/D4 transport machinery of A. tumefaciens is a prototypical T4SS and 
has been thoroughly examined in terms of substrate recognition, translocation, assembly 
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mode and architecture, and the dynamics of substrate movement through the T4SS. The 
A. tumefaciens VirB/D4 T4SS mediates the transfer of not only nucleo-protein (T-DNA) 
complexes, but also a set of virulence effector proteins into the nuclei of plant cells. The 
12 proteins (VirB1-VirB11 and VirD4) required for DNA transport and tumor 
formation are encoded by the virB and virD operons, located on the Ti plasmid 
[Cascales and Christie, 2004; Christie, 1997]. The T4SS is likely to form a secretion 
channel, which traverses the entire cell envelope and translocates proteins or protein-
DNA complexes across 3 membranes directly to the cytosol of eukaryotic host cells 
(Figure 1.1). The VirB1 to VirB11 proteins are components of the secretion apparatus 
[Alvarez-Martinez and Christie, 2009], whereas VirD4 serves as a coupling protein, 
which recognizes the substrates (T-DNA and several independently translocated 
proteins) [Atmakuri et al., 2004; De Vos and Zambryski, 1989]. The inner membrane 
channel is comprised of 4 subunits: VirB3, VirB6, VirB8 and VirB10, of which VirB10 
spans the periplasmic space. The outer membrane pore (secretion channel) consists of 
VirB7 and VirB9. The VirB2 and VirB5 components do not only take part in the 
secretion channel, but also polymerize to form an extracellular pilus. The VirB4, 
VirB11 and VirD4 proteins are three ATPases which provide energy for substrate 
transfer and assembly of the system [Alvarez-Martinez and Christie, 2009; Fronzes et 
al., 2009; Wallden et al., 2010]. After translocation, the T-DNA moves to the plant cell 
nucleus where it integrates into the plant genomic DNA [Atmakuri et al., 2004; De Vos 
and Zambryski, 1989]. The known effector proteins include VirD2, VirE2, VirE3 and 
VirF. The ssDNA-binding protein VirE2 binds to the T-strand and thus protects it from 
degradation in host cells. Both VirD2 and VirE2 facilitate transport of the T-complex 
into the nuclei of the host. VirF and VirE3 are required for full tumor formation 
[Vergunst et al., 2003]. 
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Figure 1.1. Model of the VirB/VirD4 type IV secretion system (T4SS) machinery of Agrobaterium 
tumefaciens [Zechner et al., 2012] 
(B) Pilus-associated extracellular components, T4SS components (pore complex and energizers), T4SS 
components and T4SS substrates are presented in yellow, blue, pink and green, respectively. (B) A cutout 
of Type IV secretion core complex structure. 
1.3.3 Components	of	the	Cag-T4SS		
The complete cag-PAI is flanked by the same chromosomal genes and 31 bp repeats in 
all strains analyzed. However, the cag-PAI may be split into two regions originally 
termed cagI and cagII as a result of insertion of an IS605 sequence and an associated 
genome rearrangement [Akopyants et al., 1998; Censini et al., 1996]. However, 
comparative sequence analyses of cag islands among H. pylori strains suggested that 
this rearrangement is rare (reviewed in [Fischer, 2011]). Comparison of the complete 
cag-PAI sequences for 38 representative H. pylori isolates from various geographic 
populations showed that the content and the order of genes on the cag-PAI are mostly 
conserved [Olbermann et al., 2010]. Systematic studies of 27 putative genes on the cag-
PAI in H. pylori 26695 revealed that 17 genes are absolutely essential for CagA 
translocation into host cells and 14 genes are required for full IL-8 induction by 
epithelial cells [Fischer et al., 2001b] (Figure 1.2). 
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Figure 1.2. Features of CagH, CagI and CagL (Wolfgang Fischer, unpublished) 
Genetic organization of the cag pathogenicity island in strain 26695. Gene designations and putative 
homologies to components of the A. tumefaciens T-DNA transfer system are indicated. Each gene is 
shown as a thick arrow with the orientation of transcription. The length and spacing of each annotated 
gene are shown in proportion to gene and intergenic spacing. 
 
The Cag type IV secretion system is a multi-component transporter which is responsible 
for injection of CagA across the bacterial membranes into host epithelial cells [Backert 
and Selbach, 2008]. Although the Cag-T4SS is evolutionarily related to other T4SSs, 
there are only some cag-encoded proteins with high sequence similarities to 
components of other T4SSs [Francesco et al., 2011]. By comparison with the 
prototypical T4SS VirB/VirD4 machinery in A. tumefaciens, clear similarities were 
found only for CagE (to VirB4), CagX (to VirB9), CagY (to VirB10), Cagα (to VirB11) 
and Cagβ (to VirD4). Moreover, three VirB-like protein components have been 
identified by other features, such as CagC (topological similarity to VirB2), CagL 
(functional analogy to VirB5), and CagT (lipoprotein like VirB7), (reviewed in 
[Cendron and Zanotti, 2011]. Additionally, CagW (VirB6) and CagV (VirB8) were 
found to be topologically comparable and to show weak sequence similarities to the 
respective VirB proteins as well (reviewed in [Fischer, 2011]). 
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Based on systematic studies of isogenic mutants in each cag gene, the Cag proteins can 
be divided into 4 groups according to their functions (reviewed in [Fischer, 2011]). An 
overview of characteristics and functions of cag-encoded proteins is shown in Table 1.1. 
• Essential secretion apparatus components: These proteins are required for 
CagA translocation and IL-8 induction in AGS cells.  
• Supporting components: These cag gene products are not absolutely required 
for Cag-T4SS functionality, but result in a reduced efficiency of both 
phenotypes when absent. 
• Translocation factors include Cagβ, CagZ, CagF and possibly CagD [Cendron 
et al., 2009]. They are necessary components for CagA translocation, but not for 
IL-8 induction. 
• Non-essential components: These proteins are apparently not required for any 
effects on Cag-T4SS functionality. The exact function of these proteins is still 
unknown. 
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Table 1.1. Overview of characteristics and functions of cag-encoded proteins (modified after 
[Fischer, 2011]) 
Gene Protein VirB 
homologues 
(Putative) Functions IL-8 
requirement 
CagA 
translocation 
requirement 
hp0520 Cagζ/Cag1     
hp0521 Cagε/Cag2     
hp0522 Cagδ/Cag3  OM complex +  
hp0523 Cagγ/Cag4 VirB1 PG hydrolase +  
hp0524 Cagβ/Cag5 VirD4 Coupling protein  + 
hp0525 Cagα VirB11 ATPase +  
hp0526 CagZ  Cagβ stabilization  + 
hp0527 CagY VirB10 Core complex, integrin 
binding 
+  
hp0528 CagX VirB9 Core complex +  
hp0529 CagW VirB6 IM channel +  
hp0530 CagV VirB8 Core complex +  
hp0531 CagU  Core complex, OM 
lipoprotein 
+  
hp0532 CagT VirB7  +  
hp0534 CagS     
hp0535 CagQ     
hp0536 CagP     
hp0537 CagM  OM complex +  
hp0538 CagN     
hp0539 CagL VirB5 Integrin binding  + 
hp0540 CagI   +/- + 
hp0541 CagH   +  
hp0542 CagG    + 
hp0543 CagF  Secretion chaperone  + 
hp0544 CagE VirB3/4 ATPase +  
hp0545 CagD    + 
hp0546 CagC VirB2 Pilus subunit +  
hp0547 CagB     
hp0548 CagA  Effector protein   
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1.3.4 CagA	translocation	mechanism	
The translocation process requires both N-terminal and C-terminal regions of CagA 
[Hohlfeld et al., 2006]. As mentioned before, the N-terminal region was shown to bind 
to β1 integrin, and this binding plays a critical role in CagA translocation [Fischer, 
2011; Jimenez-Soto et al., 2009; Kaplan-Turkoz et al., 2012]. Apart from this 
interaction, CagA was shown to bind to phosphatidylserine present in the outer leaflet of 
the host cell cytoplasmic membrane, which might induce its uptake into the cells 
(Murata-Kamiya, 2010). The C-terminal 20 amino acids were also demonstrated to be 
critically important for CagA translocation [Hohlfeld et al., 2006]. Two functional 
motifs found in CagA, the EPIYA motifs, and a microtubule affinity-regulating kinase 
(MARK) inhibitor (MKI) motif, which is adjacent to the EPIYA motifs, are not 
necessary for CagA translocation [Fischer, 2011]. In the bacterial cytoplasm, CagA is 
recognized by several recognition factors such as CagF, CagZ and Cagβ, in which Cagβ 
and CagZ form a stable complex at the bacterial cytoplasmic membrane [Jurik et al., 
2010]. CagF acts as a chaperone-like protein which binds close to the carboxy-terminal 
secretion motif of CagA [Fischer, 2011]. Additionally, CagD was also found to be 
involved in CagA translocation. Since CagD was observed to be localized in the 
cytosolic fraction, in the inner membrane, as well as released into the supernatant during 
host cell infection, CagD was proposed to act as a multifunctional component involved 
in CagA translocation [Cendron et al., 2009; Smith et al., 2007].  
The observation of CagA at the tips of the pili suggests that CagA might be delivered 
through these surface structures [Kwok et al., 2007]. Likewise, the presence of CagA on 
the surface of bacteria [Murata-Kamiya et al., 2010] raised the question whether pilus- 
or surface-associated CagA represents a translocation intermediate. However, the strong 
binding of CagA to integrins argues against pilus tip CagA as a translocation 
intermediate [Jimenez-Soto et al., 2009]. The uptake process of CagA into the host cell 
cytoplasm is still poorly understood.  
1.3.5 Architecture	of	the	Cag	Type	IV	secretion	system		
Numerous studies have shown that the Cag-T4SS forms needle-like appendages (also 
called T4SS pili), which are induced by cell contact at the interface between bacteria 
and gastric epithelial cells [Jimenez-Soto et al., 2009; Johnson et al., 2014; Kwok et al., 
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2007; Shaffer et al., 2011] (Figure 1.3). However, these structures were also 
sporadically found on the surface of bacteria in the absence of cell contact [Kumar et 
al., 2013; Tanaka et al., 2003]. 
 
Figure 1.3. Pilus formation [Rohde et al., 2003] 
Pili were formed at the interface between H. pylori and host cell when co-cultured with AGS cells 
analyzed by SEM. 
 
Based on studies of function, localization and interaction of individual Cag protein 
components, different models of Cag-T4SS assembly which are similar to that of A. 
tumefaciens were proposed [Backert et al., 2011; Fischer, 2011; Kutter et al., 2008; 
Tegtmeyer et al., 2011; Terradot and Waksman, 2011]. According to these models the 
H. pylori Cag-T4SS consists of a cytoplasmic complex, a translocation channel and an 
external pilus [Fischer, 2011; Tegtmeyer et al., 2011; Terradot and Waksman, 2011] 
(Figure 1.3).  
The cytoplasmic complex: 
The cytoplasmic complex of the Cag apparatus is composed of three ATPases, CagE 
(VirB4), Cagα (VirB11) and possibly Cagβ (VirD4), all of which provide energy 
required for Cag apparatus assembly and/or for CagA transport [Terradot and 
Waksman, 2011]. Cagβ is a CagA translocation factor [Fischer, 2011] and probably acts 
as a coupling protein, which can bind and recruit CagA into the Cag apparatus [Jurik et 
al., 2010; Schroder et al., 2002]. The Cagα protein acts as an ATPase with an N-
terminal domain and a RecA-like C-terminal domain [Fronzes et al., 2009]. 
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Figure 1.4. Architechture of the H. pylori Cag-T4SS (modified after [Terradot and Waksman, 2011]) 
Proteins forming the cytoplasmic complex, translocation pore and external pilus are presented in blue, 
green and yeallow/orange, respectively. CagA is located at the tip of the pilus. Others components, which 
have been shown to take part in the Cag apparatus, are shown in pink and red. OM: Outer membrane, IM: 
inner membrane. 
 
The translocation pore: 
In the last decade, the structures of several conserved T4SS proteins or protein 
fragments, either alone (VirB8, VirB9 [Terradot et al., 2005]), or in complexes 
(VirB9:VirB7 [Bayliss et al., 2007]; VirB7-VirB9-VirB10 [Chandran et al., 2009; 
Fronzes et al., 2009], VirB3-VirB10 [Low et al., 2014]), have been published and 
provided also valuable information about the structure of the core complex of the Cag-
T4SS, which spans the inner membrane and the outer membrane. In an earlier study 
[Busler et al., 2006], the core complex was proposed to be composed of CagT (VirB7), 
CagV (VirB8), CagX (VirB9) and CagY (VirB10). These Cag proteins were found to 
interact with each other by Yeast Two Hybrid (YTH) and other protein-protein 
interaction studies. Apart from the interactions with each other, these four proteins also 
showed interactions with other Cag proteins such as Cagδ, CagM, CagI, CagG and 
CagF, which are not homologous to components of other T4SSs or to any known 
bacterial proteins [Busler et al., 2006]. However, the data obtained from stabilizing 
effects, protein-protein interaction and localization studies strongly suggested that the 
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core complex consists of Cagδ, CagX, CagT and CagM at the outer membrane, and of 
CagY, CagV, CagW, CagU, and possibly others, at the inner membrane [Kutter et al., 
2008; Pinto-Santini and Salama, 2005]. 
The external pilus 
The CagC [Akopyants et al., 1998; Kalkum et al., 2002; Kutter et al., 2008], and CagL 
proteins [Kwok et al., 2007] (VirB2 and VirB5-like, respectively) are considered as 
pilus-associated components. Additionally, pili may also contain the CagY, CagX and 
CagT proteins, as detected by immunogold-labelling studies [Rohde et al., 2003; 
Tanaka et al., 2003]. The surface protein CagC [Akopyants et al., 1998] was proposed 
as a VirB2 homologue based on weak sequence similarities, however there is no direct 
evidence for the localization of CagC on the pili [Andrzejewska et al., 2006; Rohde et 
al., 2003]. Recently, a study to identify cag genes that are required for pilus formation 
showed that cagT, cagX, cagV, cagM or cagδ deletion caused a defect in pilus 
formation. In contrast, the cagY and cagC mutants were defective in T4SS function but 
not pilus formation [Johnson et al., 2014], arguing against a role of CagC as a major 
pilin subunit.  
1.3.6 The	CagH,	CagI	and	CagL	proteins:	Unique	components	of	the	Cag-T4SS	 
A systematic mutagenesis study clearly demonstrated that cagH and cagL genes are 
essential for translocation of CagA and IL-8 induction. In the same study, the cagI gene 
was reported to be required for CagA translocation, but not for IL-8 induction into host 
cells [Fischer et al., 2001b]. However, two other publications reported conflicting 
results, showing the involvement of CagI in IL-8 secretion as well [Censini et al., 1996; 
Selbach et al., 2002].  
The CagH and the CagI proteins had not been studied in detail so far. The prediction 
analysis of CagH and CagI showed that CagI (39 kDa) is a secretory protein as a result 
of a N-terminal signal sequence [Kutter et al., 2008]. In contrast, CagH (41.5 kDa) is 
rather anchored in the inner membrane via a N-terminal hydrophobic helix. It had been 
suggested that CagI may not be a component of the Cag-T4SS but rather a putative 
effector protein [Kutter et al., 2008]. Interestingly, CagI, like the CagA, CagY and 
CagL proteins has been shown to bind to β1 integrin by the YTH assay, suggesting a 
surface-exposed localization of CagI [Jimenez-Soto et al., 2009]. Bacterial interaction 
Introduction 
21 
 
partners of CagI have been investigated in a YTH assay and pull-down assays, 
indicating that CagI might interact with CagZ and CagG. Besides, an interaction 
between CagI and Cagβ was observed as well, but it was rather weak [Busler et al., 
2006]. 
Unlike CagH and CagI, CagL has been studied more in detail recently. CagL (26 kDa) 
is a VirB5-like protein with an N-terminal, Sec-dependent signal sequence [Kutter et 
al., 2008]. It is considered as a pilus associated component [Jimenez-Soto et al., 2009; 
Kwok et al., 2007] and a ligand binding to several integrin heterodimers, such as α5β1, 
αvβ5 and αvβ3 integrins, in an RGD (arginine-glycine-aspartate) motif-dependent 
manner [Conradi et al., 2012; Jimenez-Soto et al., 2009; Kwok et al., 2007; Wiedemann 
et al., 2012]. This motif, that was proposed as a common integrin binding motif [Kwok 
et al., 2007; Takada et al., 2007], is atypically located within a long alpha helix (Barden 
2013). There are conflicting results concerning the importance of this RGD motif for 
T4SS functionality in vitro. In one study, the RGD motif was shown to be critical for 
integrin β1 binding [Kwok et al., 2007]. In another study, however, the mutation of the 
CagL RGD motif caused no effect on Cag-T4SS functionality [Jimenez-Soto et al., 
2009]. Localization of CagL has been investigated using different techniques. By the 
total membrane fractionation method, CagL was detected in the soluble fraction [Kutter 
et al., 2008]. Immunofluoresence staining suggested the presence of CagL on the T4SS 
pili [Kwok et al., 2007] as well as on the surface of bacteria after cell contact 
[Tegtmeyer et al., 2010]. 
1.4 Aim	of	this	thesis	
H pylori causes multiple alterations in gastric epithelial cells through processes which 
are dependent on the activity of the Cag-T4SS, and particularly on translocation of the 
only known effector CagA protein. Although much research interest worldwide focused 
on the CagA translocation mechanism, it remains until now unclear how the Cag-T4SS 
assembles to translocate CagA across the bacterial membrane, and how CagA is taken 
up into the host cell cytoplasm. To better understand the mechanism of action of this 
important virulence factor, characterization of the function of each cag-encoded protein, 
and the relationships between them during Cag-T4SS assembly and CagA translocation, 
is required. 
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The aim of this work was to focus on three essential, but unique, components of the 
Cag-T4SS, CagH, CagI and CagL. One major aim of this thesis was to clarify the 
individual importance of the CagH, CagI and CagL proteins for Cag-T4SS 
functionality. Another aim was to identify and characterize interaction partners of these 
proteins, and possibly the functional role of these interactions. Possible functional 
domains of these proteins for secretion system activity, or for protein interactions, were 
planned to be characterized. Furthermore, the localization of these proteins in H. pylori 
should be characterized in order to gain more insight into the assembly mechanism of 
the Cag-T4SS. Finally, the influence of a small regulatory RNA that has been identified 
within the cag-PAI, on the functionality of the T4SS was intended to be analyzed. 
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2 MATERIALS	AND	METHODS	
 Materials	2.1
2.1.1 Bacterial	strains	
2.1.1.1  Helicobacter pylori	 
Table 2.1. List of Helicobacter pylori (H. pylori) strains used in this study 
Name Genotype, Description and Reference 
P12 Klinisches Isolat (888-0) der Abteilung ‘‘Medizinische 
Mikrobiologie und Immunologie‘‘der Universität Hamburg [Schmitt 
and Haas, 1994] 
P12 strep P12 transformed with NCTC 11637 (strepR) 
PT-H005 (P12∆cagIL)  cagI and cagL deletion mutant (double mutant), P12 transformed 
with pPT2 (catR) [this work] 
PT-H009 (P12∆cagIL/L) cagI and cagL deletion mutant complemented cagL, PT-H005 
transformed with pWS255 (kanR) [this work] 
PT-H011 (P12∆cagIL/I) cagI and cagL deletion mutant complemented cagI, PT-H005 
transformed with pWS322 (kanR) [this work] 
PT-H012 (P12/∆cagIL/IL(pPT3)) cagI and cagL deletion mutant complemented cagI and cagL, PT-
H005 transformed with pPT3 (catR) [this work] 
PT-H014 (P12∆cagIL/IMycL) cagI and cagL deletion mutant complemented cagI and cagL (N- 
terminal Myc tagged-CagI), PT-H005 transformed with pPT4 (catR) 
[this work] 
PT-H023 (P12cagPM45)  cagP replaced by C-terminal M45 tagged-CagP, P12 transformed 
with pPT7 (catR) [this work]  
PT-H030 (P12/∆cagP/cagPM45) cagP deletion mutant complemented cagP (C-terminal M45 tagged-
CagP), WSP543 transformed with pPT20 (kanR) [this work] 
PT-H047 (P12/∆cagIL/IL(pPT9) 
or P12/∆cagIL/IL∆C) 
cagI and cagL deletion mutant complemented cagI and cagL 
(CagL∆C), PT-H005 transformed with pPT9 (kanR) [this work] 
PT-H054 
(P12/∆cagIL/IL(pPT10)) 
cagI and cagL deletion mutant complemented cagI and cagL 
(CagL∆C+CC), PT-H005 transformed with pPT10 (kanR) [this work] 
PT-H058 
(P12∆cagIL/I∆CL(pPT11)) 
cagI and cagL deletion mutant complemented cagI and cagL 
(CagI∆C), PT-H005 transformed with pPT11 (kanR) [this work] 
PT-H061 
(P12∆cagIL/I∆CL(pPT12)) 
cagI and cagL deletion mutant complemented cagI and cagL 
(CagI∆C+CC), PT-H005 transformed with pPT12 (kanR) [this work] 
PT-H084 
(P12∆cagIL/I∆CL(pPT13)) 
cagI and cagL deletion mutant complemented cagI and cagL (C-
terminus deletion CagI), PT-H005 transformed with pPT13 (kanR) 
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[this work] 
PT-H093 (P12∆cagH/H) cagH deletion mutant complemented cagH, WSP696 transformed 
with gene bank plasmid HP2kb05G17 (ermS, strepR) (in cis) [this 
work] 
PT-H095 (P12∆cagIL/ILC128S) cagI and cagL deletion mutant complemented cagI and cagL (CagL 
C128S), PT-H005 transformed with pPT24 (kanR) [this work] 
PT-H109 (P12∆cagIL/ILD132A) cagI and cagL deletion mutant complemented cagI and cagL (CagL 
D132A), PT-H005 transformed with pPT25 (kanR) [this work] 
PT-H101 (P12∆cagH/HD265A) cagH deletion mutant complemented cagH (CagHD265A), WSP696 
transformed with pPT28 (ermS, strepR) [this work] 
PT-H099 (P12∆cagH/HC265S) cagH deletion mutant complemented cagH (CagHC265S), WSP696 
transformed with pPT29 (ermS, strepR) [this work] 
PT-H110 (P12∆cagIL/IL∆CPISD) cagI and cagL deletion mutant complemented cagI and cagL (CagL 
∆CPISD), PT-H005 transformed with pPT32 (kanR) [this work] 
PT-H112 (P12∆cagH/H∆CPIGD) cagH deletion mutant complemented cagH (CagH∆CPIGD), WSP696 
transformed with pPT33 (ermS, strepR) [this work] 
WSP128 (P12∆PAI) cag-PAI deletion mutant, P12 transformed with pJP46 (kanR) 
(Wolfgang Fischer) [Fischer et al., 2001b] 
WSP498 (P12∆cagL) cagL deletion mutant, P12 transformed with pWS290 (catR) 
(Wolfgang Fischer) [this work] 
WSP500 (P12/∆cagL/L) cagL deletion mutant complemented cagL, WSP498 transformed 
with pWS255 (kanR) (Wolfgang Fischer) [Jimenez-Soto et al., 2009] 
WSP543 (P12∆cagP) cagP deletion mutant, P12 transformed with pWS316 (catR) 
(Wolfgang Fischer) [this work] 
WSP597 (P12∆cagI/I(320)) 5’ cagI deletion mutant, P12 StrepR transformed with pWS320 (ermR) 
(Wolfgang Fischer) [this work] 
WSP629 (P12∆cagI (320/326)) 5’ cagI deletion mutant, marker-free, WS597 transformed with 
pWS326 (strepR) (Wolfgang Fischer) [this work] 
WSP639 (P12∆cagI/I(320//322)) 5’ cagI deletion mutant (marker-free) complemented cagI, WS629 
transformed with pWS322 (kanR) (Wolfgang Fischer) [this work] 
WSP644 
(P12P12∆cagI/I(320/326/322)) 
5’ cagI deletion mutant complemented cagI, WS597 transformed 
with pWS322 (kanR) (Wolfgang Fischer) [this work] 
WSP645 (P12∆cagI/I(320/327)) cagI deletion mutant, marker-free, WS597 transformed with pWS327 
(kanR) (Wolfgang Fischer) [this work] 
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WSP692 (P12∆sRNA) sRNA deletion mutant, P12 transformed with pWS426 (catR) 
(Wolfgang Fischer) [this work] 
WSP696 (P12∆cagH) cagH deletion mutant, P12 StrepR transformed with pWS423 (ermR) 
(Wolfgang Fischer) [this work] 
WSP717 (P12∆cagP+sRNA) cagP and sRNA deletion mutant, P12 transformed with pWS433 
(catR) (Wolfgang Fischer) [this work] 
WSP736 (P12∆cagP/P+sRNA) cagP mutant complemented cagP and sRNA, WSP543 transformed 
with pWS338 (kanR) (Wolfgang Fischer) [this work] 
WSP912  
(P12∆cagH/H (pWS534)) 
cagH mutant complemented cagH WSP696 transformed with 
pWS534 (in trans) (Wolfgang Fischer) [this work] 
C: C-terminal motif coding DNA 
sequence 
CC: coiled-coil structure coding 
DNA sequence  
 
2.1.1.2 Escherichia coli 
Table 2.2. List of Escherichia coli (E. coli) strains used in this study 
Name Genotype and Reference 
TOP10 F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacO74 recA1 ara∆139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG (Invitrogen, Karlsruhe) 
DH5α F-Φ80d lacZ ∆M15 ∆(lacZYA-argF) U169 deoR recA1 endA1 hsdR17 (rK-, 
mK+) phoA supE44 λ- thi-l gyr A96 relA1 (Invitrogen, Karlsruhe) 
BL21(DE3)  Genotype: F-, ompT, hsdS(r-B, m-B), gal, dcm, _DE3 (lacI, lacUV5-T7 gene 1, 
ind1, sam7, nin5) 
This E. coli strain was used for the overexpression of the GST- and MBP- fusion 
proteins 
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2.1.3 Broth	and	culture	media	
Table 2.3. List of broth and culture media used in this study 
Culture media 
and nutrients 
Production and Source 
LB liquid medium  20 g/l Lennox medium (Gibco/Invitrogen, Carlsbad, USA), autoclaved  
LB-plates  32 g/l Lennox-L-Agar (Gibco/Invitrogen, Carlsbad, USA), autoclaved  
SOC Medium 20 g/l tryptone, 5 g/l yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 
mM MgSO4, 20 mM glucose (Invitrogen, Carlsbad, USA), autoclaved 
Brucella-Broth 
(BB)  
28 g/l Brucella Broth (Falcon BD, Franklin Lakes, USA), autoclaved  
Serum plates  36 g/l GC-Agar-Base (Oxoid, Darmstadt, Germany), autoclaved and subsequently 
added 10 ml/l Vitamin-Mix, 80 ml/l Horse serum, 5 mg/l Trimethoprin, 1 mg/l 
Nystatin  
Cholesterol plates 36 g/l GC-Agar-Base (Oxoid, Darmstadt, Germany), autoclaved and subsequently 
added 0,4% cholesterol, 10mg/l Vitamin-Mix, 5 mg/l Trimethoprin, 1 mg/l 
Nystatin 
Vitamin mix  100 g/l α-D-Glucose, 10 g/l L-Glutamin, 26 g/l L-Cystein, 0.1 g/l Cocarboxylase, 
20 mg/l Fe(III)-Nitrate, 333 mg/l Thiamine, 13 mg/l p-aminobenzoic acid, 0.25 g/l 
Nicotinamidadeninindinucleotid (NAD), 10 mg/l Vitamin B12, 1.1 g/l L-Cystine, 1 
g/l Adenine, 30 mg/l Guanine, 0.15 g/l L-Arginine, 0.5 g/l Uracil  
2.1.4 Cell	lines	
AGS (Human Adenogastric carcinoma cell line (ATCC CRL-1739)) 
2.1.5 Inhibitors	and	media	supplements	
Table 2.4. List of inhibitors and media supplements used in this study 
Media supplements Solvents Concentrations 
Ampicillin (Amp) 
(Sigma-Aldrich, St. Louis, USA)  
Water 100 µg/ml 
Chloramphenicol (Cat)  
(Merck, Darmstadt, Germany)  
Ethanol 30 µg/ml (E. coli) 
6 µg/ml (H. pylori) 
Erythromycin (Erm) Ethanol 250 µg/ml (E. coli) 
10 µg/ml (H. pylori) 
Kanamycin (Kan) 
(Merck, Darmstadt,Germany) 
Water 50 µg/ml (E. coli) 
8 µg/ml (H. pylori) 
Streptomycin (Strep) Water 250 µg/ml (E. coli) 
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(Life Technologies) 250 µg/ml (H. pylori) 
Trimethoprim  
(Sigma-Aldrich, St. Louis, USA)  
DMF 
Dimethylformamid 
5 µg/ ml 
Nystatin (Nys)  
(Merck, Darmstadt, Germany)  
DPBS 440 µl/l (H. pylori) 
β-D-thiogalactopyranosid  (IPTG) Water  
5-Brom-4-chlor-3- 
indoxyl-β-Dgalactopyranosid (X-Gal) 
DMSO 
Dimethylsulfoxid 
40 µg/ml (E. coli) 
2.1.6 Plasmids	
Table 2.5. List of of plasmids and vectors used in this study 
Plasmid/Vector Description and references 
pPT2 pBluescript II SK (+), catR, H. pylori P12 cagI::cat; cagN and cagL flanking regions 
[this work] 
pWS290 digested with SalI and BamHI (cagN); pWS325 digested with 
EcoRV/BamHI (cat cassette and cagH); and ligated to pBluescript II SK (+) 
(SalI/EcoRV) 
pPT3 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12 cagI 
and cagL [this work] 
Constructed by PCR from P12 genomic DNA using primers WS311 and WS304 
(cagI and cagL), digested with SpeI and KpnI; and ligated to pWS241(SpeI/KpnI) 
pPT4 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12 N-
terminal myc-cagI and cagL [this work] 
constructed by PCR from P12 genomic DNA using primers WS311 and PT1 (cagI 
(3’)), digested with SpeI and BamHI; and primers PT2 and WS308 (cagI (5’) and 
cagL), digested with KpnI and BamHI; and ligated to pWS241 (SpeI/KpnI) 
pPT6 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12 N-
terminal M45-cagI and cagL [this work] 
Constructed by PCR from P12 genomic DNA with primers WS311 and WS552 
(cagI (3’)), digested with SpeI and BamHI, and PT2 and WS304 (cagI (5’) and 
cagL) (BamHI/XhoI); and  ligated to pWS241 (SpeI/SalI) 
pPT7 pSMART, catR , H. pylori P12 N-terminal M45 tagged-cagP; cagQ and cagM 
flanking regions [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb04P16 using primers 
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WS461 and WS550, digested with BamHI and SalI; and ligated to cat cassette 
(BamHI/SalI)  
pPT8 pGEX4T3, ampR, H. pylori P12 cagL lacking DNA sequence encoding for the C-
terminal motif [this work] 
constructed by PCR from P12 genomic DNA using primers WS435 and JP52 
(cagL), digested with BamHI and XhoI; and ligated to pGEX4T (BamHI/XhoI) 
pPT9 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12 cagL 
lacking DNA sequence encoding for the C-terminal motif (SpeI/XhoI) [this work]. 
constructed by PCR from P12 genomic DNA using primers WS311 and WS559 
(cagI and cagL), digested with SpeI and XhoI; and ligated with pWS241(SpeI/SalI) 
pPT10 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12, 
cagL lacking DNA sequence encoding for the C-terminal motif and the coiled-coil 
structure, and cagI [this work] 
constructed by PCR from P12 genomic DNA using primers WS311 and WS560 
(cagI and cagL), digested with SpeI and XhoI; and ligated to pWS241(SpeI/SalI)  
pPT11 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12, cagI 
lacking DNA sequence encoding for the C-terminal motif, and cagL [this work] 
constructed by PCR from P12 genomic DNA using primers WS311 and WS561 
(cagI), digested with SpeI and XhoI; and primers WS304 and WS564 (cagL), 
digested with KpnI and XhoI; and ligated to pWS241(SpeI/KpnI)  
pPT12 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12, cagI 
lacking DNA sequence encoding for the C-terminal motif and the coiled-coil 
structure [this work] 
constructed by PCR from P12 genomic DNA using primers WS311 and WS562 
(cagI), digested with SpeI/XhoI; and primers WS304 and WS564 (cagL), digested 
with KpnI and XhoI; and ligated to pWS241(SpeI/KpnI) 
pPT13 H. pylori shuttle-plasmid, pWS241, kanR, cagA promoter region, H. pylori P12, cagI 
lacking DNA sequence encoding for the C-terminal part containing cagL 
transcriptional start site, and cagL [this work] 
constructed by PCR from P12 genomic DNA using primers WS311 and WS563 
(cagI and cagL), digested with SpeI and XhoI; and primers WS304 and WS564 (cagI 
and cagL), digested with KpnI/XhoI; and ligated to pWS241(SpeI/KpnI) 
pPT14 pGEX4T3, ampR, H. pylori P12 cagI lacking DNA sequence encoding for the C-
terminal motif [this work] 
constructed by PCR from P12 genomic DNA using primers WS307 and WS561 
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(cagI ), digested with BamHI and XhoI; and ligated to pGEX4T (BamHI/XhoI)  
pPT15 pGEX4T3 ampR, H. pylori P12 cagI lacking DNA sequence encoding for the C-
terminal motif and the coiled-coil structure and [this work] 
constructed by PCR from P12 genomic DNA using WS307 and WS562 (cagI), 
digested with BamHI/XhoI; and ligated to pGEX4T (BamHI/XhoI) 
pPT16 pGEX4T3, ampR, H. pylori P12 cagI lacking DNA sequence encoding for the C-
terminal region containing cagL transcriptional start site [this work] 
Constructed by PCR from P12 genomic DNA using primers WS307 and WS563 
(cagI), digested with BamHI and XhoI; and ligated to pGEX4T (BamHI/XhoI) 
pPT17 pGEX4T3, ampR, H. pylori P12 cagL lacking DNA sequence encoding for the C-
terminal motif [this work] 
constructed by PCR from P12 genomic DNA using primers WS435 and WS559 
(cagL), digested with BamHI and XhoI; and ligated to pGEX4T (BamHI/XhoI) 
pPT18 pGEX4T3, ampR, H. pylori P12 cagL lacking DNA sequence encoding for the C-
terminal motif and coiled coil structure and (SpeI/XhoI) [this work] 
Constructed by PCR from P12 genomic DNA using primers WS435 and WS560 
(cagI), digested with BamHI and XhoI; and ligated to pGEX4T (BamHI/XhoI) 
pPT19 pWS311, kanR, H. pylori cagA promoter, (XpaI to KpnI) containing SalI exchanged 
to pWS311 (KpnI to XpaI) [this work] 
pPT20 H. pylori shuttle-plasmid, pWS311, kanR, cagA promoter, H. pylori P12 C-terminal 
M45 tagged-cagP [this work] 
Constructed by PCR from P12 genomic DNA using primers WS568 and WS550 
(cagP), digested with NdeI and SalI; ligated to pPT19 (NdeI/SalI) 
pPT24 H. pylori shuttle-plasmid, kanR, pWS241, cagA promoter, H. pylori P12 cagL 
(C128S), and cagI [this work] 
Constructed by inverse PCR from pPT3 using primers WS617 and WS616; and 
religated 
pPT25 H. pylori shuttle-plasmid, kanR, pWS241, cagA promoter, H. pylori P12 cagL 
(D132A), and cagI [this work] 
constructed by inverse PCR from pPT3 using primers WS617 and WS615; and 
religated 
pPT28 pSMART-hc Kan, kanR, H. pylori P12 cagH (D265A); cagI and cagG flanking 
regions [this work]  
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constructed by inverse PCR from gene bank plasmid pHP2kb05G17 using primers 
WS620 and WS619; and religated 
pPT29 pSMART-hc Kan, kanR, H. pylori P12 cagH (C261S); cagI and cagG flanking 
regions [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05G17 using primers 
WS620 and WS618; and religated 
pPT31 pSMART-hc Kan, KanR, H. pylori P12 cagH lacking DNA sequence encoding for 
the C-terminal motif; cagI and cagG flanking regions [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05G17 using primers 
PT4 and PT5; and religated 
pPT32 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagL lacking DNA 
sequence encoding for CGISD, and cagI [this work] 
constructed by inverse PCR from pPT3 using primers WS617 and PT8, religated  
pPT33 pSMART-hc Kan, kanR, H. pylori P12 cagH lacking DNA sequence encoding for 
CPIGD; cagI and cagG flanking regions [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05G17 using primers 
WS620 and PT9; and religated  
pWS241 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagA (Wolfgang 
Fischer) [Hohlfeld et al., 2006] 
pWS255 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori 26695 cagL (Wolfgang 
Fischer) [Jimenez-Soto et al., 2009] 
pWS290 pBluescript II SK(+), catR; H. pylori P12 cagL::cat; cagI and cagH flanking regions 
[Jimenez-Soto et al., 2009] 
pWS311 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagA (Wolfgang 
Fischer) 
pWS316 pSMART-hc Kan; kanR;H. pylori P12 cagP::cat with cagQ and cagM flanking 
regions (Wolfgang Fischer) [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb04P16 using primers 
WS406 and WS407; ligated with BamHI/SalI; and ligated to cat cassette 
(BamHI/SalI) 
pWS320 pSMART-hc Kan; kanR; ermR; H. pylori P12 cagI(5’)::rpsl-erm with cagI(3’) and 
cagH flanking regions (Wolfgang Fischer) [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05N02 using primers 
WS418 and WS419, ligated with BamHI/SalI; and ligated to rpsL-erm gene cassette 
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(BamHI/SalI) 
pWS322 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagI (Wolfgang 
Fischer) [this work] 
constructed PCR from P12 genomic DNA using primers WS311 and WS308, 
digested with SpeI and XhoI; and ligated to pWS241 (SpeI/SalI)  
pWS325 pSMART-hc Kan, catR, H. pylori P12 cagI::cat, cagI(3’) and cagH flanking regions 
(Wolfgang Fischer) [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05N02 using primers 
WS418 and WS419, digested with BamHI and SalI, and ligated to cat gene cassette 
(BamHI/SalI) 
pWS326 pSMART-hc Kan, kanR, ermR, H. pylori P12 cagI::rpsL-erm, cagI(3’) and cagH 
flanking regions (Wolfgang Fischer) [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05N02 using primers 
WS418 and WS419, digested with SalI, and religated 
pWS327 pSMART-hc Kan; kanR; ermR; H. pylori P12∆cagI marker-free, cagL and cagH 
flanking regions (Wolfgang Fischer) [this work] 
constructed by inverse PCR from gene bank plasmid pHP2kb05N02 using primers 
WS420 and WS421; and blunt-end religated 
pWS337 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagP (Wolfgang 
Fischer) [this work] 
Constructed by PCR from P12 genomic DNA using primers WS371 and WS439 
(cagP), digested with KpnI and SpeI; and ligated to pWS241 (KpnI /SpeI) 
pWS338 H. pylori shuttle-plasmid, kanR, cagA promoter, H. pylori P12 cagP [this work] 
Constructed by PCR from P12 genomic DNA using primers WS371 and hp537r 
(cagP and sRNA), digested with KpnI and NdeI; and ligated to pWS311 (KpnI/NdeI) 
pWS423 pSMART-hc Kan; ermR; H. pylori P12∆cagI marker-free, cagI and cagG flanking 
regions (Wolfgang Fischer) [this work] 
pWS426 pBluescript II SK(+), catR, H. pylori P12 sRNA::cat (Wolfgang Fischer) [this work] 
constructed by PCR from P12 genomic DNA using primers RB19 and WS439 
(cagQ, cagP flanking regions), digested with XhoI and SpeI; and primers WS438 
and WS155 (cagM flanking region), digested with SalI and BamHI; ligated to cat 
cassette (BamHI/SalI) and pBluescript II SK(+) (BamHI/SpeI) 
pWS433 pBluescript II SK(+), catR, H. pylori P12 cagP+sRNA::cat, cagQ and cagM flanking 
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regions (Wolfgang Fischer) [this work] 
constructed by PCR from P12 genomic DNA using primers WS524 and WS461 
(cagP and sRNA) digested with KpnI and BamHI; and ligated to pWS426 
(BamI/KpnI) 
pWS534 Plasmid, kanR, alpA promoter, H. pylori P12 cagH (Wolfgang Fischer) [this work] 
Constructed by PCR from P12 genomic DNA using primers WS638 and WS198 
(cagH); digested with NdeI and NotI, digested with pLH2 (NdeI/NotI) 
pHP2kb05G17 pSMART-hc Kan, kanR, cagG, cagH, cagI  
pHP2kb04P16 pSMART-hc Kan, kanR, containing cagM, cagP and cagQ 
pHP2kb05N02 pSMART-hc Kan, kanR, containing cagH, cagI and cagL 
pBluescript® II 
SK(+) 
Cloning vector 
pMal (g) Expression MBP fusion protein, ampR 
pMal-cagH pMal(g), ampR, H. pylori P12 cagH (Wolfgang Fischer) 
pGEX4T3 Expression GST fusion protein, ampR 
2.1.7 Oligonucleotides	
Table 2.6. List of oligomucleotides used in this study 
Oligo Sequence (5’-3’) Description 
PT1 GC GGA TCC CAG ATC CTC TTC TGA GAT 
GAG TTT TTG TTC AGA ACC AGC TTT TAA 
TTC GGC TTG AGC 
Sense primer containing 
BamHI for introducing 
epitope-Myc tagged-CagI 
PT2 GC GGA TCC ATA GAA GCT CAA TCT AAT 
GCC AAA G 
Antisense primer containing 
BamHI for cagI 
amplification 
PT4 G ATC GGATCC AAA CGA CCG ATT AGC 
AAA TT 
Sense primer containing 
BamHI for cagI 
amplification 
PT5 GG GGA TCC AAG ATC ATT GTC AAA TGA 
TTT TCT 
Sense primer containing 
BamHI for cagI 
amplification 
PT6 G GAA AGA GAT ATG AAA TGT TTT TTA AGC 
ATA TTT TC 
Antisense primer for cagH 
mutagenesis (CagH∆C) 
PT7 TCA TTG CAC CCT TTC TGT TAA GTA GCT Sense primer for cagH 
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ATC  mutagenesis (CagH∆C) 
PT8 TTG CTG TTC AGC AGT CTT TTG G Sense primer for cagL 
mutagenesis (CagL∆CPISD) 
PT9 AAA GTT CTT GCC GTT TAT TGC TAT GC Antisense primer for cagH 
mutagenesis (CagH∆CPIGD) 
WS155 CG GGA TCC GAC TAT TCA AAG  GGA TTA 
TTC 
Antisense primer containing 
BamHI for sRNA deletion 
WS158 CCA TCG ATG GTA AAA ATG TGA ATC GT cagA promoter for 
sequencing 
WS198 A CCG CTC GAG CTT TAA GAA GGA GAT 
ATA CAT ATG GCA GGT ACA CAA GCT A 
Antisense primer containing 
XhoI for cagH amplification 
WS268 GCG ATA TCT TCT ATA TAA GC Kanamycin resistance 
cassette for sequencing 
WS303 GGACT AGT TCT AAA GTT ATT  GTC AAA TG Antisense primer containing 
SpeI for cagL amplification 
WS304 GG GGT ACC TCA TTT AAC AAT GAT CTT AC Sense primer containing 
KpnI for cagL amplification 
WS307 TA GGA TCC CCG GTA ATA ACG CTT GAA 
CCC G 
Antisense primer containing 
BamHI for cagI 
amplification 
WS308 ACC GCT CGA GTC ATT TGA CAA TAA CTT 
TAG 
Sense primer containing 
XhoI for cagI amplification 
WS311 GG ACT AGT GAA GTG AGG AAA GAG ATG 
TG 
Antisense primer containing 
SpeI for cagI amplification 
WS313 GG ACT AGT GAA TAA AGG AGT  CAA AAA 
TAT G 
Antisense primer containing 
SpeI for cagG amplification 
WS371 CG GGT ACC TCA TAA GAA CCA ATT TTG CC Antisense primer containing 
KpnI for cagP amplification 
WS406 GC GGA TCC CAA AAT TGG TTC  TTA TGA 
TTC 
Antisense primer containing 
BamHI for cagP deletion  
WS407 A CGC GTC GAC  AAT CGG TCG TTT CAT TTT 
GG  
Sense primer containing SalI 
for cagP deletion,  
WS418 A CCG GTC GAC TAA AAA ACA T TT CAT 
ATC TC 
Sense primer containing SalI 
for cagI deletion, 
phosphorylated 
WS419 A CCG GTC GAC GGA TCC GAC AAC GCT 
CAA TAC ATC G 
Antisense primer containing 
SalI, BamHI for cagI 
deletion, phosphorylated 
WS420 CAT ATC TCT TTC CTC ACT TC Sense primer for cagI 
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deletion, phosphorylated 
WS421 AAA ACA CTC GTG AAA AAT ACC Antisense primer for cagI 
deletion,  phosphorylated 
WS435 CG GGA TCC GAA GAT ATA ACA AGC GGC 
TTA AAG 
Antisense  primer containing 
BamHI for cagL truncation 
WS438 A CCG GTC GAC GTT TCT ATC CAA AAA 
ACA CAG G 
Sense primer containing SalI 
for sRNA deletion 
WS439 GC GGA TCC A AGT AGG GTA TCT TGG Antisense primer containing 
BamHI for sRNA 
amplification 
WS461 GC GGA TCC TTC GTC CAA AAA TTT CTC 
AAG AC 
Antisense primer containing 
BamHI for cagQ 
amplification  
WS524 GC GGT ACC TAG AGT CTT ACT TGA GAG 
AC 
Sense primer containing 
KpnI for cagQ amplification  
WS550 A CGC GTC GAC TTA TAA GAT CCT GGT TTC 
TGT TTC AAA AGG CGG CAA ACG ATC CCT 
GCT CCT GTC TAA GAA CCA ATT TTG CCA 
TTG 
Sense primer containing SalI 
for introducing M45 tagged-
CagP 
WS552 GCGGA TCC TAA GAT CCT GGT TTC TGT 
TTC AAA AGG CGG CAA ACG ATC CCT GCT 
CCT GTC AGC TTT TAA TTC GGC TTG AGC 
Sense primer containing 
BamHI for M45 tagged-CagI 
WS559 A CCG CTC GAG TTA CCT TTC TTG TAA GTA 
TTG TCG 
Sense primer containing 
XhoI for cagL truncation 
WS560 A CCG CTC GAG TTA ATT CTT TAG GCT TTC 
TAC AAG 
Sense primer containing 
XhoI for cagL truncation 
WS561 A CCG CTC GAG TTA AGC AAT GTT TCT TGC 
TGT CG 
Sense primer containing 
XhoI for cagI truncation 
(CagI∆C) 
WS562 A CCG CTC GAG TTA TAA GGT TTT GAT TTC 
TCC ATT G 
Sense primer containing 
XhoI for cagI truncation 
(CagI∆C+CC) 
WS563 A CCG CTC GAG TTA TTG GGT ATT AAT TTT 
TTG TTT TTC 
Sense primer containing 
XhoI for 3’ cagI truncation  
WS564 A CCG CTCGAG ACA GCA AGA AAC ATT 
GCT AGC TC 
Antisense primer containing 
XhoI for cagL amplification 
WS568 ACG CTA CAT ATG AAA CGA CCG ATT AGC Antisense primer containing 
NdeI for introducing cagP 
amplification 
WS615 ATC GGA TAT TCC GGA TTG CTG TTC Sense primer for cagL 
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mutagenesis (CagLC128S) 
WS616 AGC GGA TAT TCC GCA TTG CTG TTC Sense primer for cagL 
mutagenesis (CagLD132A) 
WS617 AAT TTT AGT TCT TTA TTG TGA GGG GAA G  Antisense primer for cagL 
mutagenesis (general primer, 
phosphorylated) 
WS618 TGC CCT ATT GGG GCC AAA GTT CTT G Antisense primer for cagH 
mutagenesis (CagHD265A) 
WS619 TCC CCT ATT GGG GAC AAA GTT CTT G Antisense primer for cagH 
mutagenesis (CagHC261S) 
WS620 TGC AGG AGT GGT CAT AGG ATT AGT G  Sense primer for cagH 
mutagenesis (general primer, 
phosphorylated) 
WS638 A TG CGG CCG CTC ACT TCA CGA TTA TTT 
TAG TTT G 
Sense primer containing 
NotI for cagH  
JP52 A CCG CTC GAG TAA AAT TGT GCTTT TTT G Sense primer containing 
XhoI for cagL 
HP537r A CGT CTC GAG GAT TTT TGC AAG CAT CTT 
A 
Antisense primer containing 
XhoI for cagM 
RB19 CCG CTC GAG CTA GAG TCT TAC TTG AGA Sense primer containing 
XhoI for cagQ 
UB023 AGC GCT CAT AGT TGC AAG CT Antisense primer for cagI 
qPCR  
UB024 GCT CAA TCT AAT GCC AAA GAA AAA GC Sense primer for cagI qPCR  
UB044 GAA AAC ACT CGT GAA AAA TAC CAT ATC T Antisense primer for cagL 
qPCR  
UB045 GAC GGT GAG CTG GTG ATA TGG Sense primer for cagL qPCR  
Restriction sites are underlined. 
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2.1.9 Antibodies	
Table 2.7. List of antibodies used in this study 
Antibodies Description 
Primary antibodies 
α-CagA 
(AK257) 
Polyclonal antibody against the C-terminal part  of CagA from H. pylori 185-144 
(Rabbit) (1:5000) [Odenbreit et al., 2000] 
α-CagI 
(AK250) 
Polyclonal antibody against the C-terminal part (peptide 327-345) of CagA from H. pypori 
(Rabbit) (1:1000) [this work] 
α-CagH 
(AK294) 
Polyclonal antibody against the MBP fusion protein (Rabbit) (Firma Gramsch) (1:1000) 
[this work] 
α-CagL 
(AK271) 
Polyclonal antibody against the  H. pylori CagL protein (Rabbit) (1:1000) [Jimenez-Soto 
et al., 2009] 
α-CagX 
(AK290) 
Polyclonal antibody against the H. pylori CagX protein (Rabbit) (1:2000)  
α-RecA 
(AK263) 
Polyclonal antibody against CagL protein from H. pylori (Rabbit) (1:1000) [Fischer and 
Haas, 2004] 
α-AlpB 
(AK262) 
Polyclonal antibody against the H. pylori AlpB fusion protein (Rabbit) (1:2000) 
[Odenbreit et al., 2009] 
α-P-Tyr 
(4G10) 
Monoclonal antibody against the Tyrosine phosphorylated protein (Mouse) (Millipore, 
Schwalbach, Germany) (1:10000) 
α-Myc tag Monoclonal antibody against the Myc protein (Mouse) (Cell signaling Technology, USA) 
(1:1000) 
α-His tag Monoclonal antibody against the Myc protein (Mouse) (1:10000) (Antibodies online, 
USA) 
α-GST Monoclonal antibody against the Glutathion-S-Transferase GST protein (Mouse) 
(1:10000) (GenScript, USA) 
α-MBP  Monoclonal antibody against the MBP protein (Mouse) (1:1000) (Sigma-Aldrich, St. 
Louis, USA) 
Secondary antibodies 
α-Mouse 
IgG POX 
Horseradish peroxidase-conjugated polyclonal antibody against mouse IgG (Goat) 
(1:10000) (Dianova, Sigma-Aldrich, St. Louis, USA) 
α-Rabbit 
IgG POX 
Horseradish peroxidase-conjugated polyclonal antibody against rabbit IgG (Goat) 
(1:10000) (Dianova, Sigma-Aldrich, St. Louis, USA) 
α-Mouse 
IgG AP 
Alkaline phosphatase-conjugated monoclonal against mouse IgG (Goat) (1:2000) 
(Dianova, Sigma-Aldrich, St. Louis, USA) 
Protein A 
AP 
Alkaline Phosphatase (AP) coupled to protein A (1:5000) (Sigma-Aldrich, St. Louis, 
USA) 
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2.1.10 Proteins	and	enzymes	
Table 2.8. List of proteins and enzymes used in this study 
Protein/Enzyme Company 
Fetal calf serum (FCS)  PAA, Pasching, Austria  
Horse serum  Carlsbad, USA  
Bovine serum albumin (BSA) Sigma-Aldrich, St. Louis, USA  
Takara-Ex Taq-Polymerase  TaKaRa Bio Inc., Otsu, Japan  
Takara-LA Taq-Polymerase  TaKaRa Bio Inc., Otsu, Japan  
PowerScript DNA Polymerase Biotech, Germany 
Phusion High-Fidelity DNA polymerase  Thermo Scientific, USA 
Proteinase K Roche, Germany 
Lysozyme  Roche Grenzach-Wyhlen, Germany 
T4 DNA ligase Thermo Scientific, USA 
Restriction enzymes  Roche, Grenzach-Wyhlen and NEB, Germany 
Fermentas, Germany 
RNA free DNAse Thermo Scientific, USA 
Purified CagI and CagL Terradot’s lab, Baltimore, USA 
Purified α5β1 (closed and open forms) Lea Hostel 
2.1.11 Standard buffers 
SDS sample buffer (2X): 100 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 20% (v/v) 
glycerol, 10% (v/v) β-mercaptoethanol, 0.2% (w/v) bromphenol blue 
PBS: 27 mM KCl, 1.38 M NaCl, 15 mM KH2PO4, 80 mM Na2HPO4  
TBS: 150 mM NaCl, 20 mM Tris-HCl, pH 7.5  
An asterisk (*) denotes the addition of protease inhibitors into a buffer at the following 
concentrations: 1mM PMSF, 1 mM Sodium vanadate, 1 µM Leupeptin, 1 µM Pepstatin. 
2.1.12 Consumables	and	Equipment	
2.1.12.1 Consumables	
X-Ray film (Fuji Film, Dussendorf, Germany), Dialysis membranes for small volumes 
(Pierce), PVDF membrane (Bio-Rad, Hercules, USA), BD Falcon 15 and 50 ml (BD 
Biosciences, Flanklin Lakes, USA), 0.2 µm- Sterilefilters (Millipore, Schwalbach, 
Germany), ELISA Maxisorp plates (Nunc), Cell scrappers (Falcon), FACS tubes 
(Becton Dickinson), Freezing Tubes 2 ml (Nalgene), Protein G agarose (Roche 
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Diagnostic, Germany), Double-distilled water (Roth, Germany), Amylose resin 
(Biolabs, Germany), Glutathione sepharose 4B (GE Healthcare, Sweden), Cholesterol 
(Gibco, Invitrogen). 
2.1.12.2 Equipment	
Voltage Units PowerPac 300 (BioRad, Hercules, USA), PAGE-Mini Gel System Mini-
Protean IIITM (BioRad, Hercules, USA), Agarose Gel Electrophoresis chamber 
(BioRad, Hercules, USA), Anaerobic Incubator MI122C (Scholzen, Wittenbach, CH), 
Centrifuge Biofuge 15 R and Megafuge 3.0R (Heraeus, Hanau, Germany), Ultra-
centrifuge OptimaTM TL (Beckman Coulter Inc., Fullerton, USA), Cell Disruptor; 450 
Sonifier Analog (G. Heiermann, Germany), French press SIM AMINCO Spectronic 
(New York), Vacuum-centrifuge Savant SpeedVac DNA 110 (GMI, Ramsey, USA), 
Wettern blot-Apparature semi-dry (Biotech Fischer, Reiskirchen, Germany), Gel-
documentation system Quantity One 4.4.0 (BioRad, Hercules, USA), FACS-Canto II 
(BD Biosciences, Germany), Fridge (Liebherr, Biberach a.d. Riss, Germany), ABI 
Prism 7000 Real-Time PCR (ABI, USA), Gene Pulser TM Electroporation (BioRad, 
Hercules, USA), Magnetic Stirrer MR 3001 (Heidolph, Schwabach, Germany), Scale 
(Biotech Fischer, Reiskirchen, Germany), Microwave (AEG, Nürnberg, Germany), 
Water bath 1012 (GFL, Burwedel, Germany), Eppendorf Thermomixer® comfort 
(Eppendorf, Hamburg, Germany).  
2.1.13 Molecular	markers	
Figure 2.1. List of molecular markers used in this study 
Molecular marker Company 
DNA- Gel electrophoresis GeneRulerTM 1 kb DNA Ladder (MBI Fermentas, St. Leon-Roth, 
Germany) 
Protein Electrophoresis Prestained Protein Molecular Weight Marker, 26612 (MBI Fermentas, St. 
Leon-Roth, Germany) 
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2.1.14 Commercial	Kits	
Table 2.9. List commercial kits used in this study 
Kit Company 
illustra GFX PCR DNA and Gel Band Purification Kit GE-Healthcare, Buckinghamshire, UK 
QIAprep Spin Miniprep KitTM  Qiagen, Hilden, Germany 
QIAamp DNA Mini KitTM  Qiagen, Hilden, Germany 
TOPO-TA-CloningTM-Kits with pCR2.1-TOPOVector Invitrogen, Carlsbad, USA 
Alexa Fluor 647 Monoclonal Antibody Labeling Kit Invitrogen, Carlsbad, USA 
Wizard® Plus SV Minipreps DNA Purification System Promega, Madison, USA 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific, Germany 
Power SYBR® Green PCR Master Mix Life Technology, USA 
2.2 Methods	
2.2.1 Microbiological	methods	
2.2.1.1 Cultivation	and	freezing	of	E. coli	
E. coli strains were incubated and cultured either on LB agar plates or in liquid LB 
medium at 200 rpm in a shaking incubator at 37oC for normal growth with the 
corresponding antibiotics for selection. 
The cultivation of E. coli strains for protein expression was done by growing bacteria at 
37oC in the shaker at 200 rpm till the OD600 reached 0,4 and inducing with IPTG 1mM 
at 27oC for 3-4 h with appropriate antibiotics. 
E. coli strains were stored by suspending bacteria from LB agar plates in the liquid LB 
medium supplemented with 20% glycerol, and frozen at -70oC in cryogenic tubes. 
2.2.1.2 Cultivation	and	freezing	of	H. pylori	
H. pylori strains were cultivated on supplemented GC agar plates (section 2.1.2) at 37°C 
under microaerobic conditions (5% O2, 10% CO2, 85% N2) for 2-3 days from glycerol 
stock and 24 h before being recultured. For liquid culture, bacteria from GC agar plates 
were inoculated with an OD550 of 0.2 in a small BB medium (Oxoid, TFS) 
supplemented with 0.4% glycerol (Gibco) and agitated at 90 rpm for 24 h and 
transferred to the main culture with an OD550 of 0.05 for 24 h. 
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H. pylori strains were stored by suspending bacteria from GC agar plates in the liquid 
BB medium supplemented with 10% FCS, 20% Glycerol, and frozen at -70oC in 
cryogenic tubes. 
2.2.1.3 Determination	of	optical	density		
Bacteria from agar plate were suspended in a desired medium or PBS. The suspension 
was then diluted to a appropriate dilution in plastic cuvettes. The optical density (OD) 
of bacteria was measured by spectrophotometer at a wavelength of λ550 (OD550) for H. 
pylori and λ600 (OD600) for E. coli against a respective blank. 
2.2.1.4 Preparation	of	chemically	competent	E. coli	cells	
E. coli chemically competent cells were produced by the rubidium method. Briefly, an 
overnight liquid culture of E. coli was inoculated in 100 ml of LB medium and grown 
until it reached an OD550 of 0.5 to 0.6 at 37oC in a shaking incubator (180 rpm). The 
cultivated culture was chilled on ice for 30 min and centrifuged at 4000 rpm for 15 min 
at 4oC. The cell pellet was suspended in 40 ml of TFBI buffer. After 5 min incubation 
on ice, cells were centrifuged and followed by suspending in 4 ml of TFBII buffer. 
Competent cells were then aliquoted into 50 µl and frozen in liquid nitrogen. The cells 
were further stored at -70oC.  
TFBI buffer: 30 mM potassium acetate CH3COOH, 100 mM RbCl, 10 mM CaCl2, 50 mM 
MnCl2, 15% (v/v) glycerol, pH 5.2 adjusted with 0.2 M CH3COOH, sterilized. 
TFBII buffer: 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% (v/v) glycerol, pH 6.5 
with KOH, sterilized. 
2.2.1.5 Transformation	of	chemically	competent	E. coli	cells	
An aliquot of E. coli competent cells was thawed on ice for 30 min before adding DNA 
samples (500 mg of ligation and 5-10 mg of plasmid) and followed by 30 min on ice 
incubation. Heat shock was done by immersion in a pre-heated water bath at 42ºC for 
60 seconds. After adding LB medium (1 ml), the cells were incubated in a 37oC shaking 
incubator at 200 rpm for 1 h and plated on appropriate antibiotic selective LB agar 
plates for overnight at 37oC. 
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2.2.1.6 Natural	transformation	into	H. pylori	(modified after [Haas et al., 1993]) 
H. pylori strains from GC agar plates were suspended in PBS or BB medium 
supplemented with 10% FCS. Bacterial suspension was adjusted to an OD550 of 0,2 and 
added to a 24-well plate (1 ml). The plate was incubated at 37oC, 10% CO2 for 1-2 h. 
The mobility of bacteria was checked under a microscope before adding DNA (500 ng) 
and incubated for another 4-6 h. Bacteria were collected by centrifugation at 1000 g for 
5 min and resuspended in BB medium and plated on appropriate antibiotic selective GC 
agar plates for 3-5 days at 37oC under micro-aerobic conditions. The clones were 
restreaked on a fresh selective plate for further testing. 
2.2.1.7 Electroporation	of	H. pylori	(according to [Segal and Tompkins, 1993]) 
H. pylori strains from GC agar plates were suspended in PBS. bacterial suspension (1 
ml) with an OD550 of 1 was washed once with PBS and followed by 2 times of washing 
with of electroporation buffer (500 µl). Bacteria were pelleted by centrifugation at 1000 
g for 5 min. Bacteria were resuspended in EB buffer (40 µl) and transferred to a pre-
chilled cuvette. After adding DNA (500 ng), an electroporation pulse at 2.5 kV, 200 Ω, 
25 µF was applied. Subsequently, 1 ml of BB medium containing 10% FCS was added 
directly to bacterial suspension. This suspension was incubated for 4 h in a 24-well plate 
before being pelleted and plated on appropriate antibiotic selective GC agar plates for 3-
5 days at 37oC under micro-aerobic conditions. The clones were restreaked on selective 
plates for further testing. 
Electroporation buffer (EB): 272 mM saccharose; 15% (v/v) glycerin; 2.43 mM 
K2HPO4; 0.57 mM KH2PO4 
2.2.1.8 Plate	transformation	of	H. pylori 
H. pylori strains from GC plates were transferred to a fresh GC plate. An amount of 500 
ng DNA plasmid was suspended with bacteria in a small area of the circle with a 
diameter of 2 cm for 24 h. The bacteria were then recultured on a selective plate and 
incubated for 3-5 days at 37oC under micro-aerobic conditions. The clones were 
restreaked on fresh selective plates for further testing. 
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2.2.2 Genetic	and	micromolecular	methods	
2.2.2.1 Extraction	of	nucleic	acids	
2.2.2.1.1 Genomic DNA isolation from H. pylori 
The isolation of chromosomal DNA from H. pylori was performed according to the 
manufacturer's instructions with the QIAamp Tissue Kit from Qiagen (Hilden, 
Germany). H. pylori cells were grown for overnight at 37°C under micro-aerobic 
conditions on a GC agar plate and then one fourth of the plate was suspended in Lysis 
buffer. The chromosomal DNA was eluted from the column by adding 100-200 µl of 
sterile distilled water. The DNA concentration in the eluate was measured on a 
NanoDrop ND-1000 spectrophotometer (PeqLab). 
2.2.2.1.2 DNA plasmid isolation from E. coli 
Plasmid preparation by boiling procedure 
Bacteria on the plate was suspended in STET buffer (300 µl). After adding 15 µl of 
lysozyme solution, bacterial suspension was incubated on ice for at least 5 min and 
boiled for 1 min in order to lyse the cells and release DNA. The lysate was centrifuged 
for 30 min at room temperature and the supernatant was transferred in 1 V isopropanol 
and incubated at -20oC for 10 min before being centrifuged at 20000 g for 10 min. The 
DNA containing pellet was washed with 70% ethanol and dried out by Speed Vac and 
resuspended in double-distilled water (50-100 µl). 
STET-buffer: 8% glucose, 5% double-distilled water Triton X100, 50 mM EDTA, 50 
mM Tris pH 8.0 
Lysozyme: 10 mg/ml in STET buffer 
QIA Prep Spin Miniprep Kit 
Plasmid DNA was prepared from E. coli cells using the QIAprep Spin Miniprep Kit 
(Qiagen) according to the instructions of the manufacturer. DNA was eluted with 50-
200 µl double-distilled water and DNA concentration in the eluate was measured with a 
NanoDrop ND-1000 spectrophotometer (PeqLab). 
2.2.2.1.3 Extraction and isolation of DNA from agarose gel 
Materials and Methods 
43 
 
After PCR amplification or restriction digestion, the DNA fragments were separated on 
1% agarose gels and stained with solution containing 0.1% (w/v) methylene blue. The 
DNA bands of interest were excised and purified from agarose gel using illistra GFX 
PCR DNA and Gel band Purification Kit (GE Healthcare) according to the instructions 
of the manufacturer. The DNA was eluted from the column with an appropriate amount 
of double-distilled water and quantified with a NanoDrop ND-1000 spectrophotometer 
(PeqLab) for concentration. 
2.2.2.1.4 RNA extraction from H. pylori 
Total RNA was isolated from H. pylori strains grown in liquid cultures for 16-24 h by 
the hot phenol method [Sharma et al., 2010]. Briefly, bacterial cells from 10 ml of 
liquid cultures (OD550 of 0.8-1.0) were mixed with a stop solution containing 95% 
ethanol and 5% phenol and collected by centrifugation. Pellets were resuspended in 600 
µl of TE buffer (pH 8.0) containing 0.5 mg/ml lysozyme and added with 60 µl of 10% 
SDS. The suspension was  incubated at 64°C for 2 min, mixed with 66 µl of 1M sodium 
acetate (pH 5.2), and extracted with 750 µl of phenol at 64°C. Traces of phenol were 
removed from the aqueous phases by extraction with 750 µl chloroform and 
centrifugation at 12000 g for 15 min. RNA was precipitated from the aqueous phases 
with ethanol/sodium acetate (30:1 (v/v)) (pH 6.5), redissolved in DEPC-treated water, 
and treated with RNase-free DNase I (Fermentas). Total RNA was analyzed on 
nondenaturing 1.0% agarose gels and quantified with a NanoDrop ND-1000 
spectrophotometer (PeqLab). 
TE buffer (Tris-EDTA): 10 mM Tris, 1 mM EDTA  
2.2.2.2 DNA	gel	electrophoresis	
The DNA and RNA molecules were separated by electrophoresis on agarose gel ranging 
from 1-2%, depending on the size of the molecules in TAE buffer at 80 V for 50 min. 
Before loading on the agarose gels, the DNA or RNA samples were mixed with one 
fourth volume of GEBS buffer. The gels were stained with either ethidium bromide (1 
mg/ml) and observed under UV light at 260 nm using Molecular Imager Gel Doc XR 
system (Bio Rad) or stained with methylene blue (0.1% (w/v)) as described above 
(section 2.2.2.1.3). 
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1X TAE buffer: 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA. 
GEBS buffer: 20% (v/v) glycerol, 50 mM EDTA, 0.05% (w/v) bromophenol blue, 
0.5% (w/v) N-Lauryl Sarcosyl. 
2.2.2.3 Restriction	digestion	
Plasmid DNA and PCR fragments were purified using illistra GFX PCR DNA and Gel 
band Purification Kit (GE Healthcare) before being digested with restriction enzymes 
obtained from Thermo Fisher Scientific or Roche Applied Science and the 
corresponding buffers according to manufacters’instructions. The double digestion was 
conducted by determining the appropriate buffer which is compatible for both enzymes. 
Approximately 500 ng of DNA were used for diagnostic digests and up to 3 µg for 
preparative purposes with 0.5-1 U/µl enzyme in the reaction. To separate the digested 
vector from the small DNA fragment, the incubation time ranged from 1 h to overnight. 
The band of interest was excised and purified using preparative agarose gel 
electrophoresis as described above (section 2.2.2.1.3)  
For cloning of PCR products with phosphorylated primers and increasing of the directed 
mutagenesis efficiency, the PCR phosphorylated fragments were subjected to DpnI 
digestion for 2 hours before being ligated.  
2.2.2.4 Ligation		
For cloning of the DNA fragments into vectors, a ligation reaction was performed for 
ON in a 10 µl final volume, including T4 ligase (1 µl) , T4 ligase buffer (1 µl)  (Roche 
or Fermentas) and digested vector and insert DNA. The ratio of vector to insert was 1:3, 
and calculated by formular:  
 
The ligation was then heated up to 65oC for 5 min to inactivate T4-ligase and added 
directly into the transformation of competent E. coli cells. 
2.2.2.5 Reverse	Transcription	and	cDNA	synthesis	
In order to get the full length mRNA transcripts encoding for proteins of interest, the 
synthesis of first strand cDNA was performed by using RevertAid™ First Strand cDNA 
  ?? ?? ?????? ? ?? ???? ?? ???????? ???? ?? ??????  x molar ratio of  
??????
?????? 
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Synthesis Kit (Thermo Scientific). First, the amount of 1.0 µg of total RNA was treated 
with 1 U (1 µl) of DNAse I (Thermo Scientific) for removing the single and double 
stranded DNA at 37oC for 1 h. The RNA was used directly for cDNA synthesis after 
being inactivated by heating at 65oC for 10 min in the presence of 1M EDTA. A 
mixture of 1.0 µg DNA-free RNA, 1 µl random Hexamer primer (100 µM) and water 
with the final volume of 12 µl was incubated for 5 min at 65°C and chilled on ice. The 
reaction then was added 4 µl 5 x RT buffer, 1 µl Ribolock RNase Inhibitor (20 U/µl), 2 
µl 10 mM dNTP, RevertAid M-MuLVRT (20 U/µL) with the final volume of 20 µL. 
The mixture was incubated for 5 min at 25°C followed by 60 min at 42°C and 
terminated by heating at 70°C for 5 min. The reverse transcription reaction product was 
directly used in PCR applications or stored at -20°C. For long-term storage, cDNA 
samples were stored at -80oC. 
2.2.2.6 	Polymerase	chain	reaction	
The DNA fragments were amplified from genomic DNA, plasmid DNA or cDNA using 
Ex Taq (Takara), LA Taq (Takara) or PAN polymerase (Clontech) as instructions of 
manufacturer following the protocol presented in Table 2.10.  
Table 2.10. Standard PCR protocol 
Step Temperature Time Cycles 
Initial denaturation 94oC 1 min 1 
Denaturation 94oC 30 sec  
Annealing  48-54oC 30 sec 30 
Elongation 68 oC     Ex taq and LA Taq 
72oC      PAN Taq  
30 sec/1 kb  
Final elongation 68oC      Ex taq and LA Taq 
72oC      PAN Taq 
10 min 1 
 
2.2.2.7 Colony	PCR	
Colony PCR is a quick method of screening for plasmid inserts directly from E. coli 
colonies. PCR components were mixed and kept on ice. A small amount of colony was 
added to the PCR reaction. PCR was done by standard protocol for PAN polymerase 
(section 2.2.2.6). 
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2.2.2.8 Site-directed	mutagenesis	PCR	
Site-directed mutagenesis PCR was used for introducing the point mutations and 
deletions in the plasmid DNA using Phusion High-Fidelity DNA polymerase (Thermo 
Scientific) according to the protocol provided by the manufacturer (Table 2.11). The 
entire plasmid was amplified using phosphorylated primers. A small amount of 5 ng 
was used. 
The linear PCR products containing desired mutations were digested with DpnI 
restriction enzyme, which cleaves methylated DNA from the template for 1 h at 37oC, 
and re-ligated using T4 Ligase (Fermentas).  
Table 2.11. PCR mutagenesis protocol 
Step Temperature Time Cycles 
Initial denaturation 98oC 30 sec 1 
Denaturation 98oC 30 sec  
Annealing  48-54oC 30 sec 25 
Elongation 72oC 30 sec/1 kb  
Final elongation 72oC 10 min 1 
2.2.2.9 qPCR	
Quantitative PCR was carried out using the ABI 7700 of Applied Biosystems, according 
to the manufacturer’s instructions. The first strand cDNA was synthesized using random 
hexamer primers. The cycle conditions for real-time PCR are shown in Table 2.12.  
Table 2.12. Quantitative PCR protocol 
Step Temperature Time Cycles 
Initial denaturation 95oC 1 min 1 
Denaturation 95oC 30 sec  
Annealing  59 - 61oC 30 sec 43 
Elongation 72 oC      30 sec  
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2.2.2.10 DNA	sequencing	
DNA sequencing was purchased from GATC (Kempten, Germany) with standard 
primers or specific primers for the corresponding DNA sequence. The analysis of the 
sequences was carried out by the DNAMAN program and CLC DNA Workbench 6.  
2.2.3 Protein	methods	
2.2.3.1 Preparation	of	whole	H. pylori	bacterial	lysates	for	SDS-PAGE	
Whole bacterial lysates for SDS-PAGE were prepared by suspending the bacteria from 
a 24 h agar plate in PBS and adjusting to an OD of 7.0. The samples were mixed with 2 
X SDS sample buffer (1:1) (v/v)) and incubated for 10 min at 95oC and followed by 
centrifugation at 13000 rpm for 5 min.  
SDS sample buffer (2 X): 100 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 20% (v/v) 
glycerol, 10% (v/v) β-mercaptoethanol, 0.2% (w/v) bromphenol blue, and 10% (v/v) 
mercaptoethanol. 
2.2.3.2 SDS-PAGE	
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using the Laemmli gel system. 10 µl of whole cell lysates with OD550 of 10 
suspended in 2 X SDS sample buffer were loaded on a 6-15% SDS gel, depending on 
the size of the protein of interest, under denaturing condition. A pre-stained Protein 
Molecular Weight Marker was loaded in parallel for size-determination. Protein gels 
between 6-15% were made from a 30% acrylamide solution in a separating gel buffer 
(1.5 M Tris/HCl pH 8.8). The concentration of Stacking gel was always on 5% in a 
Stacking buffer (1.0 M Tris/HCl pH 6.8) is set (Table 2.13). The separation of proteins 
was carried out in an electrophoresis buffer at a voltage of 80-130 V for approximately 
80 min to 120 min. 
Table 2.13. Preparation of polyacrylamide gels 
Components Separating gels Stacking gel 
 6% 10% 12% 15%  
dH2O 2.6 ml 1.9 ml 1.6 ml 1.1 ml 0.68 ml 
Acrylamide 30% 1.0 1.7 2.0 2.5 0.17 
1.5 M Tris HCl pH 8.0 1.3 1.3 1.3 1.3  
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1.5 M Tris HCl pH 6.8     0.13 
SDS 10% 0.05 0.05 0.05 0.05 0.01 
10% APS 0.05 0.05 0.05 0.05 0.01 
TEMED 0.004 0.02 0.02 0.02 0.001 
 
Electrophoresis buffer: 250 mM glycine, 0.1% (w/v) SDS, 25 mM Tris-HCl pH 8.3 
2.2.3.3 Detection	of	proteins	on	Polyacrylamide	gel	
The SDS-PAGE was stained with a Coomassie solution according to [Zehr et al., 1989]. 
The gel was fixed for 20 min and then washed with a distaining solution on a shaker 
until all relevant bands were visible.  
Coomassie solution: 0.275% (w/v) coomassie brilliant blue R250 (Biomol), 50% 
methanol, 10% acetic acid. 
Destaining solution: 10% methanol, 10% ethanol, 7.5% acetic acid. 
2.2.3.4 Western	blotting	
2.2.3.5 Transfer	of	proteins	to	PVDF	membrane	
For immunoblotting, the separated molecules from SDS-PAGE after electrophoresis, 
were transferred or blotted onto a methanol activated polyvinylidene difluoride (PVDF) 
membrane using semi-dry blotting chambers (Biotec-Fischer). The transfer sandwich 
was assembled with a stacking gel and pieces of filter paper on each side of the 
sandwich, which had been soaked in anode I/II and cathode buffers on the 
anode/cathode side of the gel and membrane, respectively. Electro-transfer proteins 
from the gel on the Membrane were done for 75 min at room temperature with a current 
of 1.2 mA/cm2 for 60-70 min. After transfer, the membrane was either dried (1 h at 
37°C or overnight at room temperture) or directly used for immunoblotting. The dried 
membrane was briefly reactivated with methanol before further purposes. 
Anode I buffer: 300 mM Tris-HCl pH 10.4, 10% methanol 
Anode II buffer: 25 mM Tris-HCl pH 10.4, 10% methanol 
Cathode buffer: 25 mM Tris-HCl pH 9.6, 40 mM 6-amino caproid acid, 10% methanol 
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2.2.3.6 Detection	of	immobilized	proteins	with	antibodies	
In order to prevent any nonspecific bindings of antibodies to the surface of the 
membrane, the membranes were blocked with a blocking buffer for at least 1 h at room 
temperature. The primary antibodies against the target proteins with appropriate 
dilutions were applied to the blots for overnight at 4oC or 2 h at room temperature. The 
blots were washed 3-5 times for 10 min each with TBS-T and followed by incubating 
with HRP-conjugated secondary antibody or protein A, alkaline phosphatase conjugate 
solution according to the manufacturer’s recommended ratio for 1 h at room 
temperature. The blots were further washed 3-5 times for 10 min each with TBS-T. 
Upon addition of the primary antibody, either the chemiluminescent substrate 
(Immobilon Chemiluminescent HRP Substrate, Millipore) which is catalyzed by 
horseradish peroxidase (POX) bound to the secondary antibody, or AP substrate which 
forms an insoluble black-purple precipitate when reacted with alkaline phosphatase was 
applied to the blots. The chemiluminescence reaction was detected with X-ray films 
(Fuji Medical X-Ray Films Super RX, Fujifilm) or via a Bio-Rad ChemiDoc XRS.  
Blocking buffer: 5% skim milk in TBS 
Primary and secondary antibody solution: 1% skim milk in TBS-T buffer  
AP substrate: 0.1 M Tris-HCl, pH 9.6; 7 mM MgCl2; 0.1 mg/ml nitro-blue tetrazolium 
chloride in 0.1 M Tris-HCl, pH 9.6; 0.05 mg/ml 5-bromo-4-choloro-indolyl phosphate 
in dimethylformamide 
2.2.3.7 Removal	of	immune	complexes	from	PVDF	
The blots were incubated in a stripping buffer (50 mM NaOH) for 30 min with some 
agitation. After 2 times washing with TBT-T, the blots were blocked with blocking 
buffer or dried and activated with methanol before further use. 
2.2.3.8 Determination	of	protein	concentration	
A colorimetric assay, which based on an absorbance shift of the dye Coomassie Brilliant 
Blue G-250 was applied to determine the concentration of protein solutions. A series 
dilution of the standard BSA (0-0.6 mg/ml) and serial dilution of protein samples were 
prepared with Protein Assay Dye Reagent Concentrate (Bio-Rad) according to the 
instructions of the manufacturer. Absorbance shift of Coomassie Blue dye to 595 nm 
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was measured in 96-well plates (Costar EIA/RIA plate, flat well, medium binding, 
Corning) using a Tecan Sunrise microplate reader. 
2.2.3.9 In	vitro	phosphorylation	assay	
The ability of the cells to phosphorylate CagA was checked by performing an infection 
assay using using total lysates of bacteria. AGS cells were grown in RPMI media 
supplemented with 10% Fetal Calf Serum (FCS) with a confluency of 70-80%. The 
infection (MOI of 60) was done in 6 well plates for for 3-4 h at 37oC in 5% CO2. After 
infection, cells were washed with PBS and harvested by scrapers in PBS*. After being 
centrifuged at 500g for 10 min at 4oC, cells were resuspended in 25-30 µl PBS* and 
lysed in SDS sample buffer for Western blot detection of phosphorylated proteins. 
2.2.3.10 ELISA	for	IL-8	quantification	
An EILSA was performed to measure the concentrations of IL-8 protein produced by 
AGS cells during infection assays. An immunoabsorbent 96-well plate was coated with 
50 µl diluted IL-8 antibody (3 µl/ml in coating buffer) and 50 µl of coating buffer per 
well at 4oC for over night. The plate was washed 4 times with 200 µl wash buffer and 
followed by blocking with 200 µl blocking buffer. The plate was covered and incubated 
for 2-4 hours at room temperature or 4oC overnight. After 3 times of washing, the 
dilution series of human IL-8 medium ranged from 0 to 800 pg/ml and appropriate 
dilutions of samples were added. Standard human IL-8 and samples were diluted in 
RPMI medium with 10% FCS with the final volume of 100 µl per well. The plate then 
was incubated at 4oC for ON. Four time washing steps were repeated to remove 
unbound antigen. To detect the bound IL-8, 100 µl of a solution containing biotylated 
anti IL-8 antibody (0.5 µl/ml in washing buffer with 10% FCS) was added. The 
biotylated antibody was incubated at room temperature for 1-2 hours and followed by 6 
times of washing and adding prepared conjugate solution (Streptavidin-Biotin-POX). 
After 1 h incubation, the plate was washed 6 times with washing buffer and added 100 
µl TMB substrate solution (1:1) (Millipore) per well and incubated for 30 min at room 
temperature in the dark. The reaction was stopped with 50 µl 1M H2SO4 and measured 
using a wavelength of 450 nm with subtraction of a 570 nm wavelength in a Tecam 
Sunrise ELISA plate reader. The data analysis was done using Magellan 3 Software. 
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Coating-buffer: 100mM Na2HPO4 pH 9.0 
Washing buffer: PBS with 0.05% Tween 20 
Blocking buffer: PBS with 10% FCS 
Conjugate solution: 200 µl 50mM Tris pH 7.6; 1.5 µl solution A; 1.5 µl solution B. 
Mix well and incubate for 30 min at room temperature then add 9.8 ml 50 mM Tris pH 
7.6. 
2.2.3.11 Immunoprecipitaion	
Immunoprecipitation (IP) is one of the most commonly used methods for verification of 
protein-protein interactions. In this experiment, a protein antigen – a bait protein is 
captured from out of H. pylori lysate using an antibody that specifically binds to that 
particular protein and the interaction partners which have been bound to the bait protein 
are subsequently identified by Western blotting. In this work, IP experiments were 
performed for investigating possible interactions of CagH, CagI and CagL the Cag-
T4SS. 
H. pylori grown on 24 h GC agar plate were suspended and washed twice with PBS. 
The start bacterial lysates were prepared with the OD550 of 10. The bacterial pellets were 
resuspended in a pre-chilled RIPA buffer with an OD550 of 15 in 500 µl for one 
direction of IP and lysed by ultra-sonication treatment (20 sec intervals 20 sec of rest, 
output 2-4, duty cycle 20-30%) using Sonifier 250 (Branson). The intact cells were 
removed by low speed centrifugation for 10 min at 4oC and followed by 30 min at 
20000 g at 4oC. To remove un-specifically reacting proteins, bacterial lysates were 
incubated with 50 µl prewashed G agarose beads (Roche Diagnostic) (3 times at 20000 
g for 30 sec) for 2 h at 4oC and centrifuged at 20000 g for 10 min. The specific 
antibodies (5 µl) against proteins of interest were added into the supernatant after 
discarding the pellet and the samples were incubated for over night at 4oC. The 
prewashed G agarose beads (50 µl) were added to the samples and incubated for another 
2 hours at 4oC. The antigen-antibody-protein G complexes were pulled down by 
centrifugation at 20000 g at 4oC for 10 min. After 3 times of washing with RIPA buffer 
for removing unspecific binding, proteins were eluted from the beads by adding 50 µl 
SDS sample buffer and boiling at 95oC for 10 min.  
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In this thesis, IP-CagI, -CagL and -Myc were done using CagI, CagL and Myc 
antibodies, respectively. 
RIPA buffer: 150 mM NaCl, 1 mM EDTA, 0.5% Nornidet P40, 0.25% sodium 
deoxycholate, protease inhibitors (1% PMSF, 1%v, 0.1% leupeptin, 0.1% pepstatin). 
2.2.3.12 Pull-down	experiments	
The pull-down experiments were carried out to confirm the interaction between CagI, 
CagL and CagH proteins. The method involves in the binding of GST/MBP fusion 
proteins coupled beads to proteins of interest.  
For production and purification of GST/MBP fusion proteins, E. coli BL21 (DE3) 
containing plasmids listed in Table 2.14, overnight cultures were diluted in fresh LB 
medium and grown at 37°C and 200 rpm in LB medium supplemented with 
ampicillin/kanamycin for GST and MBP fusion proteins, respectively, until they 
reached an OD600 of 0.5-0.6 before inducing IPTG with a final concentration of 1 mM 
for 3 h. The cultures (50 ml) were centrifuged (4000 g, 10 min, 4°C) and the bacterial 
pellet was resuspended in one tenth volume of lysis buffer (5 ml). Bacterial lysates were 
prepared by ultra-sonication treatment (20 sec intervals 20 sec of rest, output 2-4, duty 
cycle 20-30%) using Sonifier 250 (Branson). Intact cells were removed by low speed 
centrifugation for 10 min at 4oC and followed by 30 min at 20000 g at 4oC. The lysates 
were incubated with Triton X100 with the final concentration of 1% for 30-60 min in 
order to reduce the amount of inclusion bodies. The lysates were then applied for 
centrifugation at 20000 g for 30 min at 4oC.  
Lysis buffer: 1X PBS, 0.5% Nornidet P 40, 1 mM EDTA, 1% PMSF, 1% vanadat, 
0.1% leupeptin, 0.1% pepstain 
Table 2.14. List of plasmids for expression of GST- and MBP- fusion proteins 
GST constructs MBP constructs 
pWS258 H-MBP 
pPT14 pMal(g) (control) 
pPT15  
pPT16  
pPT8  
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pPT17  
pPT18  
pGEX4-T3 (control)  
 
2.2.3.12.1 GST pull-down 
Coupling: 1 ml bed volume of Glutathione Sepharose 4B beads (GE Healthcare) was 
prepared by washing 3 times with PBS* (spin at 5000 rpm for 5 min). The E. coli 
pellets containing unlysed bacteria were discarded and the supernatants were incubated 
with for at least 3 hours or overnight under gentle agitation in order for the bait proteins 
to be captured on beads. After 3 times of washing with PBS* (spin at 5000 rpm for 5 
min), the beads were suspended in the 1 volume of PBS* (1 ml) PBS*. A 50 µl of 
suspension was used for Western blotting and for pull-down experiments.  
Elution: After triple washing of the matrix with 10 bed volumes each of PBS*, the 
GST-CagL fusion protein and GST control protein were eluted in three fractions with 
10 volumes of elution solution for 10 min each at room temperature and then 
concentrated using Amicon Ultra 4 (10000 NMWL). The concentration of each protein 
was measured by Bradford assay (section 2.2.3.8).  
Elution buffer: 50 mM Tris-HCl, pH 8.2, and 30 mM reduced Glutathione 
Pull-down: H. pylori lysates containing putative prey proteins were prepared as 
described in section 2.2.3.11. Bacterial lysates were pre-incubated for 2 hours with 50 
µl MBP beads to avoid unspecific bindings. After 10 min centrifugation at 20000 g at 
4oC, the supernatant was collected and incubated with 50 µl bait proteins coupled 
Glutathione Sepharose beads suspension for overnight. The GST coupled beads were 
used as a negative control. The samples were centrifuged at 20000 g at 4oC for 10 min 
and followed by 2 washing steps. The complexes were eluted from the beads by adding 
of SDS sample buffer (50 µl) and boiling at 95oC for 10 min.  
2.2.3.12.2 MBP pull-down 
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Coupling: 1ml bed volume of the amylose resins (New England Biolabs) was prepared 
by washing 2 times with 5ml water and 2 times with 5 ml column buffer (spin at 3500 
rpm for 3 min). The lysates containing MBP fusion proteins were prepared as 
mentioned in section 2.2.3.12.1 and mixed with equilibrated resin overnight at 4oC. 
After 5 times of wash with column buffer (spin at 3500 rpm for 3 min), 1 volume of 
PBS* (1 ml) was added and samples were stored at 4oC. 40 µl of suspension was used 
for Western blotting and for pull-down experiments.  
Pull-down:  
For investigating the possible direct interaction between CagH, CagI and CagL, the 
amount of 5 µg of each purified CagI or CagL proteins were added into a 50 µl CagH 
coupled beads and filled it up to 100 µl using PBS*. The samples were then incubated at 
4oC for 3 hours and washed 3 times with PBS* by centrifugation at 20000 g for 30 s at 
4oC. The complexes were eluted from the beads by adding 50 µl of SDS sample buffer 
and boiling at 95oC for 10 min.  
For another strategy to check the interaction between CagH and CagL, 5 µg of GST-
CagL was mixed with 50 µl of MBP-CagH coupled Amylose beads and incubated at 
4oC for 2 hours and washed 3 times with PBS* by centrifugation at 20000 g for 30 s at 
4oC. As controls, MBP coupled Amylose beads and GST alone were used. 
Column buffer: 1 mM EGTA, pH 8.0; 200 mM KCl; 50 mM Tris-HCl, pH 8.0; 1 mM 
EDTA, pH 8.0; 10% (v/v) glycerol; 
2 mM sodium metabisulfite (Na2S2O5), 0.5 mM DTT, 1 mM PMSF freshly added. 
Lysis buffer for MBP fusion proteins: 1 mM EGTA, pH 8.0; 100 mM KCl; 50 mM 
Tris-HCl, pH 8.0; 1 mM EDTA, pH 8.0; 1 M NaCl;  
00.5 mM DTT, 1 mM PMSF, protease inhibitors freshly added. 
Lysis buffer for GST fusion proteins: PBS* supplemented with 0.5% Nonidet P40. 
2.2.3.13 Membrane	protein	fractionation	
H. pylori were grown in 200 ml BB medium supplemented with 4% cholesterol for 24 
h. Bacteria were then harvested, washed, and resuspended in 3 ml Lysis buffer. Bacteria 
were lysed as above (section 2.2.3.11), and bacterial lysate was centrifuged for 10 min 
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at 7000 g to remove unbroken cells and cell debris. The supernatant was collected and 
separated by ultracentrifugation (60 min, 230000 g) into the soluble fraction containing 
cytoplasmic and periplasmic proteins and total membrane fraction.  
Proteins in the soluble fractions were concentrated by chloroform-methanol 
precipitation [Wessel and Flugge, 1984]. Briefly, 300 µl of the sample were mixed 
carefully by hand with 600 µl methanol, 200 µl chloroform, and 200 µl of water. After 
centrifugation at 20000 g for 2 min, the upper organic phase was removed without 
disturbing interphase containing protein while the membrane fractions were washed 
with and resuspended in preparation buffer. For differential extraction, triton X-100 was 
added to the membrane suspension to a final concentration of 1% (w/v), and the mixture 
was incubated on ice for 30 min in order to isolate membrane proteins and then 
fractionated by ultracentrifugation (45 min, 230000 g). The pellet was then resuspended 
in in preparation buffer and the supernatant was concentrated as above. 
Lysis buffer: 10 mM Tris-HCl, pH 8.0, 1 mM PMSF, 1 µM leupeptin, 1 µM pepstatin 
2.2.3.14 Sucrose	density	gradients	
Sucrose density gradients are based on the migration of inner and outer membrane 
vesicles according to their different densities when exposed to the elevated centrifugal 
force. A discontinuous sucrose gradient was prepared by loading the decreasing sucrose 
density solutions ranging 60% (w/v) to 25% (w/v) in M buffer upon one another in 
SW41 rotor tubes, followed by overnight equilibration at 4°C. Total membrane fractions 
resuspended in Triethanolamine buffer were layered on top of the density gradients and 
centrifuged at 4oC for 17 h at 285000 g. The eight fractions were collected, and proteins 
were concentrated by precipitation described above (section 2.2.3.13). 
M buffer: 50 mM triethanolamine, pH 7.5; 1 mM EDTA 
2.2.3.15 Limited	Proteinase	K	Digestion	
This method was carried out in order to access the susceptibility of bacterial surface 
exposed proteins with proteinase K digestion. H. pylori were grown on GC agar plates 
for 24 hours, harvested and washed in PBS, and resuspended at a density of 6×107 cells 
per ml in proteinase K buffer. This suspension was incubated at room temperature for 
30 min. To stop the reaction, PMSF was added to the reaction with the final 
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concentration of 5 mM. Bacterial cells were then washed twice with PBS and 
resuspended in PBS (1/10 v/v) and 2X SDS sample buffer.  
Proteinase K buffer: 50 mM Tris-HCl, pH 7.4; 150 mM NaCl, 1 mM CaCl2, 1 mM 
MgCl2, 1 mM KCl containing 1 mg/ml proteinase K  
2.2.3.16 Labeling	of	α5β1	integrin	with	Alexa	Dye	
The 2 forms of purified α5β1 integrin (active and inactive) were labeled with Alexa dye 
using Fluor 647 Monoclonal Antibody Labeling Kit obtained from Invitrogen according 
to the instructions of the manufacturer with some modifications. Briefly, the glycerol 
and Tris from the storage buffer of 100 µg proteins was removed from the sample by 
dialyzing against PBS (-KCl) in Slide-A-Lyzer dialysis cassettes (100K MWCO, 
Thermo Fisher Scientific) for 4 hours in dark at 4oC and followed by adding one tenth 
volume of 1M NaHCO3. The samples were transferred to the vial of reaction dye (250 
µg) then incubated at room temperature in the dark for 1 hour under agitation. To purify 
labelled integrins, the samples were loaded on the prepared spin column containing 
purification resin and centrifuged for 5 min at 1100g. Protein concentration and degree 
of labeling were measured by UV-VIS module of a NanoDrop ND-1000 spectrometer 
(PeqLab) at 280 n (A280) and 650 nm (A) and stored at -20oC.  
PBS(-KCl): 7.7 mM Na2HPO4, 2.5 mM NaH2PO4, 150 mM NaCl 
2.2.3.17 Staining	of	H. pylori	with	integrin	coupled	Alexa	Fluor	647	
H. pylori strains were grown on cholesterol plates for at least two passages so that the 
serum proteins in bacteria which would cause a fault positive in binding assay were 
reduced. Bacteria were harvested and suspended in PBS (-Ca, -Mg) by pipetting. 
Bacterial suspension was adjusted to an OD of 0.4 and distributed in 100 µl aliquots on 
a 96 well plate. 100 µl aliquots which contained 0.4 µg of the active and in active 
integrins were added to the wells. After 1 h incubation, the plate was centrifuged at 
3000 rpm for 10 min at 4oC and followed by washing with 200 µl PBS before adding 
200 µl of PBS and measuring APC level fluorescent emission on a FACS-Canto II (BD 
Biosciences) with side scattering as a threshold for the events. 
To induce the production of pili, bacteria were subjected to an infection with AGS cells 
(confluency of 70-80%) with OD550 of 0.2 (MOI of 60). After 1 h infection, unbound 
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bacteria were washed 1 time with PBS and centrifuged at 3000 rpm for 10 min at 4oC. 
The bacterial pellets were resuspended by pipetting in PBS and used for binding assay 
as described above. 
2.2.4 Statistical analysis 
All values were mean values +/- standard errors. The data collected from at least 3 
independent experiments and the significant difference were analyzed by One-way 
ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001) using Graphpad Prism5 software.  
 
Results 
58 
 
3 RESULTS	
3.1 Role	of	the	CagH,	CagI	and	CagL	proteins	for	T4SS	functionality	
3.1.1 Features	of	the	CagH,	CagI	and	CagL	proteins	
The CagH (39 kDa), CagI (42 kDa) and CagL (29 kDa) proteins are components of the 
Cag Type IV Secretion System of H. pylori. In strain 26695, the genes encoding for 
CagH, CagI and CagL proteins were shown to be located in a putative operon, which 
may contain five genes (cagF, cagG, cagH, cagI and cagL) or even more genes 
[Sharma et al., 2010]. One study on transcriptional units of the Cag-T4SS suggested a 
conserved existence of 11 operons in different strains, in which cagI-cagL and cagG-
cagH were found to be organized in 2 different operons [Ta et al., 2012]. By promoter-
trap and reverse transcription PCR analyses of ORFs and intergenic transcripts, the 
cagG promoter was found to drive expression of the operon cagG-cagH, while the 
opreron cagI-cagL might be controlled by a promoter within the cagG-cagH genes [Ta 
et al., 2012] (Figure 3.1A). A closer look on the putative cagFGHIL operon revealed 
that cagH, cagI and cagL have overlapping ORFs, in which the 3’ end of cagI ovelaps 
with the start codon of cagL and the Shine-Dalgarno sequence of cagI overlaps with the 
stop codon of cagH (Figure 3.1A).  
In order to characterize the CagH, CagI and CagL proteins, the amino acid sequences of 
these proteins were analyzed by the Phobius software. CagI and CagL are characterized 
by a predicted N-terminal signal peptide for being exported into the periplasmic space, 
whereas CagH is predicted to have one single transmembrane helix and is thus most 
likely a cytoplasmic membrane protein (Figure 3.1B). Interestingly, analysis of the C-
terminal amino acid sequences of these 3 proteins showed a high identity of 6 amino 
acids from each protein (CagH (TKIIVK), CagI (SKVIVK) and CagL (SK(I/V)IVK)) 
(Figure 3.1C).  
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Figure 3.1. Features of CagH, CagI and CagL 
(A) Genetic organization of the cag pathogenicity island in strain P12. Each gene on the cag-PAI is 
shown as a thick arrow with the orientation of transcription. The length and spacing of each annotated 
gene are shown in proportion to the real sizes. The genes of interest, cagH, cagI and cagL (denoted in red 
arrows) have overlapping open reading frames. The identified transcriptional start sites are represented by 
bent arrows (blue according to [Sharma et al., 2010], green according to [Vannini et al., 2014]; red 
according to [Ta et al., 2012]). SD: Shine-Dalgarno sequence. (B) The prediction software analysis 
(Phobius) suggested that CagI and CagL are secreted across the inner membrane as a result of an N-
terminal signal peptide denoted by a red line, whereas CagH is predicted to be a cytoplasmic membrane 
protein with a transmembrane region indicated by a gray peak. The predicted non-cytoplasmic region is 
presented in blue. (C) The sequence comparison of CagH, CagI and CagL using the MegAlign software 
reveals a conserved C-terminal motif. The C-terminal motif containing 6 amino acids of each protein is 
highlighted in red, (CagH (TKIIVK), CagI (SKVIVK) and CagL (SK(I/V)IVK)). 
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3.1.2 Deletion	and	complementation	of	the	cagH,	cagI	and	cagL	genes	
3.1.2.1 The	CagH,	CagI	and	CagL	proteins	are	required	for	Cag-T4SS	
functionality	
With the aim of investigating the role of CagH, CagI and CagL in functionality of the 
Cag-T4SS, a set of mutants and complemented strains were constructed (Figure 3.2A). 
In order to avoid polar effects of the mutations, we constructed marker-free deletion 
mutants for the analysis of gene function. The principle of the system for generating 
maker-free deletion mutants was described earlier [Dailidiene et al., 2006] and is shown 
in Figure 3.2B. The P12∆cagH deletion mutant was constructed by replacement of the 
cagH gene with an rpsL-erm cassette using plasmid pWS4231. The P12∆cagI marker-
free deletion mutant was constructed in such a way that the 3’ region of cagI was kept 
to avoid a transcriptional effect on cagL by deletion of a transcriptional start site located 
in the 3’ part of cagI (constructed using plasmid pWS320). These plasmids were 
constructed as described in section 2.1.5. The cagL gene was deleted from P12 by 
transforming with plasmid pWS290 [Jimenez-Soto et al., 2009]. The presence of CagH, 
CagI and CagL proteins in the deletion and complemented mutants were checked by 
Western blotting using the corresponding antibodies. As shown in Figure 3.3A, CagI 
and CagL were absent in the corresponding mutants and could be restored by genetic 
complementation. In the absence of CagI, CagL levels were considerably reduced, and 
the same effect was observed for CagI in the P12∆cagL mutant. Since the cagL gene is 
the last gene of the putative operon cagGHIL, the absence of CagI in the P12∆cagL 
mutant background cannot be caused by insertion of the cat cassette, but was rather due 
to the lack of the cagL gene product.  
In the case of CagH, the P12∆cagH mutant was defective in production of full levels of 
CagI and CagL as shown in Figure 3.3A. Both phenotypes were rescued by 
complementation in cis using the gene bank plasmid pHP2kbG17. Unfortunately, we 
were not able to construct an unmarked deletion mutant to exclude a polar effect caused 
by insertion of the rpsL-erm cassette (data not shown). Likewise, we could not 
                                                 
1
 Was performed by Evelyn Weiss 
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complement the P12∆cagH mutant using a standard chromosomal integration vector 
because E. coli cells seemed not to tolerate of cagH (data not shown). Nevertheless, we 
were able to complement this mutant in trans using plasmid pWS534, in which the 
cagH gene is not integrated into the chromosome, but into the naturally occurring 
plasmid pHel12 (Lea Holsten), and expressed under the control of the alpA promoter. 
The resulting strain (P12∆cagH/H(pWS534) recovered CagI and CagL production2 
(Figure 3.3A). These results indicated that insertion of the rpsl-erm cassette did not 
influence the expression of downstream genes cagI and cagL, or at least did not cause a 
strong reduction of transcription. The reduced levels of CagI and CagL observed in this 
mutant are thus more likely due to the absence of CagH, suggesting a stabilizing effect 
of CagH on CagI and CagL. Taken together, these observations suggest that the stability 
of each protein in this putative complex depends on the presence of the others. 
To determine the requirement of these 3 proteins for CagA translocation and IL-8 
induction, infection experiments of AGS cells with strain P12 and the deletion and 
complemented strains were performed. Tyrosine phosphorylation of the CagA protein 
was examined by Western blotting, and IL-8 induction was analyzed by a sandwich 
ELISA. Figure 3.3B shows that in comparison to the P12 wild-type strain, the mutants 
failed to translocate CagA into AGS cells and were completely abolished in IL-8 
induction. The complementation of the deletion mutants restored both CagA 
translocation and IL-8 secretion after AGS cells infection. Additionally, in the case of 
CagH, the complementation of the P12∆cagH mutant not only in cis but also in trans 
rescued all of the defects observed in the absence of this protein (Figure 3.3B), 
suggesting an important role of CagH in functionality of the Cag-T4SS. However, it 
remained unclear whether the deficiency of the cagH mutants in CagA translocation and 
IL-8 induction are absolutely due to CagH itself or rather due to the reduction of CagI. 
To sum up, we conclude that CagH, CagI and CagL are required for CagA translocation 
and IL-8 induction. They are thus essential components of the Cag-T4SS.  
                                                 
2
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Figure 3.2. Schematic representation of constructs used for cagH, cagI, and cagL deletion and 
complementation 
(A) The cagH, cagI and cagL deletion mutants were generated from strain P12 by transforming with 
plasmids pWS423, pWS320 and pWS290, respectively. For complementation in trans, cagI and cagL 
were introduced into the recA locus of the P12∆cagI and P12∆cagL strains using plasmids pWS322 and 
pWS255, containing a kanamycin resistance cassette, respectively, whereas cagH was complemented in 
the cagH locus of the P12∆cagH strain replacing the rpsL-erm cassette using the gene bank plasmid 
HP2kb05G17. (B) Principle of the system for generating a marker-free deletion mutant. In the first step, 
the P12 wild-type strain carrying a point mutation in the rpsL gene (rpsL*, strepR) was transformed with 
plasmid containing an rpsL-erm cassette which confers dominant streptomycin susceptibility and 
selectable erythromycin resistance. The resulting strain was used for the second step to remove the rpsL-
erm cassette by transforming with a plasmid containing no insertion and selecting for streptomycin 
resistance and erythromycin susceptibility. 
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Figure 3.3. Functional analysis of the Cag-T4SS components CagH, CagI and CagL 
(A) Whole cell lysates of the P12 wild-type strain and the indicated mutants as well as complemented 
strains were immunoblotted using CagI and CagL antibodies. (B) Functionality of the Cag-T4SS in strain 
P12 and the indicated mutants was tested by performing infection assays of AGS cells to determine CagA 
tyrosine phosphorylation. The IL-8 values induced by the P12 wild-type strain were set to 100% and other 
values were normalized to these values (%). The data collected from at least 3 independent experiments 
were statistically analyzed by One-way ANOVA (***P < 0.001). 
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3.1.2.2 CagI	is	not	absolutely	required	for	CagL	production	
As mentioned above, cagI and cagL genes are located in a putative operon and they 
have overlapping open reading frames (Figure 3.1A). Furthermore, they were shown to 
be transcribed into one transcriptional unit (mRNA) [Ta et al., 2012]. For further 
investigation of the role of CagL in the absence of CagI, a set of cagI mutants was 
constructed (Figure 3.4). The 5’ part of cagI was either deleted and replaced by a 
streptomycin sensitivity/erythromycin resistance gene cassette in the mutant 
P12∆cagI(320) or deleted without insertion for generating a marker-free deletion mutant 
P12∆cagI(320/326). Since the 3’ part of cagI has been predicted to harbor an alternative 
transcriptional start site of cagL [Sharma et al., 2010], cagI was deleted completely in 
the mutant P12∆cagI(320/327) in such a way that the Shine-Dalgarno sequence of cagH 
is used as a ribosome binding site for cagL allowing the transcription directly from 
cagH to cagL (Figure 3.4). As expected, the production of CagI was lost in all the cagI 
mutant individuals. The presence of the CagL protein was analyzed by Western blotting 
and the results showed that deletion of cagI led to a strong reduction of CagL with 
different levels. The complementation of cagI into the chromosomal recA locus was 
done for these mutants by transforming with plasmid pWS322 containing cagI under the 
control of the cagA promoter. CagI and CagL immunoblots of whole bacterial lysates 
from these complemented strains in comparison to the P12 wild-type strain and deletion 
mutants indicated that the complementation restored not only CagI but also CagL 
production. Surprisingly, in the precise deletion of the cagI gene, the P12∆cagI(327) 
strain produced normal levels of CagL, suggesting that CagI is not absolutely required 
for CagL production (Figure 3.5A). Unfortunately, our attempts to complement this 
mutant with a chromosomal integration vector containing the cagI gene were not 
successful (data not shown). Nevertheless, the results provided evidence that deletion of 
the cagI gene and its replacement by a resistance gene cassette does not cause any polar 
effects on the expression of downstream the cagL gene but rather that CagI has a direct 
stabilizing effect on CagL. 
As shown before, CagL itself is important for CagA translocation and IL-8 secretion. 
However, to definitively determine whether the varying CagL levels caused by deletion 
of the cagI gene are involved in Cag-T4SS functionality, or whether CagI itself is 
responsible for the deficiency in CagA phosphorylation and IL-8 induction, infection 
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experiments of AGS cells were performed with the P12 wild-type strain, the deletion 
and complemented strains. As shown in Figure 3.5B, all the cagI mutant strains were 
unable to phosphorylate CagA and induce IL-8 by AGS cells. Even the mutants 
P12∆cagI(320) and P12∆cagI(320/326), which produced a smaller amount of CagL in 
respect to the P12 wild-type strain were defective in CagA translocation and IL-8 
secretion. The wild-type phenotype was significantly restored by complementation of 
these mutants with plasmid pWS322 containing full-length cagI which had been 
integrated into the recA locus and expressed under the control of the cagA promoter. 
The results indicate that not the different levels of CagL are responsible for the defect of 
the Cag-T4SS, but rather that CagI itself is required for a proper functionality of the 
Cag-T4SS.  
 
Figure 3.4. Schematic representation of constructs used for generating deletion mutants of cagI and 
complemented strains 
The P12∆cagI mutants generated using plasmids pWS320 and pWS326 have retained the 3’ part of cagI 
containing the cagL transcriptional start site, whereas the mutant generated using pWS327 contains no 
trace of cagI. Instead, the Shine-Dalgarno sequence of cagH is used as a ribosome binding site for cagL 
allowing the transcription directly from cagH to cagL. The complementation of these mutants was 
performed in trans using a chromosomal integration vector containing cagI (pWS322). The cagI gene 
was integrated into the recA locus and expressed under the control of the cagA promoter. 
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Figure 3.5. Analysis of CagI and CagL production in different cagI mutants 
(A) CagI and CagL immunoblot analysis from whole cell lysates of strain P12 and the indicated mutants 
or complemented mutants. (B) Functionality of the Cag-T4SS from strain P12 and the indicated mutants 
was tested by performing infection assays of AGS cells to determine CagA tyrosine phosphorylation.  
The IL-8 values induced by the P12 wild-type were set to 100% and other values were normalized to 
these values (%). The data collected from at least 3 independent experiments were statistically analyzed 
by One-way ANOVA (***P < 0.001). 
 
3.1.2.3 CagL	has	a	stabilizing	effect	on	CagI		
Since the complementation of a complete cagI deletion mutant (strain P12∆cagI(327)) 
(section 3.1.2.2) was not successful (data not shown), another approach was applied to 
generate a mutant which lacks the complete cagI gene. A double mutant (strain 
P12∆cagIL) lacking both cagI and cagL was constructed from the P12 wild-type strain 
by replacing both cagI and cagL with a chloramphenicol resistance gene cassette using 
plasmid pPT2 (Figure 3.6). The loss of CagI, and CagL production in this mutant was 
tested by immmunoblotting as shown in Figure 3.7A. As expected, the P12∆cagIL 
double mutant was defective in production of CagI and CagL. Subsequently, this mutant 
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was complemented using chromosomal recA integration vectors containing either cagI 
(pWS322) alone, cagL alone (pWS255), or both genes together (pPT3). These plasmids 
were constructed as described in section 2.1.5. The complementation of the double 
mutant with cagI alone (strain P12∆cagIL/I) restored production of the CagI protein, but 
at lower levels than the P12 wild-type strain, whereas complementation with cagL alone 
(strain P12∆cagIL/L) resulted in production of CagL at wild-type levels (Figure 3.7A). 
Wild-type phenotypes were rescued when both genes were complemented (strain 
P12∆cagIL/IL). Thus, in the same mutant background, the complementation of both 
genes (cagI and cagL) recovered production of CagI at the level of the P12 wild-type 
strain, whereas the complementation of cagI only did not. Notably, as mentioned before, 
the effect of CagL on CagI was observed in the cagL knock-out mutant as well (Figure 
3.3A). Taken together, these data provide evidence for a stabilizing effect of CagL on 
CagI. In contrast, CagL production showed unchanged levels in the presence or the 
absence of CagI, providing the first hint that CagI is not absolutely required for CagL 
production and/or stability.  
The functionality of these mutants was assessed by infection experiments of AGS cells. 
The results obtained from IL-8 induction and CagA phosphorylation showed that 
deletion of cagI and cagL resulted in a deficiency of the double mutant (strain 
P12∆cagIL) for both phenotypes. Neither the cagI nor cagL-complemented double 
mutant has an ability to translocate CagA and induce IL-8. In contrast, complementation 
of this mutant with cagI and cagL together (strain P12∆cagIL/IL) fully rescued the P12 
wild-type phenotype (Figure 3.7B). These data confirmed that CagI and CagL are 
independently required for Cag-T4SS functionality.  
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Figure 3.6. Schematic representation of constructs used for generation of the P12∆cagIL double 
mutant and for complementation of this mutant 
The P12∆cagIL double mutant was constructed by transforming plasmid pPT2 containing a 
terminatorless chloramphenicol resistance cassette into strain P12. The resulting strain subsequently, the 
P12∆cagIL double mutant was complemented with plasmids contaning cagI or cagL, or both genes 
(pWS322, pWS255 and pPT3, respectively). The genes were integrated into the recA locus and expressed 
under the control of the cagA promoter. 
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Figure 3.7. Functional analysis of the P12∆cagIL double mutant 
(A) Whole cell lysates from strain P12 and the indicated mutant strains were immunoblotted using CagI 
and CagL antibodies, respectively. The production of CagI and CagL was defective in strain P12∆cagIL, 
and restored by genetic complementation. (B) Functionality of the Cag-T4SS from the P12∆cagIL double 
mutant and complemented strains was tested by performing infection assays of AGS cells to determine 
CagA tyrosine phosphorylation. The IL-8 values induced by the P12 wild-type strain were set to 100% 
and other values were normalized to these values (%). The data collected from at least 3 independent 
experiments were statistically analyzed by One-way ANOVA (***P < 0.001). 
 
3.1.2.4 cagI deletion	does	not	influence	cagL transcription	
To corroborate the conclusion drawn above that cagI deletion results in the CagL 
protein destabilization, rather than a loss of the cagL transcription, a quantification of 
cagL transcript levels in the different cagI mutants which produced varying levels of 
CagL was performed. For this purpose, total RNA from liquid cultures of the P12 wild-
type strain and the different cagI mutants was prepared and used for cDNA synthesis 
via a reverse transcription using a random primer. Subsequently, conventional PCR and 
real-time PCR were carried out using specific primer pairs for cagL gene and primers 
for 16S RNA. The specific primers for cagL and 16S RNA were designed for 
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amplifying a fragment with the size of 91 bp and 79 bp, respectively. The control PCR 
showed amplified PCR bands for cagL using specific primers WS379 and WS304, and 
16S RNA using primers UB044 and UB045 from cDNAs but not from mRNA samples 
(Figure 3.8A), showing that the preparation of cDNA was not contaminated by genomic 
DNA. The quantification of cagL mRNA by qPCR showed no significant difference 
between the P12 wild-type strain and most of the different cagI mutants (Figure 3.8B). 
Interestingly, however, in the mutant P12∆cagI(327), in which the entire cagI gene had 
been deleted, the cagL mRNA transcript level was 6,04 ± 4,67 fold increased in respect 
to the P12 wild-type strain. As mentioned above, this mutant produced normal amounts 
of CagL in comparison to the wild-type strain, nevertheless was defective in CagA 
translocation and IL-8 induction. This suggests that the decreased CagL stability was 
overturned by the higher cagL transcription rate in this mutant. Taken together, these 
data demonstrated that the transcription of cagL is not generally influenced by deletion 
of cagI. 
 
Figure 3.8. cagL transcription analysis 
The P12 wild-type strain and the indicated cagI mutants were cultured in liquid media to mid exponential 
phase before being harvested for RNA extraction and cDNA synthesis. (A) The control PCR was done 
from cDNA templates using primers pair WS379 and WS304 for cagL, and UB020 and UB021 for 16S 
RNA. (B) Quantitative real-time PCR using primers UB044 and UB045 was carried out to analyze the 
transcript levels of cagL in each cDNA samples. The analysis of 16S RNA transcript levels was 
performed in parallel for normalization. The values obtained from P12 wild-type were set to one and 
other values from at least 3 independent experiments were given in relation to P12 with standard errors of 
the mean and statistically analyzed by One-way ANOVA. 
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3.1.3 Localization	of	CagI	and	CagL	
To characterize the CagH, CagI and CagL proteins, we sought to localize these unique 
Cag protein components in H. pylori. Except for CagL, there were no experimental data 
available about the localization of these proteins in H. pylori. The CagL protein has 
been described as a cytoplasmic or periplasmic protein [Kutter et al., 2008], a pilus-
covering protein [Kwok et al., 2007] or a membrane-associated protein [Tegtmeyer et 
al., 2010]. In the current study, different approaches were used for localization of these 
proteins.  
For subcellular localization of CagI and CagL, H. pylori cells were fractionated into a 
soluble and an insoluble fraction containing membrane-associated components. The 
insoluble components were then extracted by the non-ionic detergent Triton X-100, 
which preferably solubilizs cytoplasmic membrane proteins [Pattis et al., 2007]. The 
presence of CagI and CagL proteins was tested by Western blotting using CagI and 
CagL antibodies. As shown in Figure 3.9A, CagI was found both in the membrane 
fraction and the soluble fraction containing cytoplasmic and periplasmic proteins. CagI 
was not extracted completely by Triton X-100, suggesting that it might be inner 
membrane-associated. Unlike CagI, CagL was mostly found in the soluble fraction and 
only a minor part in the total membrane fraction which was not solubilized by Triton X-
100. The fractionation of the P12 wild-type strain and the P12∆cagI was performed in 
parallel and the results indicated that there is no significant difference between the P12 
wild-type strain and the cagI deletion mutant. Control immunoblots showed that the 
outer membrane-associated proteins CagX and AlpB were present only in the 
membrane fraction and were not extracted by Triton X-100, whereas the inner 
membrane-associated protein RecA was considerably extracted with this detergent.  
To gain more evidence for the localization of CagI and CagL, the total membrane 
vesicles which had been suspended in Triethanolamine buffer were also subjected to 
sucrose density gradient centrifugation. Each fraction from sucrose gradients was 
examined for the presence of CagI, CagL, and as a control, of the outer membrane-
associated proteins CagX and AlpB and the inner membrane-associated protein RecA 
by immunoblotting. The results showed that CagI and CagL occur both in outer and 
inner membrane associated pools, whereas the control proteins CagX and AlpB were 
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present only in high density fractions and RecA was found in several fractions (Figure 
3.9B). 
Since CagI and CagL were found both in the outer and inner membrane-associated 
protein fractions, it still remained unclear whether these two proteins might be partially 
surface- exposed. To investigate a possible surface localization, CagI and CagL, as well 
as control proteins were analyzed for susceptibility to proteinase K digestion. Equal 
amounts of treated and untreated cells were immunoblotted using specific antibodies. 
As shown in Figure 3.9C, CagI and CagL were substantially digested by proteinase K 
treatment. The AlpB protein, which is known to be surface exposed, was digested 
completely, whereas the inner membrane protein RecA was not affected by proteinase 
K digestion. CagI was strongly degraded by proteinase K treatment, whereas CagL was 
only slightly reduced. 
Taken together, these observations suggest that CagI and CagL exist in a non-surface 
localization to a considerable degree, and are partly localized at the surface of bacteria 
as well.  
Immunofluoresence staninings were performed in order to localize CagI in H. pylori. 
However, the results were not conclusive because of unspecific background stainning 
(data not shown). Likewise, in this study, attempts to generate a tagged-CagI for this 
purpose have not been successful (data not shown). Therefore, surface localization of 
CagI could not be confirmed by this method. 
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Figure 3.9. Localization of CagI and CagL in baterial cell fractions 
(A) Cell pellets from 24 h liquid cultures of the P12 wild-type and the P12∆cagI strain were 
ultrasonicated and fractionated into soluble and insoluble proteins by ultracentrifugation. The 
supernatants contain soluble proteins, whereas the membrane associated and other insoluble proteins are 
located in the pellets which were subsequently extracted with 1% Triton X-100 for separating outer 
membrane-associated (TX100 insol) from inner membrane-associated proteins (TX100 sol). Anti-CagI 
and anti-CagL western blot analysis was done to compare the amounts of CagI and CagL in different 
fractions. Western blots against the outer membrane-associated proteins CagX, AlpB and the partly 
soluble and partly inner membrane-associated protein RecA were performed in parallel as controls. (B) 
The ultrasonication pellets were resuspended in preparation buffer and subjected to preparative sucrose 
density gradient centrifugation on 25-60% sucrose gradients. Collected fractions were analyzed for the 
presence of CagI, CagL and control proteins by immunoblotting with the indicated antisera. (C) Whole 
bacterial cells were subjected to limited proteolytic digestion with proteinase K. Equal amounts of treated 
(P12 PK) and untreated bacteria (P12) were immunoblotted with the indicated antisera3. 
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3.1.4 Influence	of	cag	genes	on	the	interaction	between	H. pylori	and	α5β1	
integrin	
CagL was previously found as a pilus component [Kwok et al., 2007]. It has also been 
shown that H. pylori, via the Cag apparatus, can bind to integrin α5β1 expressed on the 
host cell surface. By Yeast Two Hybrid assays and protein pull-down assay, several 
proteins of the Cag apparatus such as CagY and CagL, and the CagA effector protein, 
were found to interact with β1 integrin [Jimenez-Soto et al., 2009]. Recently, Shaffer et 
al. [Shaffer et al., 2011] reported that CagH, CagI and CagL have important roles in the 
formation of the type IV secretion-associated pili. Based on these observations, we 
sought to set up an easy assay for investigating the production of pili and the role of 
CagH, CagI and CagL proteins, by detecting the binding of integrin α5β1 to H. pylori. 
We investigated the binding of the closed and open forms of the integrin α5β1, which 
were used as purified recombinant proteins, with H. pylori (described in section 
2.2.3.16). The soluble integrin α5β1 was initially in an in inactive form (Figure 3.10, 
upper panel). To create an active form of integrin α5β1, a TEV protease cleavage was 
carried out4. With this step, a His-tag which had been used for purification of integrin 
α5β1, and a BASE peptide responsible for the interaction, were cleaved off and the open 
form (active) of integrin was released (Figure 3.10, lower panel). For detection 
purposes, these forms of integrin α5β1 were coupled to Alexa 647 dye. After 
purification and quantification, they were used at the same amounts for binding assays. 
Based on the hypothesis that pilus formation is stimulated by cell contact, we performed 
experiments under two conditions. On the one hand, bacteria were collected and 
subjected to binding assays. On the other hand, a short infection experiment with AGS 
cells was performed before unbound bacteria were harvested for binding experiments. 
Bacteria were incubated with purified and soluble Alexa 647 fluorescently labeled 
integrin α5β1 protein complex (closed and open). Several cag gene deletion mutants 
such as cagI and cagL deletion mutants were used in parallel with the P12 wild-type 
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strain and the cag-PAI mutant, which served as a positive control and a negative 
control, respectively.  
The binding of active and inactive α5β1integrins shown by the level of fluorescence 
was determined on BD Biosicence CantoII flow cytometry. Data were analyzed using 
the Flowjo software. Unexpectedly, there was no stronger binding of bacteria to the 
integrin α5β1 active and the inactive forms after being exposed to cells (data not 
shown). As seen in Figure 3.11A and B, bacteria show a higher specificity and a higher 
affinity to the inactive α5β1 integrin than to the active one. There was a significant 
decrease in binding affinity of the active and the inactive forms to the cag-PAI or cagI 
deletion mutants compared to the P12 wild-type strain. However, we observed no 
significant difference between the P12 wild-type and the cagL mutant. These data 
suggest that H. pylori were able to bind to both forms of integrin α5β1 with a higher 
affinity to the inactive form of integrin α5β1 than to the active form. These findings 
provide another experimential evidence for the role of CagI and CagL in mediating the 
binding of the Cag-T4SS to integrin. However, further studies are required to clarify 
this point. 
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Figure 3.10. Scheme for release of the C-terminal claspe of the recombinant integrin α5β1by TEV 
cleavage 
The inactive (left) and active (right) forms of the soluble integrin α5β1 forms of the soluble integrin α5β1. 
To generate the active form of integrin α5β1, a TEV protease cleavage was carried out. With this step, a 
His-tag and base peptide which had been used for purification of integrin α5β1, were cleaved off and the 
open form of integrin was released. These forms of integrin α5β1 were coupled to an Alexa 647 dye.  
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Figure 3.11. Invwhenestigation of α5β1 integrin binding 
 (A-B) Bacterial suspensions off the P12 wild-type strain and the indicated mutants were incubated with 
purified integrin α5β1 labelled with Alexa fluor 647. The cell binding measured using flow cytometry 
analysis (FACS BD CantoII) is shown in the histograms. Filled histogram corresponds to unstained P12 
wild-type control. The blue, orange, green, dark green and red curves correspond to P12, P12∆PAI, 
P12∆cagI, P12∆cagL, respectively. The representative histograms were from 5 independent experiments 
with duplicated samples. (A) Bacteria stained with the active α5β1 labelled Alexa fluor 647. (B) Bacteria 
stained with the inactive α5β1 labelled Alexa fluor 647. (A3), (B3) The fluorescence intensity was 
analyzed by FACS. Bar graphs show the mean values, and error bars indicate s.e.m. The fluorescence 
intensity from stained bacteria of the indicated strains was given in relation to unstained controls which 
were set to 1. The differences from unstained control values were analyzed by One-way ANOVA (***P < 
0.001).  
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3.2 Interaction	between	CagH,	CagI	and	CagL	
Multiple protein-protein interactions have been observed among components of well-
known type IV secretion systems from other bacterial species, as well as among Cag 
proteins of the Cag-T4SS in H. pylori. Based on the observations about expression 
levels of cagI or cagL, in the different isogenic deletion mutants generated in strain P12, 
we hypothesize that the stability of these proteins might depend on the presence of the 
other components. Such interactions might be crucial for functionality of the Cag-T4SS.  
3.2.1 Determination	 of	 CagI-	 and	 CagL-	 interacting	 proteins	 by	
immunoprecipitation	
To determine whether CagH, CagI and CagL proteins interact with each other in strain 
P12, immunoprecipitation (IP) experiments were conducted from whole cell extracts 
using the CagI antiserum. Immunoblot analysis of CagI, CagL and CagH of the 
immunoprecipitated fractions was performed using the corresponding antibodies. The 
mutants lacking either cagI or cagL were extracted in parallel and served as negative 
controls. Immunoblot analysis of CagI and CagL after IP using the polyclonal CagI 
antibody showed that CagL was successfully precipitated with CagI from a cell extract 
of the P12 wild-type strain but not from the cagI mutant. The same results were 
obtained in the reverse IP using the CagL antibody, demonstrating the specificity of the 
IP, and that CagI indeed interacts with CagL. Likewise, CagH was observed to be 
precipitated together with CagI or CagL from P12 extracts, but not in extracts of either 
the cagI or the cagL mutant (Figure 3.12). It might be that in these mutants, CagH was 
not highly expressed or unstable because of stabilizing effects between these three 
proteins, therefore it was below the detection limit of our blots. These observations 
provided evidence for the interaction of CagH, CagI and CagL proteins. They might 
form a complex in H. pylori cells. 
In order to obtain further evidence for the interaction of CagI and CagL, we performed 
IP experiments using the CagL antibody from the soluble fraction of the bacterial 
subcellular fractionation (section 3.1.3), which is supposed to contain cytoplasmic and 
periplasmic proteins. The precipitated proteins from the soluble fraction of the P12 
wild-type strain and the cag-PAI deletion mutant were examined for the presence of 
CagI and CagL proteins by Western blotting using the corresponding antibodies (Figure 
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3.12B). The results show that CagI was precipitated with CagL in the soluble fraction, 
suggesting this interaction might take place in the bacterial periplasm after being 
exported from the bacterial cytoplasm.  
 
Figure 3.12. CagH, CagI and CagL interact with each other 
(A) Whole cell lysates of the P12 wild-type strain, or its isogenic cagI or cagL mutants were tested for the 
presence of CagH, CagI and CagL proteins with the corresponding antibodies. Cell extracts from strain 
P12 and indicated mutants were subjected to immunoprecipitaton using CagI and CagL antisera. The 
immunoprecipitated proteins were checked for the presence of CagH, CagI and CagL by Western blotting 
using corresponding antisera. (B) Cell pellets from 24 h liquid cultures of the P12 wild-type and the 
P12∆PAI strains were ultrasonicated and fractionated into soluble and insoluble proteins by 
ultracentrifugation. Supernatants containing soluble proteins were used for immunoprecipitaton using the 
CagL antiserum. The immunoprecipitated proteins were checked for the presence of CagI and CagL by 
Western blotting. 
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3.2.2 Generation	of	 a	Myc	 tagged-CagI	 variant	 for	 IP	using	 the	monoclonal	
Myc	antibody	
Since CagI was very unstable and produced at low levels, working with this protein 
turned out to be very difficult. Based on the complementation established earlier 
(section 3.1.2.3) we generated a construct for introducing a tag into CagI. A Myc tag 
was chosen since it had proven to work properly in H. pylori [Jurik et al., 2010]. A Myc 
tag was first introduced at the C-terminus part of CagI. Although the resulting strains 
are able to express Myc tagged-CagI, they were not able to translocate CagA and to 
induce IL-8 (data not shown). This might be explained by interference of the Myc tag 
with the C-terminal motif of CagI, which seems to play a role in interaction of CagI 
with other Cag proteins [Shaffer et al., 2011]. The Myc coding sequence was cloned 
behind the DNA sequence coding for the N-terminal signal peptide and into a predicted 
exposed loop (residue 51) to ensure the proper translocation, resulting in plasmid pPT4 
(contructed as described in 2.1.5). The tagged-cagI construct was introduced into the 
recA locus of the double mutant P12∆cagIL and expressed under the control of the cagA 
promoter (Figure 3.13A). 
The expression of CagI-Myc and CagL was checked by immunoblotting using the CagI, 
CagL and Myc antibodies (Figure 3.13B). The results showed that the CagI-Myc fusion 
protein was expressed in the complemented mutant with a reduced amount compared to 
the level of the wild-type protein. Another tag, the M45 tag, was used to replace the 
Myc tag (plasmid pPT6), but this construct was not successful (data not shown). 
Nevertheless, infection experiments were performed to check for Cag-T4SS 
functionality of the strain producing Myc-taaged CagI. The results showed that the IL-8 
induction capability was rescued, but CagA translocation efficiency was extremely 
reduced in comparision to the P12 wild-type strain (Figure 3.13C). It might be that the 
introduced tag interfered with expression and activity of CagI. Therefore, one possible 
explanation for the reduction of CagA translocation efficiency observed in the Myc-cagI 
complemented strain might be due to the reduced amount of CagI. 
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Figure 3.13. Generation of Myc tagged-CagI 
Schematic representation of constructs used for generation of epitope-tagged CagI. The P12∆cagIL 
mutant was transformed with plasmid pPT4 containing cagI-Myc and cagL with a kanamycin resistance 
gene cassette. The Myc gene was cloned into the N-terminal part at residue 51 of cagI. The epitope-
tagged cagI together with cagL were introduced into the recA gene of the P12∆cagIL double mutant and 
expressed under the control of the cagA promoter. (B) Whole bacterial lysates of strain P12 and of the 
indicated mutants were immunoblotted using antisera against CagI, CagL and Myc proteins. (C) 
Functionality of the Cag-T4SS of the Myc-cagP-complemented mutant was tested by performing 
infection assays of AGS cells to determine CagA tyrosine phosphorylation. The IL-8 values induced by 
the P12 wild-type were set to 100% and other values were normalized to these values (%). The data 
collected from at least 3 independent experiments were statistically analyzed by One-way ANOVA (***P 
< 0.001). 
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Since CagI is still functional with respect to IL-8 induction after adding a Myc epitope 
tag into the N-terminal part of this protein, we performed immunoprecipitation 
experiments of the P12∆cagIL/IMycL strain using a monoclonal Myc antibody. The P12 
wild-type strain and the cagI (P12∆cagIL/L) and cagL (P12∆cagIL/I) mutants, which 
served as negative controls, were performed in parallel in order to show the specificity 
of this method. Immunoblots of the immunoprecipitated proteins and the starting 
materials were done using the CagI, CagL and Myc antibodies. The results showed the 
presence of the Myc and the CagI proteins in the cell preparation derived from the Myc-
tagged-CagI-complemented strain only. The CagL protein was detected to be 
immunoprecipitated with the Myc protein in cell extracts of the complemented strain, 
however it showed up with a comparative strength in the P12 wild-type strain as well 
(indicated with red arrowheads), suggesting an unspecific interaction of the monoclonal 
Myc antibody with CagL (Figure 3.14). Attempts to get rid of unspecific binding of 
contaminating proteins by a pre-incubation of cell lysates with G-agarose beads, 
removing intact cells by ultracentrifugation or using a buffer with a higher salt 
concentration were not successful. Therefore, the interaction between CagI and CagL 
could not be conclusively shown by this assay. 
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Figure 3.14. Investigation of an interaction between CagI and CagL by Myc immunoprecipitation 
Whole cell lysates of strain P12, or the indicated mutants were tested for the presence of CagI, CagL and 
Myc-CagI with the corresponding antibodies. As controls, the mutants which had been complemented 
with either cagI or cagL (strains P12∆cagIL/I and P12∆cagIL/L) were used. Cell extracts from strain P12 
and the indicated mutants were subjected to immunoprecipitaton using the Myc monoclonal antibody. 
The immunoprecipitated proteins were checked for the presence of CagI, CagL and Myc-CagI by 
Western blotting using corresponding antisera. 
 
3.2.3 Pull-down	experiments	
3.2.3.1 GST	pull-down	experiments		
To further investigate potential interactions of CagI and CagL, a direct interaction assay 
using GST fusion proteins was performed. On the one hand, for confirmation of the IP 
results, full-length versions of either CagI or CagL coupled to Glutathione Sepharose 
4B beads were used for capturing interacting proteins from H. pylori lysates. A GST 
protein which is 220 amino acids (26 kDa) in size, was added to the N-terminus of CagI 
and CagL proteins lacking their signal sequences (the first 23 and 20 amino acids, 
respectively). On the other hand, to find out a potential binding domain between CagI 
and CagL, different truncated versions of either GST-CagI or -CagL fusion proteins 
were generated in parallel and used in the same GST pull-down experiments.  
All constructs which were used for expressing fusion proteins are shown in Figure 3.15. 
E. coli BL21 (DE3) containing pWS258 and pPT8 were used for expressing full-length 
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CagI and CagL, respectively. Furthermore, as described above, CagH, CagI and CagL 
contain a conserved C-terminal motif with 6 amino acids (Figure 3.1C). Besides, a 
closer inspection of CagH, CagI and CagL amino acid sequences using the JPred 
software predicted coiled-coil structures, close to the C-terminal ends of CagI and 
CagL, but not of CagH (http://www.compbio.dundee.ac.uk/www-jpred/). Therefore, to 
investigate whether the C-terminal motifs and/or the coiled-coil structures are involved 
in interactions of CagI and CagL, we generated different truncation variants of CagI and 
CagL fusion proteins (Figure 3.15). CagI and CagL were truncated from the C-terminus 
by removing the C-terminal motif coding sequences (7 and 8 amino acid, respectively) 
or the DNA regions coding the coiled-coil structures (57 and 44 amino acids, 
respectively). The cagI gene was furthermore truncated in such a way that the predicted 
transcriptional start site of cagL located in cagI was excluded. The plasmids were 
constructed as described in section 2.1.5.  
As shown in Figure 3.16A1 and B1, full-length proteins and variants of CagI and CagL 
were expressed in E. coli (indicated by black arrowheads). The samples were 
immunoblotted using the GST monoclonal antibody and either CagI (Figure 3.16A2) or 
CagL (Figure 3.16B2) antibody. As expected, the GST protein was detected in all 
samples. Taken together with these data obtained from SDS-PAGE analysis, the results 
showed a successful production of CagI and CagL from all constructs in E. coli BL21 
(DE3). However, CagI could not be detected in E. coli lysates containing either pPT15 
or pPT16 by immunoblotting, because the CagI-specific antiserum had been generated 
using a synthetic peptide against the coiled-coil region of CagI, which is missing in 
these two truncated CagI versions. 
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Figure 3.15. Schematic representation of plasmid contructs used to generate GST-CagI-, and GST-
CagL-fusion proteins  
Full-length versions without the N-terminal signal sequences of either cagI (pWS258) or cagL (pPT8), 
and other constructs were cloned in pGEX-4T-3. The DNA sequences coding for the C-terminal motif of 
CagI (7 amino acids) and CagL (8 amino aicds) were deleted in plasmids pPT14 and pPT17, respectively. 
CagI and CagL were truncated further by removing the sequences (57 amino acids and 44 amino acids, 
respectively) coding for the coiled-coil structures (pPT15 and pPT18, respectively). In the case of CagI, 
pPT16 was constructed in such a way that the transcriptional start site of cagL from cagI was deleted 
together with DNA sequences coding for the C-terminal motif and the coiled coil structure. The signal 
sequences, the C-terminal motifs and the coiled-coil structures are indicated in grey, yellow and blue 
block arrows, respectively  
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Figure 3.16. Expression of GST-CagI fusion proteins 
(A1 and B1) Coomassie Brilliant Blue staining showed the expression of different truncation versions of 
either GST-CagI or GST-CagL. The truncated CagI versions were detected at predicted molecular 
weights of 68, 65, 61 and 42 kDa, respectively. The CagL truncations were detected at predicted 
molecular weights of 55, 54, 48, respectively. The GST protein was found at 26 kDa. (A2 and B2) 
Detection of GST-CagI and and GST-CagL via immunoblots.  
 
For coupling, cell extracts of E. coli expressing the GST-fusion proteins, or the GST 
protein alone were incubated with Glutathione sepharose 4B beads (GE Healthcare). 
These coupled beads were then used for pull-down experiments, in which cell extracts 
of the P12 wild-type strain and, cagI and cagL deletion mutants as negative controls, 
were added as described in section 2.2.3.12. To avoid unspecific bindings of H. pylori 
proteins to glutathione sepharose 4B beads, H. pylori extracts were pre-incubated with 
GST-coupled beads.  
As shown in Figure 3.17, the native CagI and CagL proteins were precipitated with the 
GST-CagL and GST-CagI beads, respectively (indicated by black arrowheads). 
However, the native CagI and CagL proteins were pulled down with the GST beads as 
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well (indicated by red arrowheads), suggesting unspecific interactions. Our attempts to 
to remove non-specific proteins prior to eluting the proteins of interest were 
unsuccessful. Because of these results, the truncated versions were not used further.  
 
Figure 3.17. Pull-down experiments to show interactions between CagI and CagL 
Whole cell lysates of the P12 wild-type strain and the indicated mutants were tested for the presence of 
CagI, CagL and GST proteins using the corresponding antibodies. As controls, lysates of P12∆cagI and 
P12∆cagL mutants were used. Cell extracts of strain P12 and the indicated mutants were subjected to 
pull-down eperiments using GST, CagI-GST and CagL-GST beads. The precipitated proteins were 
checked by CagI, CagL and GST immunoblots. 
 
3.2.3.2 MBP	pull-down	experiments		
Since the pull-down experiments using GST-fusion protein coupled beads had not been 
successful, another strategy was used to verify the interaction between CagI, CagL and 
CagH. In these pull-down assays, CagH was used as a bait protein for investigating 
possible direct interactions with the putative prey proteins CagI and CagL. The cagH 
gene which lacks the DNA sequence coding for a transmembrane region was cloned 
into pMal(g) vector and expressed in E.coli BL21 (DE3) as an MBP fusion protein (data 
not shown). A cell lysate of an induced culture of the strain producing MBP-CagH was 
incubated with the amylose resin. These MBP-CagH-coupled beads were then used for 
a pull-down assay in which either the purified target protein CagI or the CagL protein 
was added. The affinity purified protein samples were analyzed by Western blotting 
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using the CagI, CagL and MBP antibodies. As a negative control, an E. coli lysate 
containing the empty vector pMal(g) was processed in the same way, and the resulting 
MBP-coupled beads were used to show the specificity of this method.  
The MBP and MBP-CagH-fusion proteins expressed in E. coli were successfully 
coupled to the amylose resin as shown by Comassie Brilliant Blue staining (Figure 
3.18A). After adding either purified CagI or CagL protein into MBP-coupled beads and 
MBP-CagH coupled beads, precipitated proteins were immunoblotted using either the 
CagI or CagL, and MBP antibodies (Figure 3.18B). As expected, CagI was isolated with 
MBP-CagH-coupled beads but did not interact with MBP-coupled beads alone, 
suggesting the specificity of this assay. Unfortunately, in the case of CagL, CagL was 
precipitated with MBP-CagH but it was pulled down with MBP-coupled beads as well 
(indicated by a red arrowhead), suggesting an unspecific interaction of CagL and MBP 
beads Therefore, the interaction between CagL and CagH could not be confirmed using 
these assays. 
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Figure 3.18. Detection of a direct interaction between CagH and CagI 
(A) The MBP- and the MBP-CagH-fusion proteins were expressed in E. coli and coupled to the amylose 
resins. The proteins coupled to the beads were detected on SDS-PAGE by Comassie Brilliant Blue 
staining at approximately 40 and 80 kDa, respectively. (B) The purified CagI and CagL proteins were 
added to the MBP-CagH coupled beads and the MBP-coupled beads which were served as a negative 
control. The complex was eluted from beads by boiling in SDS sample buffer and analyzed by the anti-
MBP and anti-CagI or anti-CagL Western blotting.  
 
Another attempt to find out the interaction between CagL and CagH were done, in 
which MBP-CagH-coupled beads were incubated with the GST-CagL-fusion protein. 
The MBP-CagH- and GST-CagL-fusion proteins were expressed, prepared and coupled 
to the amylose resin and the glutathione sepharose 4B beads, respectively, as described 
above (section 2.2.3.12). The MBP-CagH was retained on the amylose beads, whereas 
GST-CagL was eluted from the glutathione sepharose 4B beads by adding reduced 
Glutathione. As controls, MBP-coupled beads and GST alone were used. The starting 
materials are shown in Figure 3.19A. MBP-coupled beads or MBP-CagH-coupled beads 
were mixed with GST alone or GST-CagL at the same amounts. To detect an interaction 
between MBP-CagH and GST-CagL, the affinity-purified protein samples were 
immunoblotted using MBP, GST and CagL antibodies. Unfortunately, GST-CagL 
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interacted with MBP-CagH-coupled beads as well as with MBP-coupled beads 
(indicated by red arrowheads), as shown by the CagL immunoblot. Additionally, the 
GST control blot showed an interaction with MBP control beads and MBP-CagH-
coupled beads, suggesting an unspecific binding of GST protein to MBP-coupled beads 
(indicated by red arrowheads). Interestingly, MBP-CagH-coupled beads did not show an 
unspecific interaction with GST alone and GST-CagL (Figure 3.19B).  
Together with the IP data (section 3.2), these results not only supported the conclusion 
that CagH is a part of the complex containing CagI and CagL, but also provided 
evidence for a direct interaction between CagI and CagH. 
 
Figure 3.19. Pull-down experiments to show an interaction of CagH and CagL 
(A) The MBP and MBP-CagH proteins from protein coupled beads detected on SDS-PAGE were used for 
pull-down experiments (as shown in Figure 3.10). The GST and GST-CagL fusion proteins were 
expressed in E. coli and coupled to the glutathione sepharose 4B beads and detected on SDS-PAGE by 
Comassie Brilliant Blue staining at approximately 26 and 55 kDa, respectively. (B) The purified GST or 
CagL protein was mixed to MBP-CagH-coupled beads and MBP-coupled beads which served as a 
negative control. The complex was eluted from beads by boiling in SDS sample buffer and analyzed by 
anti-MBP, anti-GST and anti-CagL Western blotting. 
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3.3 Characterization	of	CagH,	CagI	and	CagL	functional	domains	
3.3.1 Role	 of	 CagH,	 CagI	 and	 CagL	 domains	 in	 functionality	 of	 the	 Cag	
apparatus	
3.3.1.1 Truncation	of	CagH,	CagI	and	CagL	
Since the in vitro pull-down assays using GST-fusion protein were unsuccessful, we 
sought to find an in vivo assay to determine the interactions between CagH, CagL and 
CagI. Based on the complementation system described above (section 3.1.2.3), in which 
the plasmid pPT3 containing cagI and cagL  was used to complement the cagIL double 
mutant (strain P12∆cagIL), either CagI or CagL was truncated from the C-terminus in 
order to remove their C-terminal motifs or their coiled-coil structures as well. In the 
case of CagI, this protein was truncated further in order to exclude the transcription of 
cagL from a transcriptional start site within cagI, which was proposed by Sharma and 
coworkers [Sharma et al., 2010]. The plasmids pPT9 and pPT10 containing cagL 
variants, and pPT11, pPT12 and pPT13 contaning cagI variants were constructed as 
described above (section 2.1.5). Since the cagI locus overlaps at its 3’ end with the start 
codon of cagL (Figure 3.1A), cagI in all of the cagI truncation constructs was designed 
in such a way that the start codon, and the Shine-Dalgarno sequence of cagL were 
retained. Then, by complementation of the P12∆cagIL mutant, chromosomal integration 
vectors containing the cloned genes enable integration of cagI and cagL together into 
the recA locus and expression of the these genes under the control of the cagA promoter 
(Figure 3.20). The production of CagI and CagL was analyzed by immunoblotting. 
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Figure 3.20. Schematic representation of constructs used for generation of either cagI or cagL 
truncation mutants  
The C-terminal motifs of each protein were removed by transforming the P12∆cagIL double mutant with 
pPT9 and pPT11. The C-terminal motif and the coiled-coil structure together were removed from either 
CagI or CagL by transforming the P12∆cagIL double mutant with either pPT10 or pPT12. The cagL 
transcriptional start site was removed from cagI by transforming the P12∆cagIL double mutant with 
pPT13. cagI and cagL together were introduced into the recA locus and expressed under the control of the 
cagA promoter in the P12∆cagIL double mutant. The signal sequences, the C-terminal motifs and the 
coiled-coil structures are indicated in grey, yellow and blue block arrows, respectively. 
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Figure 3.21. Functional analysis the variants of CagI and CagL 
(A) Whole cell lysates from P12 and the indicated mutant strains were probed with CagI and CagL 
antibodies. Numbers in brackets indicate plasmid constructs used for complementation. (B) These 
plasmid constructs were checked for CagI and CagL expression in E. coli TOP10 by Western blotting 
using the corresponding antibodies. (C) Functionality of the Cag-T4SS of the complemented strains was 
tested by performing infection assays to determine CagA tyrosine phosphorylation and IL-8 induction. 
The IL-8 values induced by P12 wild-type were set to 100% and others values were normalized to these 
values (%). The data collected from at least 3 independent experiments were statistically analyzed by 
One-way ANOVA (***P < 0.001). 
 
The expression of CagI and CagL in all strains was examined by Western blotting 
(Figure 3.21A). As mentioned in section 3.1.2.3, the P12∆cagIL double mutant was 
successfully complemented with plasmid pPT3, containing the full-length cagI and 
cagL genes. However, when this mutant was complemented with plasmids containing 
different truncations of cagI or cagL, only CagI and CagL proteins from the pPT9 
construct were successfully complemented (strain P12∆cagIL/IL(pPT9)). CagL was 
restored to wild-type levels, but at a smaller size due to the lack of its C-terminal motif 
while CagI was expressed at a reduced amount compared to the P12 wild-type strain. 
The reduction of CagI in the absence of the C-terminal motif of CagL suggests a role of 
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this motif in stabilizing CagI. Unexpectedly, by truncating CagL further to remove the 
coiled-coil structure this protein, the resulting strain P12∆cagIL/IL(pPT10) was not able 
to produce a detectable amount of CagL, whereas it produced an extremely low level of 
CagI, as shown by a very faint band obtained in the CagI immunoblot. In the case of 
CagI truncation, CagL expression was observed in all of the mutants at considerably 
reduced amounts with respect to the P12 wild-type strain. None of the cagI 
complementation strains was able to produce CagL at wild-type levels. As mentioned 
above, the CagI antiserum recognizes part of the coiled-coil structure containing 19 
amino acids (350-368) of the protein; therefore it was obviously unable to detect 
mutated CagI in strain P12∆cagIL/IL(pPT12) and strain P12∆cagIL/IL(pPT13). 
However, the loss of CagI expression in the mutant lacking C-terminal motif (strain 
P12∆cagIL/IL(pPT11)) could not be explained (Figure 3.21A).  
Since the cagA promoter is known to be functional in E. coli, we sought to investigate 
the expression of these truncated proteins in E. coli. As shown in Figure 3.21B, in 
comparison to E. coli expressing full-length CagI and CagL together (pPT3), we found 
expression of CagL in all constructs but not in E. coli containing pPT10, which lacks 
the DNA sequence coding for the C-terminal motif and the coiled-coil structure of 
CagL. These results suggest that without these 2 parts, CagL might be misfolded and 
degraded, or could not be recognized by the CagL antibody. Therefore, CagL might not 
be detectable in strain P12∆cagIL/IL(pPT10) as well. We could not find CagI with the 
size of the corresponding protein from the P12 wild-type strain. However, a protein 
band with a size of 30 kDa was obtained in E. coli containing pPT3, pPT9, pPT10 and 
pPT11 but did not appear in the lysate of TOP10. These findings suggest that the 
polyclonal CagI antibody recognized a breakdown product of CagI from these lysates. 
Since the CagI protein is recognized by the CagI antiserum in its C-terminal part, it is 
likely that this processed CagI contains the C-terminal part of this protein. The degraded 
CagI was detected in E. coli, suggesting that the constructs pPT10 and pPT11 should 
have been expressed in H. pylori as well. However, it might be that the CagI protein 
produced by these mutants was under the detection limit of our immunoblots. The lower 
levels of CagI in the absence of CagL confirm the previous observation that CagL plays 
an important role in stabilization of CagI in H. pylori. 
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These complemented strains were then examined for Cag-T4SS functionality by 
infection experiments. Translocation and phosphorylation of CagA were checked by 
Western blotting using the CagA and 4G10 antibodies, respectively, and the ability to 
induce IL-8 were detected by ELISA. The results showed a deficiency of these strains in 
CagA translocation. The mutant lacking the C-terminal motif of CagL can produce CagI 
and CagL at comparable amounts; nevertheless it was defective in CagA translocation 
and remarkably reduced in IL-8 induction to 50% compared with the P12 wild-type 
strain. These data support the conclusion that CagL needs its C-terminal motif to be 
fully functional. However, a residual functionality is present in the absence the C-
terminal motif (Figure 3.21C).  
 
3.3.1.2 Generation	of	CagH	lacking	its	C-terminal	motif	
The existence of a conserved C-terminal motif among CagH, CagI and CagL raised the 
question whether this motif is involved in the function and the interaction between these 
three proteins. Therefore, we sought to evaluate the role of this motif on CagH stability 
and function as well. A deletion of the DNA coding for the C-terminal motif (TKIIVK) 
was introduced into the gene bank plasmid HP2kb05G17 as described above (section 
2.1.5). The stop codon of cagH, which overlaps the Shine-Dalgarno sequence of cagI, 
was retained. The resulting plasmid was used for complementation of the cagH mutant 
(strain P12∆cagH), by which the cagH gene was inserted into the chromosome by 
homologous recombination with cagG and cagI flanking regions and replaced the erm-
rpsl cassette (Figure 3.22). As seen in Figure 3.23A, the cagH mutant (strain 
P12∆cagH) was defective in production of CagI and CagL proteins, whereas the cagH 
complemented strain using the gene bank plasmid HP2kb05G17 (strain P12∆cagH/H) 
recovered both the wild-type phenotypes, suggesting an important role of this protein 
for CagI and CagL stability and/or production. Unlike strain P12∆cagH/H, the cagH 
mutant lacking the C-terminal motif (strain P12∆cagH/H∆C) showed considerably 
reduced levels of CagI and CagL compared to strain P12 (Figure 3.23A), indicating that 
this motif of CagH caused an effect on CagI and CagL stability or production. 
Functionality of the Cag-T4SS was assessed by performing infection experiments of 
AGS cells with the P12 wild-type strain, the cagH mutant and the cagH C-terminal 
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motif deletion mutant. The results showed that deletion of the C-terminal motif 
significantly blocked the translocation of CagA as well as IL-8 secretion, suggesting 
that this C-terminal motif is critical for the function of CagH (Figure 3.23B). 
 
Figure 3.22. Schematic representation of constructs for generation of the cagH C-terminal motif 
deletion mutant 
The DNA sequence coding for 6 amino acids of the C-terminal motif was removed from the gene bank 
plasmid pHP2kb-05G17 by a site directed mutagenesis PCR to generate plasmid pPT31. By transforming 
the P12∆cagH mutant containing an rpsL-erm cassette  with plasmid pPT31, cagH was reintroduced into 
the cagH locus. The C-terminal motif of cagH is indicated as a yellow block. 
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Figure 3.23. Functional role of the C-terminal motif of CagH 
(A) Whole cell lysates from strain P12 and the indicated mutant strains were probed with CagI and CagL 
antibodies. (B) Functionality of the Cag-T4SS of the complemented strains was tested by performing 
infection assays to determine CagA tyrosine phosphorylation and IL-8 induction. The IL-8 values induced 
by strain P12 were set to 100% and other values were normalized to these values (%). The data collected 
from at least 3 independent experiments were statistically analyzed by One-way ANOVA (***P < 0.001). 
 
3.3.1.3 Mutagenesis	of	a	CagH	and	CagL	conserved	internal	motif	
The crystal structure of CagL revealed a disulfide linkage between Cys128 from the α4 
helix and Cys139 from the α5 helix. This covalent bond links α4 to a three-helix bundle 
formed by the upper half of α2, α5, and α6 together with α3 [Barden et al., 2013] 
(Figure 3.24A). Careful analysis of CagH, CagI, and CagL amino acid sequences 
showed that a conserved amino acid sequence between the two cysteine residues (C128-
C139) of CagL is similarly present in CagH (C261-C272) (with a similarity of 92%) 
Results 
98 
 
(Figure 3.24B). Furthermore, the protein containing C128-C139 is close to the C-
terminus of CagL. 
To investigate the role of this disulfide bond in the function of CagH and CagL, we 
constructed site-specific mutants in which either the codons for cysteine or aspartic acid 
was substituted with serine or alanine, respectively, or the 5 residues from cysteine to 
aspartate was deleted as described in section 2.1.5. 
For introducing mutations into CagH, and CagL, the pHP2kb05G17 plasmid 
(containing cagH), or the pPT3 plasmid (containing cagI and cagL) were used for 
directed mutagenesis, respectively. The plasmids containing mutations of cagH were 
transformed into the P12∆cagH mutant, whereas those containing the cagL mutations 
were introduced into the P12∆cagIL double mutant as described before (section 
3.1.2.3).  
Bacterial cell lysates of all mutants were checked for production of CagI and CagL by 
Western blotting. Infection experiments were carried out in order to assess the 
capability of these mutants to translocate CagA and induce IL-8, and to elucidate the 
effect of amino acid substitution or deletion on functionality of the Cag-T4SS. As 
observed in Figure 3.25A, the complementation of the deletion mutants with full-length 
cagH or cagL, restored both CagI and CagL production. Meanwhile, the single amino 
acid mutations resulted in a reduction of CagI and CagL,but this did not impair the 
ability of these strains to translocate and obtain phosphorylated CagA or to induce IL-8. 
A marked reduction of CagI and CagL was observed in both the cagH and cagL mutants 
in the absence of the CPIGD/CGISD motifs. Interestingly, the smaller amounts of CagI 
and CagL produced by strain P12∆cagL/L∆CGISD were still sufficient for CagA 
translocation to occur at a low efficiency, and for IL-8 induction at almost wild-type 
levels. In contrast, the P12∆cagH/H∆CPIGD strain showed no functional CagA 
translocation and a strong reduced IL-8 induction in compared to strain P12 (Figure 
3.25B). The low amounts of CagI and CagL furthermore suggest that the deficiency of 
the P12∆cagH/H∆CPIGD strain in CagA translocation and IL-8 induction is attributable to 
CagH production. Thus, these provide evidence that CagH itself is independently 
required for Cag-T4SS functionality. 
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Figure 3.24. Schematic representation of constructs used for cagH and cagL mutagenesis 
(A) (Left) The disulfide links Cys128 to Cys139, (Right) Structure of CagL [Barden et al., 2013]. (B) 
Amino acid sequence analysis of several CagH and CagL proteins revealed a conserved amino acid 
sequence between two cysteine residues of CagL (C128-C139) and of CagH (C261-C272). To disrupt 
these disulfide bonds, cysteine 128 of CagL and cysteine 261 of CagH, respectively, were substituted 
with serine, whereas aspartic acid 132 of CagL and aspartic acid 265 of CagH, respectively were replaced 
by alanine. Furthermore, amino acids 128-132 of CagL and 261-265 of CagH were removed, 
respectively. Plasmids pPT25, pPT24, pPT32 carrying the C128S, D132A and ∆CPIGD mutations in 
cagL, respectively, were used for complementation of the P12∆cagIL double mutant, resulting in 
integration into the recA gene and expression under the control of the cagA promoter. Likewise, plasmids 
pPT28, pPT29, pPT33 carrying C261S, D265A and ∆CPIGD muations in cagH, respectively, were used 
for complementation of P12∆cagH. These plasmids were constructed from gene bank plasmid 
HP2kb05G17 by a site directed mutagenesis PCR. 
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Figure 3.25. Functional analysis of the CagH and CagL disulfide bonds and internal motifs 
(A) Whole cell lysates of the P12 wild-type strain and the indicated mutants were immunoblotted with 
CagI and CagL antisera. (B) Functionality of the Cag-T4SS from strain P12 and the indicated mutants 
were tested by performing infection assays to determine CagA tyrosine phosphorylation and IL-8 
induction. The IL-8 values induced by the P12 wild-type strain were set to 100% and other values were 
normalized to these values (%). The data collected from at least 3 independent experiments were 
statistically analyzed by One-way ANOVA (*P < 0.05, ***P < 0.001). 
3.3.2 Examination	of	domains	 involved	 in	binding	between	CagH,	CagI	and	
CagL	
3.3.2.1 Role	of	the	conserved	C-terminal	motif	
As mentioned in section 3.1.1, the presence of a conserved C-terminal motif containing 
6 amino acids in CagH, CagI and CagL (Figure 3.1C) raises the possibility that these 
motifs are recognized by a common interaction partner of these 3 proteins. To 
investigate the role of this C-terminal motif in interaction of these 3 proteins, the 
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P12∆cagH/H∆C and P12∆cagIL/IL∆C strains expressing shorter forms of CagH and 
CagL, respectively, were subjected to co-immunoprecipitation experiments using the 
CagL antibody. The P12 wild-type strain and the P12∆cagL mutant were used in 
parallel and served as positive and negative controls, respectively. The presence of 
CagH, CagI and CagL in the precipitated fractions was examined by immunoblotting. 
Immunoblots revealed that CagI and CagH were co-immunoprecipitated with CagL 
from the P12 wild-type strain and the P12∆cagIL/IL∆C mutant but not from the 
P12∆cagH/H∆C mutant (Figure 3.26), which suggests that the C-terminal motif of CagL 
is not absolutely important for interaction between CagI and CagL, and that there might 
be another interacting domain between these 2 proteins instead. In contrast, the C-
terminal motif of CagH seems to have a role in the interaction among these proteins. 
CagH and CagI were observed to interact with each other directly by MBP pull-down 
assays (section 3.2.3.2), the absence of CagH in precipitated fractions provides evidence 
for a direct interaction of these two proteins via the C-terminal motif of CagH. Since 
bacterial lysates contain a cross-reacting protein at almost the same size as CagH, it 
cannot be excluded that CagH was not produced in the mutants at the same level in the 
P12 wild-type, possibly because it is unstable due to a stabilizing effect of CagL on 
CagH, which might require the presence of the C-terminal motif. Unfortunately, the 
mutant expressing CagI lacking the C-terminal motif (strain P12∆cagIL/IL (pPT11)) did 
not produce a stable protein, therefore we could not examine the role of the C-terminal 
motif of CagI in these interactions.  
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Figure 3.26. Role of the C-terminal motifs in interactions between CagH, CagI and CagL  
Whole cell lysates of P12 wild-type strain and the indicated mutants were tested for the presence of CagI, 
CagL and CagH with the corresponding antibodies. Cell extracts of these strains were subjected to 
immunoprecipitaton using CagL antiserum (IP-L). As a control the P12∆cagL muant was used. The 
immunoprecipitated proteins were checked for the presence of CagI, CagL and CagH by Western 
blotting. 
 
3.3.2.2 Role	of	a	disulfide	bond	in	functionality	of	CagH	and	CagL		
The defect of strain P12∆cagH/H∆CPIGD in CagA translocation and IL8- induction raised 
the possibility that these 5 amino acids take part in the interactions between CagH, CagI 
and CagL. To investigate the role of these 5 amino acids for these interactions, co-
immunoprecipitation experiments using the CagL antibody were performed. The 
presence of CagH, CagI and CagL was detected using Western blotting with the 
corresponding antibodies. As seen in Figure 3.27, CagI and CagH were pulled down 
with the CagL antibody in the wild-type strain but not in the cagH mutant lacking the 
CPIGD motif. However, the lack of CagI in the precipitated fraction might also be due 
to the lower expression of CagI in this mutant. Again, we cannot exclude that the CagH 
levels produced by this mutant were low. 
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Figure 3.27. Investigation of the role of the CPIGD motif in interactions between CagH, CagI and 
CagL 
Whole cell lysates of P12 wild-type and the indicated mutants were tested for the presence of CagI, CagL 
and CagH with the corresponding antibodies. Cell extracts of these strains were subjected to 
immunoprecipitaton using CagL antiserum (IP-L). As a control, the cagL deletion mutant, P12∆cagL was 
used. The immunoprecipitated proteins were checked for the presence of CagI, CagL and CagH by 
Western blotting. 
 
3.4 Role	of	CagP	protein	or	sRNA-cagP	on	production	of	CagI	and	CagL	
With the aim of investigating the effects of different Cag components on expression of 
CagI and CagL in strain P12, isogenic mutants of all cag genes coding for proteins 
involved in the function of the Cag-T4SS were generated and examined for CagI and 
CagL protein levels by immunoblotting. As shown in Figure 3.28, CagI and CagL 
production was influenced by the absence of several cag genes. Notably, the cagX, 
cagY, cagH and cagG mutants produced virtually no CagI and several further mutants 
(∆cagδ, ∆cagW, ∆cagV, ∆cagU, ∆cagM, ∆cagL and ∆cagE) produced significantly 
reduced amounts of CagI. Interestingly, CagL levels were reduced with different levels 
in these mutants as well. In contrast, the cagF mutant produced unchanged levels of 
CagI and CagL compared to the wild-type proteins. Additionally, cagQ and cagS 
deletion mutants of strain P12 were tested, since these deletion mutants had been shown 
before to cause strain-specific effects (data not shown). Investigation of the cagP gene 
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deletion showed that deletion of cagP indeed resulted in reduced levels of CagI and 
CagL compared to strain P12 (Figure 3.31A).  
The cagP gene is probably a monocistronic gene [Ta et al., 2012]and the gene product 
comprises of 114 amino acids. However, there have been no studies confirming the 
production of CagP in vitro. Recently, Sharma et al. described transcription of a small 
non-coding RNA, named HPnc2630, upstream of cagP (Figure 3.29A) [Sharma et al., 
2010]. Using the Target RNA 2 software 
(http://cs.wellesley.edu/~btjaden/TargetRNA2/), the 5’ untranslated regions of the cagG 
and cagF genes were predicted as possible binding/target sites (Figure 3.29B). As 
mentioned before (section 3.1.1), the putative promoters upstream of cagG and cagF 
have been reported to be involved in the transcription of tcagI and cagL genes [Sharma 
et al., 2010; Ta et al., 2012]. Taken together, we hypothesized that the sRNA HPnc2630 
might act as a regulator targeting the cagG or cagF promoter to control the expression 
of  cagI and cagL.  
 
Figure 3.28. Influence of the cag gene deletion on production of CagI and CagL5 
Whole cell lysates of equal amounts of the wild-type strain P12 and of isogenic mutants in single cag 
genes were separated by SDS-PAGE and examined by immunoblotting with the anti-CagI and anti-CagL 
antisera, respectively. Representative immunoblots are shown. Note that the cagI mutant shown here was 
generated with plasmid pWS327. Arrowheads indicate the positions of CagI and CagL protein bands, 
respectively. 
                                                 
5
 was performed by Evelyn Weiss 
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Figure 3.29. Analysis of the sRNA 
(A) The sRNA which is shown in purple is located upstream of the cagP gene. The cagP and cagM gene 
nucleotides are coloured green and orange, respectively. (B) The sRNA target prediction using the Target 
RNA 2 software  (http://cs.wellesley.edu/~btjaden/TargetRNA2/) identified possible binding sites to 5’ 
UTR of cagG and cagF which are labeled in red and blue, respectively. 
 
3.4.1 Deletion	of	cagP	leads	to	abolishment	of	Cag-T4SS	functionality	
To further investigate the influence of either cagP or HPnc2630 or both, on production 
of Cag proteins. The different cagP and/or sRNA deletion and complementation strains 
were generated from strain P12 using plasmids as described in Figure 3.30 and in 
section 2.1.5. Bacterial lysates of these strains were subjected to Western blotting 
analysis using different Cag antisera. Of all antisera tested, the cagP and/or sRNA 
deletion mutants showed a reduced expression of CagI and CagL compared to P12 wild-
type (Figure 3.31A). Because of the lack of a CagP antibody, we could not check for the 
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production of the CagP protein in these strains. The ability to phosphorylate CagA and 
to induce IL-8 was analyzed after AGS cell infection of these strains. As seen in Figure 
3.31A, the mutants lacking cagP or HPnc2630 produced less CagI and CagL in 
comparison to the P12 wild-type and were deficient for CagA phosphorylation and IL-8 
expression. Unlike these strains, the sRNA deletion mutant was able to produce CagI 
and CagL at wild-type levels and had a functional T4SS (Figure 3.31B). These results 
indicated that CagP plays a role in stabilization and/or production of CagI and CagL. 
Interestingly, the complementation of P12∆cagP mutant using plasmid pWS338 
containing the sRNA upstream of cagP restored the wild-type phenotype, whereas 
complementation of this strain using plasmid pWS337 (containing only cagP) did not 
(data not shown). Therefore, it remained unclear whether the sRNA has a direct role in 
regulating the expression of CagI and CagL. 
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Figure 3.30. Schematic representation of constructs used for generation of cagP or sRNA deletion 
mutants and complemented strains 
Either cagP or the sRNA, or both, were deleted from strain P12 by insertion of a chloramphenicol 
resistance gene cassette, using plasmids pWS316, pWS426 and pWS433, respectively. The cagP deletion 
mutant was complemented using a chromosomal integration vector containing cagP together with the 
sRNA (pWS338). cagP and the sRNA were introduced into the recA locus and expressed under the 
control of the cagA promoter6. 
 
                                                 
6
 was performed by Evelyn Weiss 
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Figure 3.31. Functional analysis of cagP and the sRNA 
(A) Whole cell lysates of strain P12 and the indicated cagP and/or sRNA mutants were subjected to CagI 
and CagL immunoblots. (B) Functionality of the Cag-T4SS of the mutated or complemented strains was 
tested by performing infection assays to determine CagA tyrosine phosphorylation and IL-8 induction. 
The IL-8 values induced by P12 wild-type were set to 100% and other values were normalized to these 
values (%). The data collected from at least 3 independent experiments were statistically analyzed by 
One-way ANOVA. 
 
3.4.2 Deletion	 of	 cagP	 or	 HPnc2630	 does	 not	 exert	 a	 negative	
transcriptional	effect	on	cagI 
To analyze whether the reduction of the CagI protein in the different cagP and/or sRNA 
deletion mutants is attributable to reduced transcription of the cagI gene, cagI 
transcripts were quantified by real-time PCR using specific primers for the cagI gene, 
and primers for 16S RNA as a reference. The control PCR showed PCR amplification 
products  for the cagL and 16S RNA genes from cDNAs, but not from mRNA samples, 
suggesting that the preparation of cDNA was not contaminated with genomic DNA. As 
seen in Figure 3.32, quantification of the cagI mRNA by qPCR showed no significant 
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difference between the P12 wild-type and the various cagP and/or sRNA mutants and 
complemented strains. These results indicate that there is no transcription effect caused 
by the absence of cagP or the sRNA.  
 
Figure 3.32. cagI transcription analysis 
H. pylori strain P12 and the indicated cagP mutants were cultivated in liquid media to mid-exponential 
phase before being harvested for RNA extraction and cDNA synthesis. Quantitative real-time PCR was 
carried out to analyze the transcript levels of cagI in each cDNA sample. An analysis of 16S RNA 
transcript levels was performed in parallel for normalization. The values obtained from strain P12 were 
set to one and other values compared to strain P12 by One-way ANOVA. Bar graphs represent the means 
from at least 3 independent experiments with standard errors of the mean. 
 
3.4.3 Generation	of	a	tagged	CagP	variant	
Since the deletion of cagP and/or the sRNA did not cause any transcriptional effects, 
there might be a stabilizing effect of the CagP protein on CagI and CagL instead. For 
facilitating a characterization of the CagP protein, we intended to construct H. pylori 
strains producing tagged-CagP versions (Figure 3.33). DNA sequences coding for the 
M45 epitope tag [Hohlfeld et al., 2006] were introduced at the 3’ end of cagP. First, 
cagPM45 together with the sRNA sequence was introduced into the cagP-sRNA locus in 
strain P12, using plasmid pPT7. The production of CagI and CagL in the resulting strain 
(P12cagPM45) was examined by Western blotting, showing a reduction of CagI and 
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CagL compared to the P12 wild-type strain, but no expression of the M45 tag was 
observed (Figure 3.34A).  
Another attempt to introduce a tag into the CagP protein was carried out. Based on the 
complementation of the cagP deletion mutant using plasmid pWS338 containing cagP 
and HPnc2630, which had restored the wild-type phenotypes, another construct was 
designed to introduce cagPM45 into the recA locus using a chromosomal integration 
vector (pPT20). The resulting strain (strain P12∆cagP/PM45) was, however, not able to 
restore CagI and CagL production to wild-type levels and not fully recovered ability to 
transclocate CagA. Again, we could not detect production of the M45 tag (Figure 
3.34A).  
It has been known that the mRNA levels of cagP were low in vitro compared to other 
cag genes [Ta et al., 2012]. On the other hand, another study on expression of the cagP 
promoter in vitro provided evidence about an increased expression of cagP in the 
presence of host cells [Joyce et al., 2001]. Therefore, to investigate the expression of  
M45 tagged-CagP, infection experiments were performed. However, the 
P12∆cagP/PM45 strain lost the ability to translocate CagA (Figure 3.34B) and produced 
no M45-tagged-CagP protein, which could not be detected on the blot (data not shown). 
Another epitope tag, the Myc tag, was introduced into the CagP protein; however the 
results were the same as observed from the M45-tagged CagP (data not shown). 
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Figure 3.33. Schematic representation of constructs used for generating a tagged-CagP variant 
As a first strategy, cagPM45 together with the sRNA was integrated into chromosome to replace the wild-
type cagP-sRNA by transforming strain P12 with plasmid pPT7. In the second approach, cagP and the 
sRNA were introduced into the recA locus of the P12∆cagP mutant by transforming with plasmid pPT20, 
and were expressed under the control of the cagA promoter. In both cases, the M45 tag was introduced in 
to the C-terminal end of CagP. 
Results 
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Figure 3.34. Functional analysis of the tagged-CagP 
 (A) Whole cell lysates of the P12 wild-type strain and the indicated mutants were subjected to CagI, 
CagL imunnoblotting using the corresponding antibodies. (B) Functionality of the Cag-T4SS from strain 
P12 and the indicated mutants was tested by performing infection assays of AGS cells to determine CagA 
tyrosine phosphorylation. The IL-8 values induced by the P12 wild-type strain were set to 100% and other 
values were normalized to these values (%). The data collected from at least 3 independent experiments 
were statistically analyzed by One-way ANOVA (***P < 0.001). 
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4 DISCUSSION	
The action of the bacterial oncoprotein CagA contributes significantly to pathogenesis 
of H. pylori infection. Translocation of CagA is facilitated by a transmembrane protein 
complex containing at least 15 proteins, the Cag-Type IV secretion apparatus. The Cag 
apparatus comprises not only conserved essential components but also several 
additional proteins which are unique to this system. The activities of several essential 
components in CagA translocation have been investigated before, but complementation 
studies are often lacking. In this work, we have provided new insights into the 
functional role of three components of the Cag-T4SS that lack homologs in other T4SSs 
– CagH, CagI, and CagL.  
4.1 CagP	exerts	a	stabilizing	effect	on	CagI	and	CagL	
The data from mutagenesis studies of cag genes revealed a contribution of cagP and/or 
the sRNA associated with cagP, HPnc2630, on functionality of the Cag-T4SS in strain 
P12 (Figure 3.28, Figure 3.31B). Additionally, the results obtained from an RNA target 
prediction using Target RNA 2 software showed that HPnc2630 may bind to the 5’ 
untranslated region of the cagG and/or cagF genes, which are located upstream of cagI 
and cagL (Figure 3.29). Therefore, we hypothesized that either the cagP gene product 
might have a functional role and exert an influence on expression of cagI and cagL, or 
that the sRNA HPnc2630 may act as a regulator targeting the cagG or cagF promoter to 
control the expression of the putative operon containing cagI and cagL.  
Using gene deletion and complementation studies of cagP and/or the sRNA, we found 
that the absence of cagP or cagP together with HPnc2630 exerted an effect on 
production of CagI and CagL (Figure 3.31A), which led to a deficiency of these mutants 
in CagA translocation and IL-8 induction, suggesting that CagP might play a role in 
stability and/or production of CagI and CagL. Interestingly, the sRNA deletion mutant 
was still able to produce both CagI and CagL at wild-type levels, and was not defective 
in CagA translocation as well as IL-8 induction by AGS cells (Figure 3.31B). Similarly, 
a recent study characterized a small non coding RNA (termed cncR1) in strain G27 
[Vannini, 2013], which corresponds to the 5’ untranslated region (termed HPnc2630) 
uptream of cagP in strain 26695 [Sharma et al., 2010]. Interestingly, they found that the 
cncR1 might reduce the mRNA stability or the transcription rate of the cagP promoter 
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under normal growth conditions by showing that in the absence of the cncR1, transcript 
levels of the cagP promoter were even higher than transcript levels from the cagA 
promoter [Vannini, 2013]. In addition, a terminator containing 29 bp, which was 
identified in the 3’ region of cncR1, might strongly reduce the downstream transcription 
of the putative cagP coding sequence. Thus, it is possible that in our sRNA deletion 
mutant (strain P12∆sRNA), the high efficiency of the cagP promoter and the absence of 
the terminator resulted in an abundance of the cagP transcript and the CagP protein, 
which promoted CagI stability, and thus did not abolish the function of the Cag-T4SS. 
These results suggest that the sRNA is not absolutely necessary for the type IV-
associated function of CagP. Surprisingly, complementation of the P12∆cagP mutant 
with plasmid pWS338 containing cagP and the sRNA HPnc2630 restored the wild-type 
phenotype (Figure 3.31B), whereas complementation of this strain with pWS337 
containing only cagP, did not (data not shown), implying that the sRNA has a certain 
role in cis on cagP expression, which is not consistent with the previous conclusion. 
The plasmid pWS337 was constructed in a the way that the putative terminator located 
in the 3’ region of this sRNA was retained, while plasmid pWS338 contains the whole 
sequence spanning the cagP promoter, the sRNA and the putative cagP gene. Therefore, 
it is possible that the transcription from the cagA promoter (pWS337) could not read 
over the terminator, whereas transcription from the cagP promoter (pWS338) could. 
Importantly, we show that there is no transcriptional effect exerted by deletion of cagP 
and/or the sRNA on transcription of the cagI gene (Figure 3.32). These results are in 
line with the data provided in a recent study where the sRNA was observed to have no 
effect on the cag genes under normal growth conditions using the microarray 
transcriptional analyses and primer extension assay. In contrast, the sRNA exerts down-
regulation effects on the regulation of motility functions [Vannini, 2013]. Unfortunately, 
our attempts to construct an epitope-tagged CagP version were unsuccessful, possibly 
due to the low transcriptional level of cagP as observed in different studies 
[Boonjakuakul et al., 2005; Ta et al., 2012] and in the presence of the terminator located 
in the 3’ region of the sRNA [Vannini, 2013]. Taken together, at present, it is apparent 
that the CagP protein, but not HPnc2630, is required for the full function of the Cag-
T4SS. Further experiments should be done to characterize the function of CagP and the 
sRNA. 
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4.2 Functional	 dependence	 of	 the	 Cag-T4SS	 on	 CagH,	 CagI	 and	 CagL	
components	
The requirement of several Cag proteins for CagA translocation as well as IL-8 
induction has been demonstrated in several mutagenesis studies [Censini et al., 1996; 
Fischer et al., 2001b; Selbach et al., 2002; Shaffer et al., 2011]. Among the essential 
components of the type IV secretion apparatus, CagH, CagI and CagL are not 
homologous to any components of other bacterial T4SSs. In the current study, using 
careful mutation and complementation studies, we show that CagH, CagI and CagL are 
essential components of the Cag type IV secretion apparatus in H. pylori strain P12. 
These results are generally consistent with previous studies, which showed that the 
individual deletion of cagH [Fischer et al., 2001b; Shaffer et al., 2011], cagI [Censini et 
al., 1996; Selbach et al., 2002; Shaffer et al., 2011] and cagL [Fischer et al., 2001b; 
Jimenez-Soto et al., 2009; Kwok et al., 2007; Shaffer et al., 2011] resulted in a 
deficiency of CagA translocation and IL-8 induction. However, in previous works, 
complementation has only been performed for cagL [Jimenez-Soto et al., 2009; Kwok 
et al., 2007], showing that both phenotypes were fully restored by complementation of 
this gene. Complementation of cagH and cagI deletions has only recently been shown 
while this work was conducted [Shaffer et al., 2011]. In the case of CagI, the conflicting 
results regarding the role of CagI in CagA translocation [Wang et al., 2012] and IL-8 
induction [Fischer et al., 2001b] from gastric epithelial cells might be explained either 
by different strain-specific requirement of these components, by differences in gene 
expressions between the cagI mutants, or by differences in construction of the cagI 
deletion mutants. 
The study published during the work on this thesis [Shaffer et al., 2011], used the 
marker-free cagH and cagI deletion mutants and included complementation studies for 
functional characterization of these proteins, but determined only CagL production in 
the absence of either cagH or cagI. Other previous and recent studies used isogenic 
mutants containing resistance gene cassettes, which were not complemented [Censini et 
al., 1996; Fischer et al., 2001b; Kumar et al., 2013; Kwok et al., 2007; Selbach et al., 
2002; Wang et al., 2012]. Therefore, it could not be concluded whether the deficiency of 
either CagA translocation or IL-8 induction, or both, resulted from the absence of the 
Discussion 
116 
 
corresponding proteins, or from reduced levels of other proteins caused by a polar effect 
caused by insertion of a resistance gene cassette. In this work, we show that not only 
CagL whose essential requirement has clearly been shown before [Jimenez-Soto et al., 
2009; Kwok et al., 2007], but also CagH and CagI are required individually for CagA 
translocation and IL-8 induction. Deletion of cagI and its replacement by a resistance 
gene cassette, or deletion without a resistance marker, showed no severe transcriptional 
effects on cagL (Figure 3.8). It is worth noting that deletion of cagI led to a reduction of 
CagL to varying levels. Nevertheless, these differing CagL levels were not responsible 
for a defect of the Cag-T4SS, since the complete cagI marker-free deletion mutant 
producing wild-type levels of CagL has no functional Cag-T4SS (Figure 3.5). These 
results were substantiated by data obtained by complementation of the cagI and cagL 
double mutant with cagL only, which showed that despite producing unchanged levels 
of CagL in respect to the P12 wild-type (Figure 3.7A), the cagL complemented strain 
was not able to translocate CagA and induce IL-8 secretion, demonstrating that the 
effect has to be ascribed to the lack of CagI (Figure 3.7B). These findings suggest that 
CagI itself is required for a proper functionality of the H. pylori Cag-T4SS.  
Regarding the functional role of CagH, although we failed to construct a marker-free 
cagH mutant to exclude a possible polar effect caused by insertion of an antibiotic 
resistance cassette, the complementation of a cagH deletion mutant not only in cis but 
also in trans (Figure 3.3) recovered the defect of Cag-T4SS functionality observed in 
the cagH mutant. Taken together, we can conclude that CagH is independently 
responsible for the defect of CagA translocation and IL-8 induction, and exclude that 
these phenotypes are indirectly caused by low levels of CagI and CagL. A recent study 
in which HA-tagged cagH was complemented in the ureB locus of a cagH marker-free 
mutant reached the same conclusion [Shaffer et al., 2011]. 
4.3 CagH,	CagI	and	CagL	have	stabilizing	effects	on	each	other	
The chromosomal region containing the cagI gene was reported to be organized in an 
operon containing at least five genes (cagF, cagG, cagH, cagI and cagL), or even eight 
genes (cagC, cagD, cagE, cagF, cagG, cagH, cagI and cagL) [Sharma et al., 2010], in 
which the later three genes, cagH, cagI and cagL, or the ribosome binding sites, overlap 
each other (Figure 3.1), suggesting a physical or a functional relationship between these 
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3 gene products. As mentioned above, deletion of cagI resulted in a variable reduction 
of CagL protein levels, and deletion of cagH resulted in reduction of both CagI and 
CagL levels, originally suggesting that transcriptional effects occur. However, 
complementation of these genes in different loci successfully rescued both phenotypes, 
suggesting that the proteins are responsible for these effects. Additionally, the 
quantification of the cagL mRNA by qPCR showed no significant difference between 
the P12 wild-type and the various cagI mutants (Figure 3.8), indicating that the 
transcription of cagL is not generally influenced by deletion of cagI. Therefore, we 
concluded that the reduction of CagL was not due to a transcriptional effect caused by 
deletion of cagI, but due to a stabilizing effect of CagI on CagL.  
We provide further experimental evidence for a stabilizing effect of CagL on CagI by 
showing that the reduction of CagI levels was associated with the absence of CagL. As 
shown in Figure 3.7A, using the same mutant background (strain P12∆cagIL) for 
complementation of either cagI alone or cagI and cagL together, the cagI complemented 
strain showed a reduced level of CagI, whereas the complementation of both genes 
(cagI and cagL) recovered production of CagI at the level of the P12 wild-type. In 
contrast, CagL production showed unchanged levels in the presence or absence of CagI 
for at leat one cagI mutant (Figure 3.7A). It is likely that in the wild-type strain or in 
those cagI mutants in which the 3’ cagI region containing the cagL transcriptional start 
site was retained, CagL is at least expressed under the control of the cagL promoter. 
Since the cagL transcript level was increased in the mutant lacking complete cagI 
(strain P12∆cagI(327) (Figure 3.5), it can be assumed that the precise deletion of cagI 
resulted in an efficiency increase of cagL transcription (Figure 3.8), possibly via the 
putative cagF or cagG promoter or another promoter located within the cagFGHIL 
operon [Ta et al., 2012] suggesting that cagL transcription is deregulated in this mutant. 
Collectively, these data demonstrate that CagI is not absolutely required for CagL 
production. However, it is possible that the presence of the CagI protein and its 
interaction with CagL accounts at least partly for maintenance of CagL wild-type levels.  
In the case of CagH, the stabilizing effect of CagH on CagI and CagL was obvious by 
the marked reduction of CagI and CagL levels produced by the cagH mutant (Figure 
3.3A), given that these effects were restored by complementation of this mutant in cis 
and in trans (Figure 3.3A). Reduction of CagI levels in a cagH deletion mutant have 
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also been reported by Kumar et al. [Kumar et al., 2013] and Shaffer et al. [Shaffer et al., 
2011], but only the complementation studies done here demonstrate that this is due to 
stabilization on the protein level, and can be explained by a direct interaction of these 
two proteins as observed in Co-IP and MBP pull-down experiments (Figure 3.19). 
4.4 Cellular	 localization	 and	 interaction	 of	 the	 CagH,	 CagI	 and	 CagL	
proteins		
Based on the combined data from the gene locus analysis, transcriptional arrangement 
of genes, sequence features of the corresponding gene products, and stabilizing effects 
among CagH, CagI and CagL, it was reasonable to hypothesize that CagH, CagI and 
CagL form a complex or a subcomplex with other components of the Cag-T4SS, and 
that these interactions might play crucial roles in CagA translocation mechanism. 
Previous studies using yeast two-hybrid assays [Busler et al., 2006; Jurik et al., 2010]  
demonstrated interactions between CagI and several other Cag proteins, including 
CagG, but none of them was confirmed, except for an interaction between recombinant 
CagI and CagZ fusion proteins in vitro [Busler et al., 2006]. In the current work, we 
conducted immunoprecipitation studies that clearly demonstrate interactions between 
the native CagH, CagI and CagL proteins. The reduced CagI levels in mutants lacking 
components of the putative type IV secretion apparatus core complex (∆cagV, ∆cagW, 
∆cagX, ∆cagY, and possibly ∆cagE), or in mutants lacking components of the putative 
outer membrane-associated subcomplex (∆cagδ, ∆cagM, ∆cagX) (Figure 3.28), 
indicated that corresponding protein-protein interactions might exist. However, we were 
unable to detect any interaction of CagI (or CagL) with CagX or CagY (data not 
shown). The identified interactions between CagH, CagI and CagL are generally in line 
with the findings of two studies published while this work was conducted, in which 
CagH, CagI and CagL interactions were shown by immunoprecipitation of either CagH 
or CagI [Kumar et al., 2013], or by immunoaffinity purification of CagL from H. pylori 
lysates [Shaffer et al., 2011]. Interestingly, we found the interaction of CagI and CagL 
in the soluble fraction of cellular fractionation (Figure 3.12B), suggesting that this 
interaction might take place in the bacterial periplasm, given that both proteins possess 
N-terminal signal sequences. Furthermore, consistent with recent data gained from in 
vitro studies of Kumar et al. [Kumar et al., 2013], we show here an evidence for a direct 
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interaction between the recombinant CagH and CagI proteins by MBP pull-down 
experiments (Figure 3.19). However, our attempts to verify a direct interaction between 
CagH and CagL were unsuccessful because of unspecific interactions. We tried to prove 
whether the interaction between CagI and CagL is direct or mediated by a common 
interacting partner by using an E. coli strain expressing cagH, cagI, cagL under the 
control of the cagA promoter. However, we observed severe difficulties in expressing 
cagH without mutation in E. coli, suggesting that E. coli cells are intolerant to cagH 
gene expression. Therefore, we have not been able to produce the CagH protein in E. 
coli.  
Other than for CagL, there is little known about the localization of CagH and CagI. As 
mentioned previously, topology prediction of these proteins shows that because of the 
predicted signal sequences, CagI and CagL might be secreted proteins (Figure 3.1). 
Evidence for binding of CagI and CagL to β1 integrin, a receptor for the Cag type IV 
secretion apparatus on host cells [Jimenez-Soto et al., 2009; Kwok et al., 2007], as well 
as a direct evidence for localization of CagL on the type IV secretion pili (Kwok et al., 
2007), have been shown. By using scanning electron microscopy, Shaffer et al. showed 
that when bacteria were co-cultured with gastric epithelial cells, pili were found at the 
bacterial-host cell interface. However, the pili were not detectable in the bacteria 
lacking CagI and CagL or in the absence of cell contact. Unlike the cagI or cagL 
deletion mutants, the cagH deletion mutant was able to produce pili in the co-infection 
experiments with AGS cells, and it was speculated that CagH might be a regulator of 
pili dimensions. However, they could not detect CagH, CagI and CagL on the pili when 
H. pylori was co-cultured with AGS cells [Shaffer et al., 2011]. Another study on 
localization of CagI showed that CagI was detected on pili under non-infection 
condition using transmission electron microscopy [Kumar et al., 2013]. Furthermore, 
our preliminary data showed that deletion of cagI or cagL led to a reduction of integrin 
binding efficiency as observed in the cag-PAI deletion mutant (Figure 3.11), suggesting 
that CagI and CagL take part in the interaction between H. pylori and the host cell α5β1 
integrin receptor. Taken together, these data on CagI and CagL indicate that both 
proteins are (partly) surface exposed. Using fractionation studies and proteinase K 
digestion, we have shown that CagI and CagL are present in different subcellular pools, 
and that both proteins are partly surface-exposed. It is intriguing that these two proteins 
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do not have a similar localization pattern in bacterial cell fractions (Figure 3.9A). CagI 
is mostly associated with the membrane fractions and not readily extracted by triton X-
100, suggesting that CagI might localizes to the outer membrane. Meanwhile, in 
agreement with previous reports [Kutter et al., 2008; Rohde et al., 2003; Shaffer et al., 
2011], the majority of CagL was found in a soluble fraction, and only a smaller amount 
in the membrane fraction (Figure 3.9A). In addition, CagI and CagL seem to be equally 
distributed in membrane-associated fractions obtained by sucrose gradient 
centrifugation (Figure 3.9B). That might be explained by the limitation of this method 
in separating cytoplasmic and outer membrane proteins of H. pylori, as described 
previously [Kutter et al., 2008; Pattis et al., 2007]. However, the protease digestion 
experiments showed a higher susceptibility for CagI than for CagL (Figure 3.9C), and 
CagL was only slightly degraded by proteinase K digestion, suggesting that the majority 
of CagL is either located inside the bacteria, or that surface-associated CagL is not 
accessible for the proteinase. This finding is consistent with previous studies proposing 
that CagL was localized mainly in the periplasm [Kutter et al., 2008; Shaffer et al., 
2011]. Since pili have been found on the surface of bacteria in the absence of host cells 
[Kumar et al., 2013; Rohde et al., 2003], it remains unclear whether the surface-exposed 
CagI and CagL as observed by proteinase K digestion, is pilus-associated or just at the 
outer membrane. The multiple pools of CagH and CagL with different localizations 
might be due to the different stages of Cag-T4SS assembly.  
Unfortunately, our efforts to extract and purify pili for determination of their 
composition were unsuccessful. Therefore, we could not prove whether CagI and CagL 
are localized and interact on pili. We have so far been unable to localize CagI at the 
bacterial surface by immunofluorescence, since the CagI antiserum does not seem to 
recognize the native protein. Several attempts to generate an epitope-tagged variant of 
CagI which could be used for immunofluoresence staining and other purposes have not 
been successful either. Thus, it remains to be elucidated whether CagI is really 
associated with the pilus-like type IV surface appendages. 
4.5 Conserved	C-terminal	motifs	and	internal	motifs	contribute	to	the	
function	of	CagH,	CagI	and	CagL		
Starting from the interesting observation that there is a high similarity of the C-terminal 
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6 amino acids of CagH, CagI and CagL (Figure 3.1C), we reasoned that these motifs 
play functional roles for example as a common binding motif for interaction between 
these three proteins. In agreement with a recently published study [Shaffer et al., 2011], 
we found that the C-terminal motifs of CagH and CagL are important for CagA 
translocation and IL-8 induction (Figure 3.21C and 3.23B). However, in contrast to that 
study, deletion of the C-terminal motif from CagL did not result in the abolishment of 
IL-8 induction in our hands, but accounted only for an approximately 50% reduction of 
of IL-8 levels compared to wild-type P12 (Figure 3.21C), suggesting that CagL can 
induce IL-8 independently of its function in mediating T4SS substrate translocation. 
Interestingly, a recent study showed that recombinant CagL lacking the C-terminal 
motif retained its full adherence capability to human adenocarcinoma (MKN-45) cells 
[Barden et al., 2013]. Since CagL was proposed as a ligand for integrin binding, our 
finding indicates that in the absence of the C-terminal motif, CagL is still able to 
mediate binding of the Cag-T4SS to host cells. Assuming that IL-8 secretion is induced 
by physical interaction of the secretion apparatus with host cells, rather than by active 
type IV secretion, it seems reasonable that in the absence of the C-terminal motif, CagL 
still triggers IL-8 secretion. Which part of CagL, which might be involved in IL-8 
induction, is currently not clear. Although it has been reported that CagL induces IL-8 
secretion through the interaction of its RGD motif with integrin receptors [Gorrell et al., 
2012], other data [Jimenez-Soto et al., 2009] suggest that the RGD motif is not 
necessary for IL-8 induction. In any case, the complete deficiency of the mutant lacking 
C-terminal motif for CagA translocation indicates that different regions of CagL are 
required for IL-8 induction, and for CagA translocation, respectively. 
Unexpectedly, we failed to construct a CagI C-terminal motif deletion mutant producing 
a detectable CagI protein using the same strategy which had been used for generating 
the CagL mutant lacking the C-terminal motif. The CagI∆C mutant (strain P12∆cagIL/IL 
(pPT11)) still produced CagL, but no detectable traces of CagI (Figure 3.21A). When 
the plasmid (pPT11) was checked in E. coli, CagI was detected with a smaller size, 
indicating that it is unstable in E. coli cells (Figure 3.21B), whereas cagL is still 
expressed. This interesting finding also suggests that CagI lacking the C-terminal motif 
might have been degraded in H. pylori to a level that was under the detection limit of 
the Western blot. This instability of CagI might be explained by a direct interaction of 
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CagH and CagI (Figure 3.18), possibly via the C-terminal motifs of each protein.  
Although these motifs play important roles in functionality of the Cag-T4SS [Shaffer et 
al., 2011], there has been no study concerning the contribution of these motifs on 
interactions of CagI, CagL and CagH. In the current study, we show that the C-terminal 
motif of CagH affects the interactions between CagI and CagL, but the C-terminal motif 
of CagL does not. This result might be explained by a direct interaction of CagH and 
CagI, as suggested by MBP pull-down experiments (Figure 3.18). However, as shown in 
Figure 3.26, the amounts of CagI and CagH precipitated with CagL were reduced 
compared to the wild-type P12, suggesting that the absence of the C-terminal motif of 
CagL reduces the affinity of binding between these three proteins. Based on these 
findings, it is likely that all interactions are needed for a full functionality of the Cag 
apparatus and for a maximal induction of IL-8. 
The presence of these conserved C-terminal motifs as a common binding motif for 
interaction between these three proteins was mentioned above. On the other hand, the 
CagL structure revealed that the CGISD motif is close to the C-terminal motif of CagL; 
separated by two alpha helices [Barden et al., 2013]. These helices and these motifs are 
possibly conserved in CagI and CagH [Barden et al., 2014]; this may imply that these 
regions bind to a common interaction partner; or that region from one component 
replaces the same region from the next component. This is reminiscent of “donor-strand 
complementation’’ in type I pilus biogenesis (reviewed in [Lillington et al., 2014]). In 
this process, two proteins are involved, a periplasmic chaperone and an outer membrane 
usher. The chaperone is essential for stabilization/folding of subunits, for avoiding 
premature subunit polymerization in the periplasm, and for targeting chaperone-subunit 
complexes to the usher protein which forms the outer membrane pilus assembly site. All 
pilus subunits exhibit an incomplete Ig-like fold and an exposed hydrophobic groove 
resulting from the lack of the seventh β-strand. In addition, each subunit has a flexible 
N-terminal extension peptide of 10-20 residues. Once pilus subunits are secreted and 
folded in the periplasm, the chaperone interacts with each subunit reconstituting the 
incomplete Ig-like fold by inserting its G1 β-strand into the subunit's hydrophobic 
groove. This interaction is called donor-strand complementation. The subunit is next 
transferred to the periplasmic N-terminal domain of the usher and incorporated into the 
pilus. During incorporation into the pilus, the chaperone G1 β-strand is replaced by the 
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N-terminal extension domain of the incoming subunit. This process is termed donor-
strand exchange. In the H. pylori Cag-T4SS, a similar assembly mechanism might 
explain the conserved regions between CagH, CagI and CagL, but in the absence of a 
crystal structure of CagH-CagI-CagL complex, this remains speculative. 
As observed in the crystal structure of CagL, the protein region containing the C-
terminus and the alpha helicies α3, α4, α5, α6 contains a disulfide bond between Cys128 
located in the α4 helix and Cys139 in the α5 helix (Figure 3.24) [Barden et al., 2013]. 
Amino acid sequence analysis revealed that the sequence between these two cysteine 
residues (C128-C139) of CagL is similar to a region in CagH (C261-C272), which also 
contains two equally spaced cysteine residues (92% similarity). Particularly, Tyr225 of 
CagL was shown to form a hydrogen bond with Asp132, which is conserved between 
CagH and CagL (Figure 3.24). Therefore, we assumed that a point mutation leading to 
the loss of the disulfide bond, or deletion of some amino acids might lead to a defect of 
protein function. Using site-directed mutagenesis, this amino acid sequence was 
analyzed for its role in functionality of the Cag-T4SS and in the interactions among 
CagH, CagI and CagL. We found that neither a cysteine nor an aspartic acid substitution 
resulted in a defect of CagA translocation and IL-8 induction. However, deletion of 5 
amino acids between the two cysteine residues resulted in a marked reduction of CagI 
and CagL levels, and consequently in a deficiency in the functionality of CagH∆CPIGD for 
CagA translocation and IL-8 induction. In contrast, although the CagL∆CGISD mutant 
produced markedly reduced levels of CagI and CagL, this strain was still able to 
translocate CagA into host cells, but with a lower efficiency compared to wild-type. 
Interestingly, this strain induced IL-8 induction as the wild-type (Figure 3.25), 
supporting the finding that CagL induces IL-8 secretion independently of promoting 
CagA translocation. Besides, these data provide evidence that these five amino acids 
play an important role to stabilize the part of the CagL protein structure, which affects 
the CagA translocation process.  
4.6 The	Cag-T4SS	displays	numerous	specific	features	
The Cag-T4SS consists of several conserved components, which have been identified 
first by comparison with the A. tumefaciens VirB/VirD4 system, a prototypical T4SS 
(section 1.3.2). In general, the essential components of the T4SSs are important for pilus 
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assembly and/or substrate transfer. Interestingly, many essential components of the Cag-
T4SS are unique for the Cag apparatus, having no functional counterparts in other 
systems [Fischer, 2011]. The components analysed in the current study CagH, CagI and 
CagL show no sequence similarities to components of other T4SSs. Functional analysis 
demonstrated that CagH, CagI and CagL are critically important for translocation of the 
effector CagA protein and IL-8 induction by AGS cells. 
The existence of pilus components which might act as adhesins in establishing a tight 
bacterial contact with target cells is a distinguished feature of the contact-dependent 
T4SS systems. Both CagI [Jimenez-Soto et al., 2009] and CagL [Kwok et al., 2007] 
were observed to interact with β1 integrin in vitro, which is supported by our integrin 
binding experiments. Moreover, CagI and CagL were shown to contribute to the 
formation of pili, whereas CagH might have a regulatory role in pili dimension [Shaffer 
et al., 2011]. Taken together, it is reasonable to conclude that CagI, CagL and CagH 
might belong to the group of pilus or pilus-associated components, or that the presence 
of these proteins is at least critically important for pilus biogenesis. CagL has been 
considered before as a functional homolog of A. tumefaciens VirB5, or the VirB5 
homolog TraC of the E. coli F-type conjugation system. VirB5 is considered as the most 
divergent protein in the T4SSs [Backert and Selbach, 2008], and it is even absent in 
some systems such as the Ptl system of Bordetella pertussis [Zechner et al., 2012]. 
Since CagI and CagL were shown to function as integrin ligands and form a complex or 
a subcomplex, which seems to be important for Cag-T4SS functionality, we may 
assume that the CagI-L complex fulfils the function similar to the VirB5 protein. 
However, it has to be noted that CagL structure is very different from the VirB5 
structure [Barden et al., 2013].   
Localization studies of pilus-associated components such as VirB5 and TraC have 
shown that these proteins are first located in the cytoplasm, or associated with the inner 
membrane, and become later extracellularly secreted and incorporated to the pilus as 
their final localization. According to sequence predictions, CagH, CagI, and CagL are 
all acidic proteins with predicted isoelectric points between 4 and 6, and CagI and CagL 
are exported to the periplasm, from where they might reach the bacterial surface for 
integrin binding (Figure 3.1). Our localization studies showed that CagI and CagL exist 
in a non-surface localization at a considerable amount and partially on the bacterial 
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surface (Figure 3.9). Although we could not provide direct evidence for the presence of 
these proteins on the pili, our data support the hypothesis that they are secreted to reach 
the final localization on the pili, and then come into contact with the host cell receptor 
for facilitating the CagA translocation into host cells. The presence of CagI and CagL in 
different pools in H. pylori might be indicative of different stages of CagI and CagL 
production and incorporation into the pilus. 
Based on the model for assembly of the Cag-T4SS proposed by Fischer [Fischer, 2011], 
in which the core complex is composed of CagT, CagV, CagX and CagY, we present 
here an updated model of the Cag-T4SS (Figure 4.1). In the A. tumefaciens T4SS, VirB5 
has been shown to interact with the core complex components VirB8, and the inner 
membrane-bound NTPase VirB4. Apart from these structural components, VirB5 forms 
a complex with the major pilus subunit VirB2 [Yuan et al., 2005], which is critically 
important for the incorporation of the VirB2 proteins into T-pili. In contrast, no 
interaction between CagI (or CagL) and CagT (VirB7), CagX (VirB9), CagY (VirB10), 
or CagC (VirB2) by immunoprecipitation (data not shown) could be detected. Since the 
interaction of CagI and CagL was observed in the soluble fraction (Figure 3.12B), we 
assume that this interaction might take place in the bacterial periplasm, where both 
proteins might bind to the periplasmic part of CagH. Interestingly, although CagH is 
predicted to be an integral cytoplasmic membrane protein [Kutter et al., 2008], at least 
the N-terminus of CagH was shown to be exposed to the surface to play a role as a 
regulator of pilus dimensions [Shaffer et al., 2011]. Taken together, we speculate that 
the interaction of CagH, I and L in the bacterial periplasm may lead to the export of all 
three proteins by an unknown mechanism to the bacterial surface where they assemble, 
possibly together with further unknown components of the Cag-T4SS, to form the 
extracellular pili. Although CagC (VirB2 homolog) was proposed as a major pilus 
component due to its features [Andrzejewska et al., 2006; Kalkum et al., 2002; Kutter et 
al., 2008], there is so far no direct evidence for localization of CagC on the pilus. One 
recent study showed that despite being important for Cag-T4SS functionality, CagC was 
not required for the pilus formation [Johnson et al., 2014]. Therefore, it raises the 
question whether this protein is present on the pilus at all. Thus it is well possible that 
the T4SS pili of the Cag system are formed exclusively by CagH, CagI and CagL 
(Figure 4.1). In addition, the pilus surface was proposed to be covered locally by the 
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CagY protein. This hypothesis is supported by an interaction of the surface-exposed C-
terminus of CagY with the β1 integrin [Jimenez-Soto et al., 2009].  
Taken together, the available data suggest that the Cag-T4SS has an atypical pilus 
component. Further studies are required to elucidate the mechanism involved in pilus 
assembly. 
 
Figure 4.1. Assembly model of the Cag type IV secretion apparatus 
According to this model, the pilus is a mix of CagH, CagI, and CagL, (and possibly CagC) and covered 
by CagY. The tip of the pilus is decorated with CagL. CagH may be a pilus component and located at the 
base of the pilus, where it forms an initial complex with CagI and CagL. IM: inner (bacterial) membrane; 
PG: peptidoglycan layer; OM: outer (bacterial) membrane; CM: cytoplasmic membrane of an eukaryotic 
target cell. 
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5 CONCLUSIONS	AND	OUTLOOK	
The present study explores the role of the cag-PAI-encoded proteins, CagH, CagI and 
CagL, and their interactions in Cag-T4SS functionality in order to gain insights into the 
mechanism of pilus assembly in the process of CagA translocation. The presence of 
these proteins plays a central role in formation of the functional Cag apparatus. While 
investigating the role of the sRNA in regulating cagI and cagL expression, the role of 
the CagP protein in stabilizing these gene products was discovered. However, the 
mechanism by which this protein exerts its effects is not known, which might open up 
an interesting area for future studies. In addition, functional analysis of CagH, CagI and 
CagL and their interactions strongly suggests that the assembly of a complete pilus 
relies on these interactions. Whether the CagH, CagI and CagL proteins are 
incorporated into pili in the early stage of pilus assembly, or appear as late components 
of pili, has to  be explored further in the future. The presence of the C-terminal motifs of 
each protein and their functional significance are other important results obtained in this 
study. Whether these motifs act as common interacting regions or play a role in the 
process of pilus assembly are also points of interest for further studies.  
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ABBREVIATIONS	AND	UNITS	
Abbreviations 
A  Adenin 
ampR Ampicillin resistance 
AP Adenosintriphosphate 
APS Ammoniumpersulphate 
ATP Adenosine triphosphate 
BB Brucella Broth 
BCIP 5-Brom-4-chlor-3-indolylphosphate 
BSA Bovines Serumalbumin 
C Cytosine 
cag Cytotoxin-associated gene 
Cag-T4SS Cag Type IV Secretion System 
camR Chloramphenicol resistance 
C-termimus Carboxyl terminal end of a protein  
∆ Delta (Deletion) 
D Aspartat 
DEPC diethylpyrocarbonate 
dATP Desoxyadenosintriphosphate 
dCTP Desoxycytidintriphosphat 
dGTP Desoxyguanosintriphosphate 
DMF DMF Dimethylformamide 
DMSO DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
dNTP Deoxynucleotide Triphosphates (Mixture of dATP, dCTP, dGTP, dTTP) 
DTT Dithiothreitol 
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dTTP Desoxythiymidintriphosphate 
EDTA Ethylenediaminetetraacetic acid 
ERK extracellular signal-regulated kinases 
ermR Erythromycin resistance 
et al., From Latin, abbreviation of et (“and”) and alii (“others”) 
FACS Fluorescence-activated cell sorting 
FCS fetal calf serum 
G Glycine 
G Guanin 
GEBS Glycerol EDTA bromphenol blue sarkosyl buffer 
His Histidine 
Ig Immunoglobulin 
IL Interleukin 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kanR Kanamycin resistance  
LB-Medium Luria-Bertani-Medium 
MAPK Mitogen-activated protein kinase 
M-MuLVRT Moloney Murine Leukemia Virus 
MOPS  Morpholinepropanesulfonic acid 
MOI Multiplicity of infection 
NaCl Sodium chloride 
NBT Nitrotetrazoliumbluechloride 
N-terminus Amino terminal end of protein 
OD Optical density 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PAI Pathogenicity island 
PBS Phosphate Buffered Saline 
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PCR Polymerase Chain Reaction 
qPCR (RT PCR) Quantitative polymerase chain reaction (Real-time polymerase chain 
reaction) 
RNA Ribonucleic acid 
RNase RNA endonuclease 
RT-PCR Reverse transcription polymerase chain reaction 
PMSF Phenylmethylsulfonyl fluoride 
POX Peroxidase 
P-Tyr Phosphotyrosine 
PVDF Polyvinylidinfluoride 
RIPA Radioimmunoprecipitation assay buffer 
SDS Sodium dodecyl sulfate 
Src Tyrosine kinase 
strepR Streptomycin resistance  
T Thymin 
TEMED Tetramethylethylendiamin 
Tris Tris-(hydroxymethyl)-Aminomethan 
Tris HCl Tris-HCl Tris-(hydroxymethyl)-Aminomethan-Hydrochloride 
(w/v) weight/volume 
w/w weight/weight 
 
Units 
oC Grad Celsisus 
µ Micro- (10-6) 
A Amper 
bp Base pair 
Da Dalton 
g Gram 
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(x)g Standard gravities 
h Hour 
k Kilo-, 103 
l Liter 
M Molar (mol/g) 
m Milli- (10-3)  
n Nano- (10-9) 
rpm Rounds per minute 
sec Seconds 
U Unit (Enzyme activity = moles of substrate converted per unit time) 
V Volts 
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